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GENERAL INTRODUCTION
B cells in health and disease
All living organisms, including humans, are challenged by pathogens, such as viruses, 
bacteria, fungi, and parasites during their life. Therefore, a good functioning immune system 
is required to defend the organism against illness, or even death, caused by infections. 
The immune system consists of an innate arm, which forms a first line of defense, and an 
adaptive arm that can mount a pathogen-specific response. B and T lymphocytes both 
belong to the adaptive immune cells and express antigen receptors, which are specific for 
pathogen-derived antigens. These specific antigen receptors are called B cell receptor (BCR) 
and T cell receptor (TCR) molecules depending on the cell of origin. An enormous diversity of 
these antigen receptors is required to be able to recognize the immense number of antigens 
that might be encountered during life. To achieve this, each B and T cell expresses a unique 
BCR or TCR respectively, which contains a variable domain consisting of three framework 
regions (FR) and three complementarity determining regions (CDR), the latter being involved 
in actual antigen recognition. The variable domain is formed in a stochastic manner through 
V(D)J recombination processes in the antigen receptor genes (see below for more detail). 
B cells are key players in humoral immunity. Binding of an antigen to the BCR induces the 
activation of a signaling cascade formed by several kinase proteins which can phosphorylate 
each other as well as other signaling molecules including linkers and lipases to induce 
proliferation and differentiation processes. Upon BCR activation and a second signal B cells 
proliferate and differentiate into memory cells or into plasma cells, which secrete their BCR 
as immunoglobulins (Ig). 
The development of B cells requires checkpoints to prevent the recognition of self-
antigens and thereby autoimmune disease development, and to keep B cell proliferation and 
activation in check to prevent leukemia and lymphoma formation. Nonetheless, significant 
numbers of B cells exhibit BCRs, which are to some extent autoreactive. Hence, additional 
control mechanisms regulate B cell activation by harmful antigen specificities. Via controlling 
BCR signaling strength the genesis of autoimmune diseases or B cell malignancies can be 
prevented. Unfortunately, this control mechanism in BCR signaling as induced by self-antigens 
or by chronic infections cannot always prevent the development of leukemias or lymphomas.
Human B cell differentiation
Early B cell development in the bone marrow 
To be able to recognize an immense variety of antigens, an unlimited variety of BCR/Ig is 
required. The first step to establish this variation already occurs early in B cell differentiation. 
B cells develop in the bone marrow and the initial differentiation step after the stem cell 
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phase concerns the transition from a common lymphoid progenitor into the first progenitor B 
cell stage, the pro-B cell 1 (Figure 1). This specification process involves the concerted action 
of several transcription factors including PAX-5, which serves a the commitment factor of the 
B cell lineage 2. In this pro-B cell stage the formation of the BCR starts at the immunoglobulin 
heavy chain locus (IGH). The IGH locus contains 38-46 functional variable genes (IGHV), 23 
diversity genes (IGHD), and 6 joining (IGHJ) genes. In the pro-B cell stage recombination 
normally involves one of the IGHD genes and IGHJ genes through the induction of double 
strand DNA breaks by the lymphocyte-specific recombination activating genes 1 and 2 
(RAG1/RAG2); these breaks are subsequently repaired by general DNA repair proteins. This 
is followed by recombination of a IGHV gene to the previously formed D-J junction. After 
transcription, the newly formed V-D-J exon will be spliced to the µ-constant region (Cµ) 
exons 3 (Figure 2). In the pre-B cell stage, co-expression of this Ig heavy chain occurs together 
with the surrogate light chain, consisting of the VpreB and λ5 subunits, and together they 
form the pre-BCR. This pre-BCR is required to test the fitness of the Ig heavy chain to be 
expressed on the cell surface (reviewed in 4). Subsequently, recombination of the V to J genes 
of the Ig light chains will be performed. This will first occur for the Ig kappa (IGK) light chain 
alleles, which contain in human 34-38 IGKV genes and 5 IGKJ genes, and when this does not 
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Figure 1. B cell differentiation.
Schematic overview of the phases of B cell differentiation from hematopoietic stem cells to memory B cells and 
plasma cells. The antigen-independent early B cell development stages in the bone marrow are defined by ordered 
IG gene rearrangements. In the periphery, antigen-dependent B cell differentiation takes place. Upon antigen recog-
nition naïve mature B cells migrate to lymphoid follicles and initiate a T cell-dependent GC reaction, where the cells 
undergo extensive proliferation, somatic hypermutation (SHM) and class switch recombination (CSR). Alternatively, 
the B cells can undergo a T cell-independent differentiation in the marginal zone leading to largely unswitched 
memory B cells. (Adapted from the thesis of H. IJspeert)
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succeed in a productive Ig light chain, this process will be continued on the Ig lambda (IGL) 
alleles, which have 29-33 IGLV and 5 IGLJ genes 5, 6. 
This V(D)J recombination process induces a great variety in BCR molecules, but there are 
additional ways to create further diversity in the junction between the V, D, and J genes. This 
can be mediated by exonucleases, which can remove nucleotides. Moreover, RAG1/RAG2 
together with DNA repair proteins can create palindromic nucleotides (P-nucleotides) 
through asymmetric hairpin opening, and terminal deoxynucleotidyl transferase (TdT) can 
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Figure 2. B cell receptor formation.
A. Rearrangement of the IGH locus starts with random recombination of one IGHD gene to one IGHJ gene, followed 
by rearrangement of this D-J joint to IGHV. Subsequently, the VDJ-exon is transcribed into immature mRNA, and 
forms after splicing with the Cµ exons the Igµ mature mRNA, which is translated into Ig µ heavy chain protein. After 
rearrangement of the IGK / IGL locus into a functional light chain protein, these are expressed as a functional BCR 
(surface IgM) on the plasma membrane together with CD79a/b (B, left panel). B, right panel. The IGHV domain is 
composed of four FR regions that are separated by three CDR regions, which are essential for antigen binding by 
forming loops. (Adapted from the thesis of M. Rother)
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randomly add nucleotides (N-nucleotides). To complete formation of the junction, the 
coding ends of the V-, D-, and J-genes are ligated 7. This junction defines the essential part for 
antigen recognition, the CDR3 8.
The combination of the Ig heavy and Ig light chain will form the BCR, which is subsequently 
checked for autoreactivity. Upon recognition of self-antigen, the autoreactive B cell will 
either go into apoptosis, or become anergic, by limiting the response of BCR stimulation 
via the downstream signaling cascade. Alternatively, receptor editing, through replacement 
of the Ig light chain due to ongoing recombination events at the Ig light chain loci, can take 
place, which can rescue a B cell that was initially self-tolerant 9.
When these processes lead to a functional BCR, the B cell will leave the bone marrow and 
enter the circulation as a transitional B cell (Figure 1). At this point in development the B cells 
will start to express IgD BCRs, next to the IgM configuration, as a result of alternative splicing 
of the BCR mRNA 10. These B cells are functionally immature, since they do not respond 
to BCR stimulation. Transitional B cells are characterized by the expression of the immune 
modulatory molecule CD5 and by CD24 and CD38, and constitute 5-10% of total B cells in the 
peripheral blood of adults 11. Maturation of the transitional B cells into naive mature B cells 
is initiated by downregulation of CD24 and CD38 and finally CD5, which makes the cells fully 
competent to respond to antigenic stimulation 12. 
Antigen-dependent B-cell differentiation
Naive mature B cells require binding to their cognate antigen to induce BCR signaling, and 
subsequently need a second signal to differentiate further. This additional signal is provided 
by activated T cells via CD40 ligand (CD40L), which interacts with CD40 on the B cells. T cell-
dependent B cell responses induce the formation of germinal centers (GC). B cells within 
the GC will undergo extensive proliferation, accompanied by affinity maturation induced by 
somatic hypermutation (SHM) (Figure 1). 
This SHM process is initiated by the enzyme activation-induced cytidine deaminase (AID), 
which randomly and bi-directionally introduces DNA alterations on single strand DNA of 
transcribed IGHV and IGK/IGL V genes 13, by starting with the deamination of cytidine (C) 
into uracil (U). This generates a mismatch between the newly formed U nucleotide and the 
pre-existing guanine (G) nucleotide on the corresponding position in the complementary 
DNA strand. When cells proliferate this U nucleotide can be recognized as thymine (T) by 
high-fidelity polymerase, which results into a C to T transition mutation. As an alternative, 
the U nucleotide can also be removed by uracil-N-glycosylase (UNG), which results into an 
abasic site that can be targeted by the base excision repair machinery and can induce both 
transition and transversion mutations in all of the four nucleotides. Another possibility is 
that the U-G mismatch will be recognized by the mismatch repair machinery which also can 
induce both transition and transversion mutations into A-T bases (reviewed in 14) (Figure 3). 
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SHM mostly occurs in the GC but can also take place in the marginal zone 15, 16. Although, SHM 
can occur throughout the V genes of both heavy and light chains, it is especially apparent 
in the CDR1 and CDR2 regions 17. The functionality of the now altered BCR is selected by its 
affinity for the cognate antigen 14. 
AID mediates an additional GC process, namely class-switch recombination (CSR), the 
process whereby the constant region of the heavy chain is replaced to allow the B cell to 
switch to another Ig isotype. AID targets switch regions that contain multiple AID hotspot 
motifs and that are located upstream of the different constant regions. The CSR process 
also starts with the deamination of C into U. When AID induces two a-basic sites in close 
proximity this can induce a double strand DNA break. If this occurs in the µ-switch region 
and a switch region upstream of another constant gene, this can trigger class switching to 
IgG, IgA, and IgE (encoded by Cγ, Cα, or Cε respectively) (reviewed in 14) (Figure 3). CSR does 
not alter antigen recognition itself, but changes the function of the BCR since Ig-isotypes 
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Figure 3. Somatic hyper mutation and class switch recombination.
A. The Ig heavy chain is composed of the variable region, which is essential for antigen recognition, and one of a 
series of nine constant region genes, which determine the functional properties of an antibody. B. Somatic hyper-
mutation (SHM) starts with transcription of the variable region, when AID deaminates the C residues into U in single 
stranded DNA. The resulting mismatch can be repaired in three different ways. Via replication of the U-G mismatch, 
removal of U by UNG and subsequent repair via base-excision repair (BER), or when the U mismatch is recognized 
and repaired by the mismatch repair (MMR) machinery. 
C. For class switch recombination (CSR), AID targets Ig switch regions and thereby causes multiple single strand DNA 
breaks in close proximity to each other, which can lead to double strands DNA breaks. When two of these Ig switch 
regions are in close proximity, they can be recombined, and the intervening DNA is looped out and excised.
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have different characteristics 18. IgM is secreted as a pentamer and its main function is in 
complement activation 19. IgG is most abundantly found in serum, can act locally in tissue, 
and is mainly involved in neutralization of pathogens, even intracellularly 20. IgA functions 
in mucosal tissues, especially in the gastro-intestinal tract and is coating bacteria that are 
present 21. Finally, IgE is involved in parasitic infections and allergic responses 22. The SHM 
and CSR processes will trigger the formation of high affinity memory B cells and Ig-producing 
plasma cells 23. The growth factors BAFF and APRIL support these processes via interaction 
with TACI on B cells 24. 
Alternatively, naive B cells can be activated by antigens in a T cell-independent manner. 
In this scenario an additional signal occurs via an innate receptor such as a toll-like receptor 
(TLR), or via strong activation of multiple BCRs by antigen with a repetitive composition such 
as carbohydrate and lipid structures. This T cell-independent activation can occur in the 
marginal zone of the spleen - mostly directed against blood-borne more innate antigens - or 
in mucosal tissues 25. BAFF and APRIL support these B cells to proliferate, partly undergo CSR 
to IgG or IgA, and differentiate into plasma blasts and finally into plasma cells (reviewed in 26). 
Malignant transformation of B cells
The molecular processes that occur during B cell development pose a potential risk 
of genomic instability, which might contribute to subsequent leukemia or lymphoma 
development (reviewed in 27). The formation of the BCR during early B cell development 
requires the introduction of double strand DNA breaks in the genome by RAG1 and RAG2, 
which might also induce deletions or chromosome translocations involving non-IG genes 
including PAX5 and IKAROS, and thereby contribute to malignant transformation of precursor 
B cells into B cell precursor acute lymphoblastic leukemia (BCP-ALL) 28. In the onset of BCP-
ALL, also translocations (such as BCR-ABL1) are important, as well as mutations in genes 
that encode factors involved in (pre-)BCR signaling, or that encode transcription factors that 
are essential in B cell development 27, 29, 30. BCP-ALL is relatively predominant in children and 
young adults. 
In mature B cells, SHM and CSR processes can induce double strand breaks and genetic 
modifications, e.g. leading to IG translocations, involving the MYC and BCL genes, or leading 
to the induction of mutations in SHM hotspot-like regions, which might contribute to 
transformation and result in the mature types of leukemias and lymphomas, making AID key 
regulator in these processes 31, 32, 33. These mature lymphoid malignancies are classified based 
on histological and cytological characteristics, localization, immunophenotype and genetic 
abnormalities. Many of these features reflect the differentiation stage of the B cell from 
which the leukemia or lymphoma originated 27. Follicular lymphoma, the most common type 
of B cell lymphoma is derived from GC B cells 34. Also, diffuse large B cell lymphoma seems 
to be derived from activated B cells in the GC, in which auto-antigenic recognition plays a 
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role 35. On the far end of the B cell differentiation spectrum are plasma cells that can give 
rise to multiple myeloma, a plasma cell malignancy, which suppresses normal immune cell 
development in the bone marrow 36.
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in elderly 
individuals in the Western world. CLL is a multifactorial disease, in which both cell-intrinsic 
genetic alterations as well as cell-extrinsic stimulation via the microenvironment and the BCR 
play key roles. 
BCR-induced stimulation in CLL
Chronic antigenic stimulation is thought to be relevant in the onset of CLL , particularly in 
CLL that carry a BCR with SHM (mutated CLL, M-CLL), highlighting their origin from post-GC 
memory B cells 37. In contrast, CLL without SHM (also termed unmutated CLL, U-CLL) are 
derived from cells that potentially have been activated but that have not gone through the GC 
reaction 37. M-CLL and U-CLL show different prognosis, with M-CLL being the more indolent 
form of disease 38. Nowadays, signaling molecules functioning downstream of the BCR are 
important targets for therapy, further corroborating the importance of BCR activation in CLL.
Microenvironmental interactions in CLL
B cells are strongly dependent upon interactions with the microenvironment for their 
survival and further maturation. CLL cells also have particular interactions with other cells 
in the bone marrow and in lymphoid organs in certain niches, the so-called proliferation 
centers. The microenvironment in these proliferation centers consists of cells which are 
normally present in these organs, such as mesenchymal stromal cells in bone marrow and 
nurse-like cells (NLC) in lymphoid organs. However, these cells co-evolved with the CLL cells 
through cellular interactions in order to establish a beneficial microenvironment. This CLL 
microenvironment shows similarities with that of other tumor environments, including 
blood vessel formation to provide more nutrients, local production of growth factors, and 
protection against the elimination of the tumor cells by immune cells (reviewed in 39, 40). 
NLC are a type of macrophages that are derived from blood monocytes and are able 
to activate the BCR by presenting antigen to the CLL cells. They provide homing signals 
through secretion of the chemokines CXCL12 and CXCL13 41. CLL cells express the chemokine 
receptors CXCR4 and CXCR5 and can sense chemokine gradients. NLC also express BAFF and 
APRIL, which induce proliferation and survival of CLL cells via the BAFF receptor and the 
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) 42. 
T cells also play an important role in the activation and survival of CLL cells via CD40-
CD40-L interaction 43. In CLL patients the T cell subset distribution is shifted, and a more 
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exhausted phenotype is apparent. This change in phenotype coincides with impaired T cell 
effector function (tumor cell killing) and reduced synapse formation capacity 40, 44, 45. 
Genetic alterations in CLL
Several genetic alterations play a role in the onset and clonal evolution of CLL. It is 
suggested that passenger mutations in normal counterpart cells accumulate and could act as 
founders in leukemogenesis 46. The next steps of clonal evolution are induced by the so-called 
driver mutations, which are generally clonal aberrations that are found across patients. 
Examples of such driver aberrations are 13qdel (deletion of the short arm of chromosome 
13), trisomy 12, and mutations in myeloid differentiation primary response gene 88 (MYD88), 
encoding a key signaling molecule downstream of Toll-like receptors, which all seem specific 
drivers in many B cell malignancies, including CLL 46, 47, 48. Subclonal mutations direct the 
next phase in disease progression, and are often induced by therapy. These affect clonal 
evolution and induce an increase in proliferation and a decrease in apoptosis over other CLL 
cells 46, 49. Among these mutations are loss-of-function mutations in tumor protein 53 (TP53) 
and ataxia telangietasia mutated (ATM) genes as well as gain-of-function mutions in RAS , 
NOTCH1, and splicing factor 3B subunit 1 (SF3B1) genes 46, 47. Spliceosome component SF3B1 
is often found to be mutated in CLL and is associated with poor outcome. SF3B1 mutation 
was found to induce comprehensive changes in splicing and gene expression across several 
pathways including DNA damage response, Notch signaling, and telomere maintenance 
50. NFKBIE mutations are associated with a more advanced stage of CLL. The NFKBIE gene 
encodes IκBε, which regulates NF-κB in healthy B cells. A particular NFKBIE mutation has 
been reported to lead to a truncated protein with an abrogated function, and thereby loss of 
its inhibitory effect on NF-κB 51. Another recently identified driver mutation is found in the 
early growth response 2 (EGR2) gene, which functions as a transcription factor involved in 
haematopoeisis and downstream of ERK in BCR signaling. The EGR2 missense mutations lead 
to altered expression of EGR2 target genes in CLL and are associated with a poor prognosis 
52. In addition to mutations in coding genes, also non-coding mutations were identified to 
play a role in CLL 53. Overall, innovations in next generation sequencing in the last decade are 
shedding more and more light on the genes involved in onset and evolution of CLL.
Scope of this thesis
Next to the above described microenvironmental interactions and genetic alterations, B 
cell receptor-driven signaling is believed to essentially contribute to the immunopathogenesis 
of human CLL. The overall aim of this thesis is to evaluate functional abnormalities in the BCR 
signaling process in human CLL cells and to define their impact on CLL pathogenesis. 
In Chapter 1 an overview is presented on human B cell development and on malignant 
transformation of B cells, with a special focus on CLL and the role of the microenvironment 
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and genetic alterations. In Chapter 2 the role of signaling pathways in B cells and their 
important roles in human CLL are reviewed. Furthermore, an overview is given on novel 
therapies which target these signaling pathways in human CLL. It has been reported that CLL 
B cells have increased autonomous Ca2+ signaling, in contrast to other B cell malignancies or 
healthy B cells. As it remained unknown whether the increase in Ca2+ signaling was related to 
the mutation status of the BCR, we aimed to explore in Chapter 3 whether differences exist 
in the basal Ca2+ signaling between U-CLL and M-CLL. In chapter 4, we wanted to further 
characterize the differences in BCR responsiveness detected in human CLL and study the 
underlying molecular mechanisms. Relatives of CLL patients are known to have an increased 
risk in developing this disease. In Chapter 5 the importance of the BCR as well as genetic 
predisposition are investigated in the context of familial CLL cases. In chapter 6, we aimed 
to evaluate the effect of aging on B cell subset distribution and BCR repertoire in healthy 
individuals, and compared this with the BCR repertoire and stereotypic BCR features in 
human CLL. Finally, the implications of the studies described in this thesis are critically 
discussed in the general discussion (Chapter 7). 
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ABSTRACT
Various signal transduction pathways have been implicated in the pathogenesis of 
chronic lymphocytic leukemia (CLL), which is characterized by the progressive accumulation 
of monoclonal CD5+ B cells in the blood. B cell receptor (BCR) signaling appears to have 
a crucial role in disease onset and is thought to be induced by self- or non-self-antigen 
recognition leading to chronic stimulation. Several of the kinases functioning downstream of 
the BCR are aberrantly expressed or constitutively activated in CLL. Yet, these kinases have 
additional roles, particularly in chemokine receptor signaling, which is essential for homing 
and survival of CLL cells in lymphoid organs, or in toll-like receptor signaling. Recently, small 
molecule inhibitors of kinases in the BCR signaling pathway have shown impressive anti-
tumor activity in clinical trials. Remarkably, the observed durable responses in CLL patients 
were accompanied by transient increases in blood lymphocyte numbers, indicating the 
importance of these kinases in chemokine receptor signaling. In this review, we therefore 
highlight the role of BCR signaling and the important other associated signal transduction 
cascades for CLL cells and give an overview of novel agents that target these specific pathways 
and were shown to be successful for CLL treatment in clinical trials.
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GENERAL INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most frequently occurring type of leukemia 
in adults in the Western world. CLL is characterized by accumulation of a monoclonal 
population of small B cells with a typical immunophenotype (CD19+, CD20dim, CD5+, CD23+, 
CD27+, CD43+, surface Igdim) in the blood. Over 95% of cases are diagnosed above 50 years 
of age. To date, the overall 5-year relative survival for CLL patients is 79.2% 1. Nevertheless, 
there is a large difference in survival between individual CLL patients, varying from several 
months to a normal life expectancy 1. This heterogeneity in survival reflects the biological 
heterogeneity known for CLL, which is considered a multifactorial disease.
In CLL several genetic aberrations are found that have prognostic value. For instance, 
there are multiple chromosomal aberrations that together occur in approximately 80% of 
CLL cases. These mainly concern deletions of chromosomal regions 17p, 11q, or 13q, and 
trisomy of chromosome 12. These chromosomal deletions are associated with the loss of 
the TP53 and ATM genes, and the miR15a and miR16-1 microRNA genes, respectively; so far 
the relevant gene involved in trisomy 12 is unknown. Deletion of 17p and deletion of 11q are 
associated with a poor disease outcome, while deletion of 13q as a single event is associated 
with a milder form of disease (reviewed in 2). Over the last few years several novel mutations 
with prognostic value have been identified by next generation sequencing approaches. 
Mutations found in the NOTCH1 3 and SF3B1 genes 4 are associated with progressive disease, 
while mutations in MYD88 3 are rare and appear to be associated with an indolent form of 
disease. Although some of the identified mutations appear to act as early driver mutations 
playing a role in disease onset, mutations are never present in 100% of the clones 5. Other 
mutations may act later in evolution of the CLL clone and seem to be more important for 
disease progression. From all genetic studies it is however clear that neither the B cell 
receptor (BCR) itself, nor its signaling pathway is directly targeted by mutations. 
Instigated by the idea that CLL is generated from different stages of B cell maturation 
and activation, several cellular origins of CLL have been suggested. Marginal zone B cells 6, 
post-germinal center (GC) memory B cells 7, CD5+ B cells 8, 9, and IL-10 expressing regulatory 
B cells 10 have all been mentioned as the normal B cell counterpart from which CLL cells 
would derive. On the basis of somatic hypermutation status (SHM) of the immunoglobulin 
heavy chain variable (IGHV) genes of the BCR, it is clear that CLL cells could derive from 
pre- or post-GC B cells. CLL patients can thus be grouped into mutated CLL (M-CLL) and 
unmutated CLL (U-CLL). This division is also clinically relevant because U-CLL tend to have 
an unfavorable prognosis, with a more aggressive course of the disease and shorter time to 
first treatment, while M-CLL is associated with a more indolent disease form with a relatively 
favorable prognosis 11, 12.
Chapter 2
29
Approximately one-third of all CLL cases can be grouped on the basis of their restricted 
IGHV, IGHD, and IGHJ gene usage, and similarities in length and amino acid sequence of 
the complementarity determining region 3 (CDR3) 13. These so-called stereotypic BCRs are 
found in multiple CLL patients and the analyses of large cohorts of CLL patients enabled their 
clustering into at least 19 major subsets which contain ~12% of all CLL cases; another 18% of 
CLL cases belong to minor subsets, as was found in a study which included 7424 CLL patients 
13. The finding of BCR stereotypy is indicative of a contribution of similar antigens, thus 
implicating antigenic stimulation and thereby BCR specificity in CLL pathogenesis 13. Recently, 
it has been shown that BCR stereotypy in CLL not only has biological impact, but also bears 
clinical significance. Distinct BCR stereotypic subsets appeared to associate with differences 
in time to first treatment, thus showing added prognostic value over U-CLL/M-CLL status and 
cytogenetic aberrations 14, 15.
Taken together, these findings demonstrate that important prognostic information resides 
in the BCR molecules and indicate an important role of the BCR and downstream signaling 
pathways. Recent clinical trials have provided evidence that the therapeutic effect of various 
kinase inhibitors of the BCR signaling pathway, particularly including the Bruton’s tyrosine 
kinase (BTK) inhibitor, ibrutinib, and the phosphatidyl-inositol-3-kinase δ-isoform (PI3Kδ) 
inhibitor, idelalisib, is also dependent on the role of these kinases in chemokine receptor 
signaling. Therefore, in this review, we aim to discuss the role of BCR signaling and important 
associated other signal transduction cascades for CLL cells. We will give an overview of novel 
agents that target these specific pathways and were shown to be successful in clinical trials.
ROLE OF ANTIGENIC STIMULATION IN CLL PATHOGENESIS
In addition to the stereotypic BCR repertoire in CLL, other lines of evidence support an 
important role for antigen-driven BCR signaling in CLL pathogenesis. In particular, CLL B cells 
show low surface IgM expression and often an anergic response to BCR ligation, suggesting 
chronic BCR stimulation and signaling. Nevertheless, the degree of anergy is not equal for 
every CLL, as we will point out below. Anergy is a cellular condition that keeps a B cell capable 
of binding to its antigen, without inducing proper BCR activation, and so full activation is 
hampered. This is a strategy of the immune system for silencing auto-reactive B cells, which 
can in this way persist in the periphery 16. The finding that BCR unresponsiveness can be 
restored upon culture in vitro supports that the BCR on CLL cells is engaged by antigen in 
vivo 17. Based on CLL expression profiling studies that show upregulation of gene signatures 
consistent with BCR and nuclear factor-κB (NF-κB) activation, it has been proposed that 
the lymph node micro-environment is essential for the expansion of CLL cells in so-called 
proliferation centers 18. 
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For several CLL-derived BCRs a binding antigen has been identified. In general, most U-CLLs 
were found to express poly-reactive, low affinity BCRs, which bind self- or non-self-antigens, 
such as DNA, insulin, LPS, apoptotic cells, vimentin, myosin heavy chain 2A (MYH2A), and 
phosphoryl choline-containing antigens including oxidized low-density lipoprotein (LDL) 19, 
20, 21, 22. BCRs from stereotypic subset #1 bind to oxidized LDL 20, 22, 23. Stereotypic subset #2 
recognizes protein L, a cell-wall protein of the commensal gut bacterium Peptostreptococcus 
magnus 24 and in addition binds to cofilin-1 22. Several stereotypic CLL subsets, including #3, 
#6, and #7, are known to use the IGHV1-69 gene, which is very common in CLL and is mostly 
associated with U-CLL. CLL-derived BCRs containing IGHV1-69 and IGHV3-21 were found to 
react with the cytomegalovirus protein pUL32 25. Recently, two reports demonstrated that 
two distinct stereotypic M-CLL subsets have specificity for the Fc-tail of IgG, and thereby have 
so-called rheumatoid factor activity 26, 27. Stimulation of these specific stereotypic CLL cells 
with IgG indeed resulted in their proliferation 26. In addition, Hoogeboom et al. 28 identified 
a stereotypic M-CLL subset with IGHV3-7 gene usage with an extremely short CDR3 of 5-6 
amino acids. This stereotypic receptor is highly specific for a potent antigen called β-(1,6)-
glucan, which can be found in yeast and filamentous fungi. Antigenic stimulation of CLL cells 
expressing this particular stereotypic BCR induces proliferation 28. Collectively, these data 
provide support for an important role for antigen-driven BCR signaling in CLL pathogenesis.
In contrast to these studies, Dühren-von Minden et al. 29 observed that CLL-derived 
BCRs can be stimulated independently of external antigens, because of the presence of an 
internal epitope in framework 2 (FR2) of the IGHV domain that is recognized by their CDR3. 
This recognition induces an increased level of antigen-independent, basal or ‘autonomous’ 
signaling of the BCR, as demonstrated by increased cytoplasmic Ca2+ levels compared with 
BCRs from non-malignant B cells. Remarkably, this cell-autonomous BCR signaling was not 
observed in other B cell malignancies, including myeloma, mantle cell lymphoma, follicular 
lymphoma, and marginal zone lymphomas. These observations were predominantly made in 
an innovative in vitro assay using triple knockout (TKO) cells, which are BCR-free, conditionally 
signaling-competent mouse B-lineage cells. Upon transduction of human CLL-derived BCRs 
(or CLL-derived CDR3s) increased Ca2+ signaling was observed, while other B cell lymphoma-
derived BCRs needed anti-BCR stimulation to induce Ca2+ signaling 29. When the conserved 
FR2 epitope was mutated, leading to an amino acid change, the autonomous signaling was 
lost. Conversely, when the CDR3 region of the CLL-derived BCR was introduced in an originally 
non-autonomous signaling BCR, this BCR became autonomously active. In addition, another 
internal epitope in FR3 of both IGHV and Ig light chain V genes was identified 30, which may 
play a role in autonomous signaling in CLL as well. 
These findings fueled the controversy whether antigen-dependent or cell-autonomous 
stimulation would be important in CLL pathogenesis, but at the same time they further 
underlined the relevance of the BCR in this disease. Importantly, the two contrasting 
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observations may not be mutually exclusive, because it is conceivable that some level of 
autonomous signaling may be enhanced by ligand-dependent, antigen-driven BCR signaling. 
In support of this hypothesis, we recently found that the degree of cell-autonomous signaling 
differed between CLL subgroups, when we analyzed basal Ca2+ signaling in a series of primary 
stereotypic or heterogeneous U-CLL and M-CLL 31. We observed that basal signaling was not 
uniformly enhanced in CLL B cells, but particularly increased in M-CLL and thus associated 
with CLL IGHV mutational status. From these findings we concluded that this might reflect the 
distinct cellular origin of M-CLL and possibly a different anergic state induced by repetitive 
or continuous antigen binding in vivo 31. Perhaps CLL clones originate as antigen-dependent 
clones that become more autonomous and gain increased basal Ca2+ signaling upon mutation 
of critical amino acids in their CDR3 region. 
IMPORTANT SIGNAL TRANSDUCTION PATHWAYS IN MATURE 
B CELLS
Based on the mutations and signal transduction aberrations identified in CLL cells, as 
well as the successful treatment of CLL by small molecule inhibitors, it is becoming clear that 
three main signal transduction routes, BCR signaling, chemokine receptor signaling, and toll-
like receptor (TLR) signaling, are crucial for survival of malignant CLL cells in patients. Here, 
we first describe these signaling pathways in non-malignant mature B cells.
B cell receptor (BCR) signaling
The BCR serves as an antigen receptor and is essential for B cell fate. Surface Ig is the 
main component of the BCR signaling complex which senses the environment for molecules 
that bind with significant avidity. The BCR complex at the cell surface further consists of the 
non-covalently associated Igα (CD79a) and Igβ (CD79b) molecules, which together form a 
heterodimer via a disulphide bridge, and the BCR co-receptor CD19 (Figure 1). After antigen 
binding to the BCR the SRC-family protein tyrosine kinase LYN phosphorylates the first 
immunoreceptor tyrosine-based activation motif (ITAM) tyrosine residue of the cytoplasmic 
tails of both Igα and Igβ 32. This first phosphorylated ITAM tyrosine residue serves as a docking 
site for another protein tyrosine kinase, SYK, which can phosphorylate both ITAM tyrosines 
32, 33. LYN additionally phosphorylates tyrosine residues in the cytoplasmic tail of CD19, which 
facilitates binding and activation of PI3K and the guanine nucleotide exchange factor VAV 
33, 34, 35. PI3K can also be recruited by the cytoplasmic B cell adapter for PI3K (BCAP) 36. Class 
IA PI3K isoforms are composed of a heterodimer between a p110 catalytic subunit and a 
p85 regulatory subunit. The three different catalytic subunits, p110α, p110β and p110δ, are 
encoded by separate genes and have distinct roles. PI3Kδ (p110δ, encoded by PIK3CD) is 
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predominantly expressed in leukocytes, including B cells 37. It is known that PI3Kδ plays a 
key role in B cell function, since inhibiting this specific isoform leads to reduced activation 
downstream in the BCR signaling cascade and disturbed GC-formation 38. PI3K phosphorylates 
PIP2 to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), which then recruits BTK 
to the plasma membrane 39. Next, BTK can be fully activated through phosphorylation 
by SYK and LYN at the Y551 position, which is followed by BTK autophosphorylation at 
position Y223 40, 41, 42. This activation of BTK can be modulated by SH2-domain containing 
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Figure 1. CLL treatment targets in the B cell receptor signaling pathway.
Upon antigen binding by the B cell receptor (BCR), signaling is initiated by LYN-mediated phosphorylation of ITAMs 
in the cytoplasmic tail of Igα/β and CD19, resulting in recruitment of SYK and PI3K, respectively. PI3K generates PIP
3
 
to enable membrane recruitment of BTK. Phosphorylation of SLP65 by SYK induces a docking platform for BTK and 
PLCγ
2
, and formation of the BCR micro-signalosome, resulting into phosphorylation of PLCγ
2
 by BTK. This induces an 
influx of Ca2+, finally resulting in subsequent activation of ELK1/c-Myc, NF-κB, NFAT and FOXO transcription factors. 
In CLL, several kinases are upregulated and ZAP70 might be aberrantly expressed (see text for details). The kinases 
that are targeted by inhibitors described in this review are indicated in red.
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inositol-5’-phosphatase-1 (SHIP1) and phosphatase and tensin homolog (PTEN), which both 
inhibit association of BTK to the membrane by dephosphorylating PIP3. Recruitment of SH2 
domain-containing leukocyte protein of 65 kDa (SLP65, or B cell linker, BLNK) is essential for 
further downstream signaling, as it serves as a scaffold for the signaling molecules SYK and 
BTK, and thereby creates a docking site for phospholipase Cγ2 (PLCγ2) 43, 44. PLCγ2 is activated 
by phosphorylation through BTK at positions Y753 and Y759, which is important for its lipase 
activity. The SLP65-mediated recruitment of BTK and PLCγ2 into the complex, finalizes the 
formation of a so-called micro-signalosome, which consists of PI3K, VAV, SLP65 and PLCγ2 45, 
46 (see Figure 1). Inferred from in vitro findings in the A20 B cell line, BTK can – independently 
of its kinase activity - play a role in the recruitment of PIP5K. This generates a positive 
feedback loop via PIP2, which acts as a substrate for both PI3K and PLCγ2 47. In this way, 
BTK stimulates PIP3 production that is essential for its own activation. After the activation 
of PLCγ2 by BTK, it cleaves PIP2 to generate the second messengers inositol triphosphate 
(IP3) and diacylglycerol (DAG), which leads to the branching of the further downstream 
signaling pathways 48, although these also partially overlap. IP3 is involved in the regulation 
of intracellular Ca2+ levels after binding to its receptors on the endoplasmic reticulum 
membrane. It thereby activates, via calmodulin and calcineurin, the transcription factor 
nuclear factor of activated T cells (NFAT) 49. DAG mediates the activation of protein kinase 
Cβ (PKCβ), which is required for the activation of several mitogen-activated protein kinase 
(MAPK) family members like the proto-oncogene B-RAF (BRAF), mitogen activated protein 
kinase kinase (MEK), extracellular signal-regulated kinases 1 and -2 (ERK1 and -ERK2), and 
other downstream MAPK targets like Jun N-terminal kinase (JNK), P38, and NF-κB pathway 
components 50 (see Figure 1).
Another major branching point, besides that of PLCγ2, functions further upstream in the 
BCR signaling cascade and is induced by the activation of serine/threonine kinase AKT by 
PI3K. The downstream effector of PI3K, Ser/Thr kinase phosphoinositide-dependent kinase 
1 (PDK1) is required for the phosphorylation of AKT at the cell membrane. Fully activated 
AKT proceeds to the cytoplasm to facilitate pro-survival signaling 51. Important AKT targets 
are NFAT, forkhead transcription factors (FOXOs) and NF-κB 52. Collectively, these partially 
parallel BCR signaling routes determine the outcome of BCR stimulation, which may be very 
diverse, including proliferation, survival, cellular differentiation, apoptosis, or anergy.
Chemokine receptor signaling 
Chemokine receptors are G-protein-coupled receptors, of which 19 have been described 
so far. Given that there are 50 known chemokines, this indicates a redundancy in the function 
of chemokines 53. Chemokine receptor pathways in B cells are essential for their trafficking, 
homing and homeostasis. The chemokine receptors CXCR4 and CXCR5 are highly expressed 
on the surface of B cells 54. Binding of one of their agonists to the extracellular domains of the 
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chemokine receptor induces conformational changes in the seven-transmembrane spanning 
domain. This facilitates interactions with the intracellular heterotrimeric G-proteins and 
allows transmission of the signal (see Figure 2) 55. Heterotrimeric G-proteins are composed 
of α, β, and γ (Gα, Gβ, and Gγ) subunits. Upon dissociation of the Gα subunit, the Gβγ 
subunits can activate several downstream targets of the chemokine receptor. Both Gα and 
Gβγ subunits can activate PI3K independently, which in turn results in the activation of AKT 
and MAPK 56. The PI3K-mediated increase in PIP3 leads to a local recruitment of proteins 
containing PIP3-pleckstrin homology (PH) domains, including BTK, and is essential for 
membrane anchorage 57. Next to PI3K activation, both Gα and Gβγ subunits can directly bind 
to BTK via the PH and Tec homology (TH) domain 58. The tyrosine kinases LYN and SYK play a 
role in chemokine receptor signaling as well, as was observed in B cells that lack LYN or SYK 59. 
These kinases were found to activate BTK after CXCR4 ligation59, which was confirmed by the 
finding that CXCL12-induced ligation of CXCR4 in the presence of a SYK inhibitor reduces BTK 
Y551 phosphorylation 60. Through activation of SLP65 and PLCγ2, cleavage of PIP2 into DAG 
and IP3 occurs, which will finally result in the activation ERK1/2, and several transcription 
factors, including NF-κB and NFAT 56. Importantly, in the absence of BTK, B cells show impaired 
integrin-mediated adhesion and migration in response to CXCL13 59. Moreover, also in vivo 
homing of B cells to lymphoid organs was impaired, as was shown with adoptive transfer of 
BTK-deficient B cells into mice 59. The role described for BTK in B cell homing, is also essential 
for retention of CLL cells in lymphoid organs, as was also clearly visible in the BTK inhibitor 
trials in which lymphocytosis was observed after start of treatment 61. This will be discussed 
in more detail later in this review. 
CXCL12 
PIP3 
Gβ Gγ 
Gα 
Igα/β 
LYN 
BTK 
PLCγ2 
P 
P SYK 
SLP65 
P 
P P 
BCR 
IT
AM
 
P 
P P 
P 
ZAP70* 
PI3K 
Ca++ 
Muggen et al. - Figure 2 
CXCR4 
VA
V 
Figure 2. Roles for BTK and SYK in chemokine receptor signaling. 
A schematic overview of the chemokine receptor signaling in B cells and CLL cells, with a dual role for several of the 
signaling molecules within the BCR signaling pathway. CXCL12 induces CXCR4 activation after binding. Heterotri-
meric G protein subunits interact with BTK, which via interaction with SLP65, VAV, and PLCγ2, into Ca2+ release and 
further downstream activation of transcription factors (see text for details). The kinases BTK, SYK, and PI3K which 
are targeted by inhibitors described in this review, are indicated in red.
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Toll-like receptor signaling 
TLRs are pattern recognition receptors which are characterized by extracellular leucine-
rich repeats and intracellular Toll/interleukin-1 receptor domains. TLRs typically recognize 
structurally conserved molecules derived from pathogens, e.g. lipopolysaccharides, flagellin, 
double-stranded RNA, or bacterial DNA. TLRs play an essential role in both innate and 
adaptive immunity. TLR1, TLR4 (at low levels, increased levels are found during inflammatory 
conditions), TLR6, TLR7, TLR9 and TLR10 are all expressed in human B cells, although the 
expression levels vary according to differentiation status 62. Upon ligand interaction, TLRs 
homodimerize or heterodimerize, which leads to activation of downstream signaling 
pathways and finally results in cytokine release and co-stimulatory molecule upregulation 
63. Upon activation most TLRs recruit the adaptor protein myeloid differentiation primary 
response 88 (MYD88), with the exception of TLR3 that is MYD88-independent 63. MYD88 
then activates the recruited interleukin-1 receptor-associated kinase (IRAK) family members 
by its own or in combination with an additional adaptor molecule toll-interleukin 1 receptor 
(TIR) domain-containing adaptor protein (TIRAP). IRAK1, IRAK2, and IRAK4 interact with the 
E3 ubiquitin ligase tumor necrosis factor receptor-associated factor 6 (TRAF6) 63. Interestingly, 
it was shown in macrophages that SYK is present in both TRAF3- and TRAF6-containing 
complexes, in which SYK has opposing regulatory roles 64. In addition, BTK interacts with 
four different proteins downstream of TLR (as outlined in Figure 3), i.e. directly downstream 
of the TLR by the interaction with the TIR domain of the TLR itself, with MYD88 and TIRAP, 
and also within the complex of the IRAK family members with IRAK1, thus underlining its 
importance in regulation of the TLR signaling pathway. Activation of this final complex results 
in IκB and MAPK activation and shuttling of the transcription factors NF-κB and AP-1 to the 
nucleus 65, 66. 
Taken together, it is clear that SYK and BTK occupy a crucial position in both BCR and 
TLR signaling in B lymphocytes and therefore interconnect these two signaling pathways. 
However, it is currently unknown how B cells integrate adaptive BCR and innate TLR activation. 
SIGNALING CASCADES IN CLL
BCR signaling in CLL
CLL B cells show aberrant BCR signaling, whereby differences are found between U-CLL 
and M-CLL. Because in CLL B cells chronic engagement of the BCR by self- or non-self-antigens 
is thought to occur in vivo (described above), surface expression of IgM is generally down-
modulated. Moreover, CLL B cells often show an anergic response and several of the kinases 
downstream of the BCR show aberrant expression levels or constitutive activation.
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The tyrosine kinases LYN and SYK are overexpressed and constitutively phosphorylated 
67, 68. Both expression and phosphorylation of SYK correlate with disease prognosis, 
being higher in U-CLL than in M-CLL 68, 69. In addition, there is clear evidence for a role of 
constitutively activated PI3K, particularly the PI3Kδ isoform, in survival of CLL B cells 70. BTK 
expression levels are 2-3 fold increased in CLL 71, whilst BTK is constitutively phosphorylated 
in a substantial proportion of CLL cases 71, although its expression or activation cannot be 
correlated with prognosis 71. A crucial role for BTK in CLL leukemogenesis was confirmed in 
CLL mouse models, showing that either CLL-like disease did not develop in the absence of 
BTK 72, or that BTK inhibition significantly delayed the development of CLL 73.
Aberrant expression of the SYK-related tyrosine kinase ZAP70, which is normally expressed 
in T cells, where it signals downstream of the T cell receptor (reviewed in 74), is associated with 
U-CLL and an aggressive form of the disease 75. Surface expression of the cyclic ADP ribose 
hydrolase glycoprotein CD38 also differs between CLL samples, and its expression regularly 
coincides with ZAP70 expression 76, 77, 78, 79. CD38+ CLL cells have an increased BCR signaling 
capacity, as is revealed by increased Ca2+ influx upon anti-IgM stimulation, compared with 
Figure 3. Roles for BTK and SYK in toll-like receptor signaling . 
A schematic representation of the TLR signaling pathway. Upon TLR engagement, BTK interacting molecules TIRAP 
and MYD88 are recruited. Via interaction with a complex formed by IRAKs and TRAF6, which is stabilized by SYK, 
downstream activation of the transcription factor NF-κB is induced. For CLL, MYD88 mutations leading to aberrant 
activation of the pathway have been reported (see text for details). The kinases BTK and SYK, which are targeted by 
inhibitors described in this review, are indicated in red.
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CLL cells that do not express CD38 80. Furthermore, CD38 is not expressed homogeneously 
in all CLL cells of CD38+ cases, whereby CD38+ cells are thought to represent a proliferating 
compartment within a CLL clone 79, 80, 81. PLCγ2 phosphorylation levels are increased in CLL, 
compared with healthy donor B cells 82 and this signal transducer is clearly activated in CLL 
B cells following BCR stimulation 83. ZAP70 expression in CLL is known to enhance PLCγ2 
phosphorylation upon BCR stimulation 84. Recently, evidence was provided that primary CLL 
cells generally show a higher basal Ca2+ signaling level than B cells derived from peripheral 
blood of healthy controls 29, 85. As discussed above, division of CLL samples on the basis of 
their IGHV gene SHM status revealed a significantly higher basal Ca2+ signaling level in the 
M-CLL subgroup compared with U-CLL. The degree of basal Ca2+ signaling did not correlate 
with other BCR characteristics, including Ig expression level, the length/ composition/charge 
of HCDR3, or FR2/FR3 sequences. It therefore appears that differences in basal Ca2+ signaling 
are directed by the SHM status of the CLL subgroup, reflecting e.g. a distinct cellular origin 
or a different anergic state induced by repetitive or continuous antigen binding in vivo 85. 
However, it remains possible that the observed differences in basal Ca2+ signaling between 
U-CLL and M-CLL are not directly related to their IGHV gene SHM status, but instead reflects 
differences in proximal BCR signaling pathways between the two CLL subgroups. 
The U-CLL and M-CLL subgroups also show differences in alterations in the activation of 
molecules that are positioned more downstream in the BCR signaling cascade, including ERK, 
NF-κB and NFAT 69, 86. Constitutive phosphorylation of ERK was found to be associated with 
NFAT activation and translocation to the nucleus and as a consequence a higher anergic state 
86. Interestingly, it was recently reported that even though phosphorylated ERK (p-ERK) levels 
are quickly upregulated upon BCR ligation in M-CLL, there is also rapid loss of the signal, while 
in U-CLL ERK activation is higher and more prolonged. This finding of enhanced intensity 
and duration of p-ERK activation in U-CLL supports the idea that U-CLL cells may be better 
equipped to transmit BCR-derived signals and thus be more responsive to BCR activation 
compared with CLL cells from M-CLL cases, which appear to be more anergic 17. Moreover, 
pronounced ERK activation in M-CLL required simultaneous BCR and TLR stimulation, while 
for U-CLL monovalent stimulation was sufficient to induce pronounced p-ERK induction 87.
Mutations in BRAF in CLL are considered as one of the early driver mutations that play a 
role in disease onset 88, even though they have only been found in ~3% of CLL patients 88, 89. 
The most commonly found BRAF mutation in other cancers (V600E) is rarely found in CLL. 
BRAF mutations in CLL concern recently described mutations that target amino acids in the 
P-loop of this kinase. An example is the BRAF-G469R mutation, which leads to constitutive 
activation of ERK, although weaker than activation induced by the V600E mutation 88. In a 
recent report, a melanoma patient with a BRAF-V600E mutation who was treated with the 
specific BRAF inhibitor, vemurafinib, was found to develop CLL within 3 months of therapy 
induction. An increase in p-ERK was seen in the CLL cells of the patient. This seems paradoxical 
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because BRAF inhibition is expected to result in reduced ERK activation. However, upon 
constitutive SYK activation, as is often seen in CLL, the BRAF inhibition was overcome via 
RAS, resulting in increased ERK activation and disease onset 90. RAS mutations, both in NRAS 
and KRAS, are found in ~3 % and ~2% of CLL patients, respectively 5; however, their functional 
role in altering BCR signaling in CLL is so far unknown. Recently, inactivating mutations of the 
NF-κB inhibitor epsilon (NFKBIE) were identified in 7-10% of CLL patients and were more 
often found in U-CLL and associated with poor outcome of disease 88, 91. Since NFKBIE binds 
to NF-κB components, thus trapping the complex in the cytoplasm and preventing it from 
activating genes in the nucleus, the identified inactivating mutations might lead to release 
of NF-κB towards the nucleus 88, 91. Finally, NF-κB activation was found to be higher in U-CLL 
than in M-CLL 69 and is associated with increased survival of CLL cells 92. 
Taken together, these findings demonstrate that downstream BCR signaling is dissimilar 
between U-CLL and M-CLL, which could at least partly explain the more aggressive behavior 
of U-CLL and the milder form in M-CLL associated with a higher anergic state. Moreover, 
the expression or activation status of BCR signaling molecules and CD38 have prognostic 
impact, because they affect – in conjunction with genetic abnormalities in CLL and the BCR 
mutation status – the initiation, accumulation or expansion of CLL clones. It is to be expected 
that knowledge obtained from treatment of CLL patients with kinase inhibitors will provide 
crucial information how the BCR signaling contributes to clinical course and outcome of CLL.
Chemokine receptor signaling in CLL
The interaction with a supportive microenvironment in bone marrow and lymph nodes 
is essential for homing, survival and proliferation of CLL cells. Stromal cells, macrophages 
and nurse-like cells in these tissues provide signals via secretion of high levels of chemokines 
such as CXCL12 and CXCL13 93. Interaction with their respective corresponding chemokine 
receptors CXCR4 and CXCR5 on CLL cells is required for trafficking and homing. CLL cells 
actually have increased expression levels of these chemokine receptors 92, 93, 94, 95, 96. Activation 
of CXCR4 and CXCR5 results in ERK1/2 and STAT3 activation, which are both important for 
cell survival 97, 98. CLL cells themselves secrete high levels of the BCR signaling-dependent 
chemokines CCL3 and CCL4, which are important for interaction with T cells 99. As already 
described above for normal B cells (see also Figure 2), several kinases important for BCR 
signaling are important for chemokine receptor signaling in CLL cells as well. Especially, 
inhibition of BTK, SYK and PI3K kinases has shown this importance since lymphocytosis is 
induced in vivo, as will be further discussed below. 
 
TLR signaling in CLL
Recently, an activating mutation in the TLR signaling molecule MYD88, causing a L265P 
transition, was discovered to be present in ~3% of CLL cases, especially in M-CLL. It appeared 
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that this mutation induces activation of STAT3, IκBα, and NF-κB, via phosphorylation. In 
addition, an inactivating mutation in MYD88, E52DEL, was identified in two of 363 CLL 
patients 3, however the biological relevance of this mutation in CLL pathogenesis needs to 
be established. In another patient cohort which only included U-CLL and stereotypic subset 
#2 patients only 1% of patients showed MYD88 mutations 100. A newly published study 
showed that 4% of CLL cases have activating MYD88 mutations, and additionally identified 
mutations in TLR2 and IRAK1 which were activating or leading to truncations, respectively. 
The mutations found in the TLR pathway in this cohort were exclusively identified in M-CLL 
101. 
The L265P MYD88 mutation is identified to act as a driver mutation in CLL pathogenesis 
and its clonal evolution 5. This particular mutation is mostly found in M-CLL patients younger 
than ~50 years of age and with low CD38 or ZAP70 expression, and thus in patients with a 
favorable outcome of disease 102. The L265P MYD88 mutation is also detected in other B 
cell malignancies, including almost 80% of patients with Waldenström’s macroglobulinemia 
103 and a substantial fraction of activated B cell – diffuse large B cell lymphoma 104, which 
indicates the importance of this particular mutation in pathogenesis of several types of B 
cell malignancies next to CLL. Interestingly, these B cell malignancies parallel CLL in that BTK 
inhibition showed antitumor activity in clinical trials (see Hendriks et al. for review 105). On the 
basis of co-immunoprecipitation studies in Waldenström’s macroglobulinemia it has been 
proposed that the L265P MYD88 mutation preferentially binds and activates BTK, leading 
to enhanced survival through NF-κB activation. It is likely that this mechanism, which would 
interconnect BCR and TLR downstream pathways - is also active in L265P MYD88-expressing 
CLL cells. 
TARGETING SIGNALING PATHWAYS IN CLL MOUSE MODELS
Mouse models of human cancers provide a useful tool to elucidate the mechanisms that 
account for the natural history of the disease and evaluate the effect of different therapeutic 
approaches prior to human clinical trials. To date, various CLL-like mouse models have been 
generated using transgenesis and gene targeting approaches (see Simonetti et al. for an 
excellent recent review 106). Of these various CLL mouse models only the Eμ-TCL1 and IgH.
TEμ models showed complete disease penetrance (100%), with no obvious monoclonal B cell 
lymphocytosis stage preceding CLL development. Here we will discuss the characteristics and 
usefulness of these two CLL models for the study of human disease.
The Eμ-TCL1 mouse model was generated based on overexpression of TCL1 under the 
control of a VH promoter and the IGH intronic enhancer (Eμ) in the B cell lineage 107. The 
immunophenotypic profiling of Eμ-TCL1 mice revealed that these animals spontaneously 
2Targeting signaling pathways in chronic lymphocytic leukemia
40
develop hyperplasia of the CD5+IgM+ B cells, initially in the peritoneal cavity and then in 
lymph nodes, spleen, bone marrow and peripheral blood. Sequence analysis of BCR 
rearrangements from Eμ-TCL1 mice demonstrated a skewed murine VH repertoire with 
particular involvement of IGHV11, IGHV12 and IGHV4 gene families. Furthermore, analysis of 
IGHV gene SHM status demonstrated that TCL1-derived leukemias are identical and minimally 
divergent from germ-line sequences, similar to human U-CLL. The HCDR3s in Eµ-TCL1 mice 
are often long and contain multiple neutral tyrosine and serine residues. They also contain 
many (~55%) positively and negatively charged residues at or adjacent to the VH–D and D–
JH junctions, deriving from simple and complex rearrangement events including insertion of 
non-templated nucleotides 108. 
Since the Eμ-TCL1 mouse model stands very close to human CLL in terms of leukemia 
phenotype, antigen-receptor and disease course, it has been extensively used to study 
pathogenic mechanisms leading to CLL 106. Recently, it has been applied as a pre-clinical 
tool to investigate the efficacy and potential side effects of novel therapeutic agents. The 
Eμ-TCL1 leukemias have been tested for the effects of the BTK inhibitor, ibrutinib, or the SYK 
inhibitor, fostamatinib, (described below), following adoptive transfer in immunodeficient 
severe combined immunodeficiency or syngeneic mice respectively 109, 110. Both inhibitors 
delayed CLL disease progression in these adoptive transfer Eμ-TCL1 leukemia mouse 
models. Mimicking clinical observations in patients 61, 111, treatment of mice transplanted 
with Eμ-TCL1-derived leukemias with either ibrutinib or fostamatinib resulted in a transient 
increase in CLL numbers in the peripheral blood concurrently with a decreased tumor load 
in the spleen 109, 110. 
A second model, the IgH.TEμ CLL mouse model was generated based on sporadic 
expression of the SV40 T oncogene in mature B cells 112. SV40T is a potent oncogene able 
to transform many cell types and has been implicated in the etiology of various cancers, 
including B cell malignancies 113. Sporadic expression was achieved by insertion of a SV40 T 
antigen gene in opposite transcriptional orientation in the heavy chain locus between the 
IGHD and IGHJ regions, in the presence (IgH.TEμ) or absence (IgH.T) of an extra copy of the 
Eμ enhancer 112. Leukemic cells present in these mice displayed many characteristics also 
found in human CLL, in particular in U-CLL patients. At 6-9 months of age, most IgH.TEμ mice 
showed accumulation of a monoclonal CD5+IgM+ IgDlow B cell population. IGHV sequence 
analysis revealed preferential usage of unmutated VH11.2 and non-stochastic usage of D and 
J genes, strikingly similar to those observed in Eμ-TCL1 mice. Interestingly, unlike Eμ-TCL1 
mice, two VHJ558+ leukemias from IgH.TEμ CLL mice manifested extensive SHM, thereby 
providing an animal model for both U-CLL and M-CLL and demonstrating that pathways 
activated by the SV40 T antigen play important roles in CLL pathogenesis. The CDR3s of IgH.
TEμ mice were enriched for serine/tyrosine residues and contained multiple charged amino 
acids that might confer CDR3 flexibility and favor poly-reactivity.
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Furthermore, the IgH.TEμ CLL mouse model came up as the first mouse model to 
demonstrate the importance of BTK in CLL development. CLL formation was absent in BTK-
deficient IgH.ETμ mice 72. Conversely, transgenic overexpression of human BTK specifically 
in B cells under the control of the CD19 promoter (CD19-hBTK transgene) accelerated and 
increased CLL formation in IgH.TEμ mice. Increased CLL susceptibility of BTK-overexpressing 
B cells in IgH.TEμ; CD19-hBTK tumors was associated with frequent occurrence of CLL clones 
that expressed non-stereotypical BCRs. These BCR characteristics comprise of increased Igλ 
usage and the presence of long HCDR3 regions, frequently containing tyrosine stretches 
thereby substantiating contribution of BTK-mediated BCR signaling to CLL development 72.
In conclusion, due to complete disease penetrance and phenotypic relatedness of disease 
to CLL in humans, both Eμ-TCL1 mice and IgH.TEμ mice provide useful pre-clinical models for 
understanding the pathogenesis of CLL. In this regard, the Eμ-TCL1 mouse model has been 
extensively used in elucidating the functional role of specific molecules in the onset and 
progression of CLL in vivo in crosses of Eμ-TCL1 mice with several transgenic and knockout 
mouse models 106.
TARGETING OF SIGNALING PATHWAYS IN HUMAN CLL BY 
SMALL MOLECULE INHIBITORS
Components of the biologically relevant signaling pathways in CLL, as earlier described 
in this review, have become important innovative targets for therapy strategies over the last 
decade. To date, several of these small molecule kinase inhibitors are under investigation 
– either as a monotherapy or in combination strategies - in CLL patients and in patients 
with other types of B cell malignancies (outlined in Table 1). Impressive clinical results are 
obtained for several of these inhibitors which target signaling pathways, and these will be 
further outlined in this review. 
BTK inhibitor, ibrutinib 
Considering the significant expression levels and the important role of BTK in several 
signaling pathways implicated in CLL pathogenesis, BTK seemed an important target for 
CLL therapeutic intervention strategies. Ibrutinib (PCI-32765, Pharmacyclics), is an orally 
available potent inhibitor that irreversibly and covalently binds to the cysteine at position 
481 in the BTK kinase domain and thereby blocks its kinase activity. Although ibrutinib 
does not prevent Y551 phosphorylation of BTK by SRC-like kinases and SYK, it prevents BTK 
autophosphorylation at position Y223 114.
Ibrutinib was originally described in 2007 as one compound of a series of irreversible 
BTK inhibitors and its in vivo efficacy was first evaluated in a mouse model of rheumatoid 
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arthritis 114. It was subsequently reported that CD40- or BCR-activated CLL cells cultured 
in the presence of ibrutinib showed abrogated survival pathways, including ERK and PI3K 
signaling and NF-κB shuttling to the nucleus. Ibrutinib treatment increased apoptosis 
and resulted in a reduction in survival signals induced by the microenvironment, and in 
decreased interaction with stromal cells 71. In the Eµ-TCL1 mouse model of CLL, ibrutinib 
reduced disease progression and caused a transient early lymphocytosis (described above). 
Ibrutinib inhibits cell migration in response to tissue homing cytokines CXCL12 and CXCL13, 
consistent with a crucial role for BTK in chemokine-controlled B cell migration and homing 
59, and it reduces DNA synthesis 109. Ibrutinib was also found to reduce secretion of the BCR-
dependent chemokines CCL3 and CCL4 by CLL cells, both in vitro and in vivo 109. A more detailed 
explanation of the effects of ibrutinib on chemokine-controlled adhesion and migration of 
CLL cells was provided by De Rooij et al., who showed that the drug inhibits integrin α4β1-
mediated adhesion to fibronectin and VCAM1 60. Furthermore, ibrutinib prevented CXCL12-, 
CXCL13-, and CCL19-induced signaling, adhesion, and migration of primary CLL cells. These 
findings indicate that ibrutinib disables retention and homing of CLL cells in their growth- 
and survival-inducing microenvironment in lymph nodes and bone marrow, which might well 
explain the CLL regression observed in clinical trials 60. For MCL it was additionally shown that 
treatment with ibrutinib reduced the expression of the chemokine receptor CXCR4 on MCL 
cells, whereas lowered plasma chemokine levels were seen 115. It is thus likely that expression 
of CXCR4 will also be reduced in CLL upon treatment with ibrutinib. To date, little is known 
regarding the interplay between chemokine receptor signaling and BCR signaling during B 
cell activation. Therefore, it is not clear whether ibrutinib mainly acts directly on chemokine 
receptor signaling, or whether ibrutinib downregulates chemokine responsiveness more 
indirectly through its effect on BCR signaling (See Figure 2). In this context, it has been shown 
that BCR signaling strength can model CXCL13-mediated B cell migration, whereby strong 
BCR signals halt B cell migration and weak signaling allow B cells to migrate in response to 
CXCL13 116. Conversely, CXCL13/CXCR5 signaling may have costimulatory function in BCR-
triggered B cell activation. Because integrin-mediated adhesion plays a critical role in B cell 
activation, it is conceivable that ibrutinib may additionally act through effects on integrin 
activity (since BCR signaling also controls integrin α4β1 (VLA-4)-mediated adhesion of B cells, 
through SYK, BTK and PI3K) 117. 
In a first phase 1 clinical trial with various different relapsed/refractory B cell malignancies, 
including 16 CLL patients, it was observed that ibrutinib was safe and well-tolerated with 
mild-to-moderate toxicity. It showed a clinical response in these patients with an overall 
response rate (ORR) of 79% without any signs of progressive disease 118. Therefore, an 
additional phase 1b/2 study was started in 85 refractory and relapsed CLL patients, mostly 
having high-risk disease. Two different doses of ibrutinib were tested in this study, but 
no significant differences were found between the two groups in ORR, which was ~71%. 
Chapter 2
43
The observed responses were found to be independent of various adverse prognostic 
characteristics, including advanced-stage disease, the number of previous therapies, and 
presence of 17p/TP53 deletion. Notably, the ORR was dependent on IGHV mutation status: 
~77% and ~33% in U-CLL and M-CLL patients, respectively. Because an additional ~42% of 
M-CLL patients showed a partial response with lymphocytosis, inclusion of these patients 
would bring the ORR of MCLL close to that of UCLL 61. The observed progression free survival 
(PFS) rate was ~75% and the overall survival (OS) was ~83%, at 26 months after start of 
therapy, implying that durable remissions were seen in patients with relapsed/refractory 
CLL upon ibrutinib treatment 61. It was found in this phase 1b study that proliferation of 
CLL cells was directly inhibited by ibrutinib. Moreover, activities of BTK and PLCγ2 as well 
as downstream signaling molecules, AKT and ERK, were all coordinately downregulated 
over time. This strongly suggests that blocking proliferation via inhibition of BTK-mediated 
signaling may contribute to clinical responses in ibrutinib-treated CLL patients 119. Importantly, 
in CLL patients, ibrutinib induced a transient increase in blood lymphocyte levels, which 
coincided with a reduction in lymph node or spleen size. This asymptomatic lymphocytosis 
is explained by an inhibitory effect of ibrutinib on BTK function in chemokine receptor 
signaling, which causes re-distribution of CLL cells from the tissue compartments into the 
peripheral blood 120, 121. The ibrutinib-induced lymphocytosis resolved in most patients within 
eight months and developed at similar frequencies (~80%) in patients with U-CLL and M-CLL 
61. Nevertheless, in U-CLL patients, lymphocyte counts normalized more rapidly and more 
frequently. A fraction of CLL patients showed prolonged lymphocytosis, lasting >1 yr, but PFS 
was not reduced compared with CLL patients with limited or transient lymphocytosis. Thus it 
appears ibrutinib-induced prolonged lymphocytosis does not indicate a suboptimal response 
or early relapse 61, 73. 
Recently, the results of ~3 year follow-up of ibrutinib treatment were published 122. 
Patients who did not receive any other treatment on forehand, showed an ORR of ~84% 
(~23% and ~61% complete and partial response, respectively). Relapsed/refractory CLL 
patients showed an even higher ORR of ~90% (~7% complete and ~83% partial response). 
Three years after start of therapy both median PFS and median OS were not reached. It 
appears that prolonged ibrutinib treatment is well tolerated and induces increased and 
improved responses over time 122. This shows the potential of ibrutinib to improve quality 
of life of CLL patients for extended time, providing a significant advance in CLL treatment 
options. Moreover, the authors reported that toxicity associated with ibrutinib, including 
cytopenia, fatigue, diarrhea and infections, diminished with continued treatment. It 
is important to note, however, that in this study only a low number of high-risk patients 
with cytogenetic abnormalities (which may incidentally develop ibrutinib resistance, see 
below) were included 122. Recently, atrial fibrillation was reported as a potentially therapy-
limiting adverse effect occurring in ~3.5-~6.5% of ibrutinib-treated patients 122, 123. Although 
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BTK and its family member TEC kinase were found to be expressed in human heart tissue, 
further experiments are required to establish functional effects of ibrutinib on myocytes 123. 
Importantly, infectious complications with ibrutinib treatment are quite limited and might 
partially be related to the potential of ibrutinib to inhibit its TEC-family member interleukin-
associated T-cell kinase (ITK). ITK inhibition promotes T-helper-1 cell differentiation and was 
shown to diminish infection morbidity 124. Thus, it cannot be excluded that the usage of very 
specific BTK inhibitors that have limited specificity for related kinases might in this context 
even be disadvantageous.    
Relapses of ibrutinib monotherapy are very recently described and occur in approximately 
~5% of CLL patients, but the mechanisms of resistance are largely unidentified. One patient 
who first had a partial response after eleven months upon treatment with ibrutinib, showed 
a relapse at 21 months after treatment initiation. RNA sequencing revealed a thymidine-to-
adenine mutation at nucleotide 1634 of the BTK complementary DNA, leading to a C481S 
cysteine-to-serine mutation in BTK at the binding site of ibrutinib. Structural modeling 
suggested that the C481S mutation would change irreversible binding of ibrutinib to 
reversible binding and thereby allow BTK activation. The C481S mutation was detected in 
samples collected when progressive disease was first noted (~88% of reads) and before dose 
escalation (~92% of reads), but not in those collected before ibrutinib administration or while 
the patient was having a response. These findings strongly suggesting that the mutation 
was acquired during therapy 125. This was recently confirmed by highly sensitive molecular 
methods, showing that among CLLs not previously exposed to ibrutinib, the C481S variant is 
absent or undetectable 126. The BTK mutation leading to a C481S substitution was found in five 
additional relapsed CLL patients, using a whole exome sequencing approach. Furthermore, 
in ibrutinib-resistant patients three distinct mutations in PLCγ2 were identified. The R665W 
and L845F substitution mutations in PLCγ2 are both potential gain-of-function mutations 
that lead to autonomous BCR activity, whilst the mutation leading to S707Y substitution was 
previously described as an activating mutation. In this way, these PLCγ2 mutations are believed 
to overcome BTK inhibition 125. These mutations have been found in a minority of patients 
and therefore the vast majority of relapses upon ibrutinib treatment cannot be explained by 
these mutations alone. It is remarkable that resistance was particularly observed in patients 
with increased genomic instability, including those with del(17p13.1), del(11q22.3), or a 
complex karyotype 125. Therefore, patients with increased genomic instability may benefit 
most from combination therapies designed to limit development of ibrutinib resistance.
Collectively, these findings demonstrate that ibrutinib is a potent therapeutic agent for 
treating CLL as a monotherapy. However, relapses occur associated with mutations in BTK 
and PLCγ2. To date, it is unknown how frequently these mutations occur, and which other 
mechanisms of resistance may explain the cases not carrying a mutation in these two genes. 
Furthermore, it is not clear which combination therapy might best circumvent these events. 
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The first study in which ibrutinib was given in combination with rituximab (anti-CD20 
antibody) therapy showed that combination of these therapeutics is safe 127. It was 
additionally shown that the combination of ibrutinib and rituximab induced responses 
in a large proportion of patients with high-risk CLL. Responses were durable, and ~78% 
of patients were free of disease progression and OS at 18 months was ~84% 127. One of 
the most notable findings in this study was the short duration of ibrutinib-associated 
redistribution of lymphocytosis. Fewer patients had persistent lymphocytosis than with 
single-agent treatment, likely caused by the addition of rituximab 127. Collectively, these data 
show promise for the use of ibrutinib in combination with other treatment strategies, as is 
currently being further investigated. Likewise, a recent Phase 1b study showed that ibrutinib 
enhanced the efficacy of immunochemotherapy (with rituximab and bendamustine or with 
fludarabine, cyclophosphamide, and rituximab), without additive toxicities 128. Because the 
response rates to ibrutinib in combination with bendamustine and rituximab were higher 
than to ibrutinib alone, it now becomes important to assess overall safety and efficacy 
profiles of combination therapies in clinical trials, particularly given the additional toxicity 
of chemotherapy. For instance, the combination of rituximab and bendamustine with the 
addition of ibrutinib or a placebo is currently investigated in relapsed/refractory CLL patients 
in phase 3 trials 128, 129.
SYK inhibitors (fostamatinib, entospletinib, P505-15, and PRT318)
SYK plays an important role in BCR-mediated survival and is constitutively activated in CLL 
68, 130. Kinase activity of SYK leads to the assembly of the BCR micro-signalosome by connecting 
SLP65, BTK and PLCγ2 (see Figure 1). Moreover, inhibition of SYK signaling prevented CLL cells 
from interacting with the microenvironment and promotes apoptotic signals 68, 131. Therefore, 
targeting SYK represents a promising therapeutic approach for CLL treatment.
It has been demonstrated that the SYK inhibitor, fostamatinib (R788, Astra Zeneca/Rigel 
Pharmaceuticals), decreases phosphorylation of the proximal BCR signaling regulators SLP65 
and PLCγ2, as well as key players in more downstream pathways such as ERK, AKT, and NF-κB. 
Fostamatinib - a pro-drug which is converted to an active drug, R406 with activity against 
SYK 132 – is the first oral SYK inhibitor in development as a novel therapeutic approach for 
lymphoid malignancies. Fostamatinib effectively inhibits BCR signaling in vivo, resulting in 
reduced proliferation and survival of CLL cells and significantly prolonged survival of Eµ-TCL1 
mice 110. In fact, fostamatinib was initially developed for treatment of autoimmune disease; 
in a phase 2 study in rheumatoid arthritis patients SYK inhibition by fostamatinib reduced 
disease activity, although substantial adverse effects were observed 133. In the first phase 
1/2 clinical trial investigating fostamatinib in relapsed B-cell NHL and CLL, clinical efficacy 
was noted in a variety of B cell malignancies with the highest response rate observed in 
CLL/SLL patients 134. Sixty-eight patients with various recurrent B cell malignancies were 
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treated with fostamatinib in a phase 2 study. The highest response rate (~55%) was observed 
in patients with SLL/CLL, and their median PFS was 6.4 months. Common toxicities observed 
in this study included diarrhea, fatigue and cytopenia 134, which might be related to off-target 
activity against related kinases, including Fms-like tyrosine kinase (FLT3), Janus-like kinases 
(JAK) or lymphocyte-specific protein tyrosine kinase (Lck). All treated CLL patients had 
increased peripheral blood lymphocyte counts in the first period after treatment initiation, 
which showed that the effects of SYK inhibition were not limited to BCR signaling. Indeed, 
it was found that SYK inhibition also affected expression of CCL3 and CCL4 in nurse-like cell 
co-cultures and its sensitivity to chemotaxis by CXCR4 and CXCR5 68, 99. 
Entospletinib (Gilead Sciences, Inc.) is another SYK inhibitor that is highly selective 
and orally efficacious and under clinical evaluation for CLL patients 135. In a phase 2, open-
label, single-arm safety and efficacy study entospletinib was evaluated in a cohort of 41 
patients with relapsed/refractory CLL. The estimated PFS rate was ~70% at 24 weeks after 
start of therapy, and the ORR was ~61%, which only included partial responses. Most of 
the evaluable patients (~95%) experienced a reduction in tumor size, including all patients 
with a 17p deletion/TP53 gene mutation, or with other genetic abnormalities linked to poor 
prognosis. Additionally, ~62% of the evaluable patients showed a tumor reduction of at least 
~50% 136. Additionally, an in vitro study in CLL samples showed that entospletinib reduced 
AKT phosphorylation, and that this agent in combination with the PI3Kδ inhibitor, idelalisib 
(discussed below) showed synergistic inhibition of CLL cell viability and disrupted BCR and 
chemokine receptor signaling, compared to its use as single agent 137. To obtain more insight 
into the clinical effects of entospletinib, evaluation will be required in a larger series of CLL 
patients as is currently being performed.
Recently, preclinical characteristics of two novel small molecule SYK inhibitors, P505-15 
and PRT318 (both Portola Pharmaceuticals), were evaluated. In contrast to fostamatinib, 
which is relatively non-specific, these novel inhibitors are highly selective, as e.g. P505-15 
(also known as PRT062607) has an anti-SYK activity that is >80-fold higher than its affinity 
for other kinases. Both P505-15 and PRT318 effectively decreased CLL viability after BCR 
stimulation and in nurse-like cell co-cultures. Parallel to previous findings for fostamatinib 
also secretion of CCL3 and CCL4 and migration towards the CXCL12 and CXCL13 chemokines 
was inhibited 132. Oral administration of P505-15 produced dose-dependent anti-
inflammatory activity in rodent models of rheumatoid arthritis 138, whereas in a xenograft 
model in mice this compound prevented BCR-mediated splenomegaly 139. Treatment of 
primary CLL cells with P505-15 in vitro resulted in a concentration-dependent decrease in 
AKT phosphorylation. Although P505-15 manifested modest single agent activity against CLL 
survival, the compound was synergistic with fludarabine at nanomolar concentrations, which 
is important given the dose-limiting toxicity associated with fludarabine treatment 139. 
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Taken together, the reported results of the first clinical studies of the SYK inhibitors, 
fostamatinib and entospletinib, in CLL indicate that the observed ORRs are slightly lower 
(~55% and ~61% respectively) than those found for ibrutinib and idelalisib (see below), 
which were ~70%. However in-depth comparisons of the various clinical trials of individual 
inhibitors is complicated by differences in patient inclusions, e.g. proportions of patients 
with high-risk patients with cytogenetic abnormalities, treatment history or age, and 
variation in follow-up time. So, it remains possible that the ORRs with SYK inhibitors in CLL 
are not that different from those with BTK or PI3Kδ inhibitors. The preclinical studies on 
novel SYK inhibitors, P505-15 and PRT318, provide a strong basis for clinical development 
of these novel compounds in CLL, next to the traditional SYK inhibitors, fostamatinib and 
entospletinib. Particularly, since an optimal treatment strategy for an individual patient is 
not only determined by the observed ORRs for a particular inhibitor, but also depends on 
how well the therapy is tolerated, the observed quality of life improvement and whether the 
patients develops resistance. 
PI3K inhibitor idelalisib (CAL-101, GS-1101)
Expression of PI3Kδ is restricted to cells of hematopoietic origin, whereby in B cells it plays 
a key role in proliferation and survival. As mentioned above, the PI3K pathway is constitutively 
activated in CLL and this is dependent on PI3Kδ 70. The highly-selective oral PI3Kδ inhibitor, 
idelalisib (CAL-101, GS-1101, Calistoga Pharmaceuticals) stimulated apoptosis in primary CLL 
cells ex vivo in a dose- and time-dependent manner, which was shown to be independent of 
IGHV mutational status or recurrent cytogenetic aberrations. Idelalisib-mediated cytotoxicity 
induced an increase in caspase activity which was not rescued by co-culture on stromal cells. 
Additionally, idelalisib abolished normal CLL cell protection from spontaneous apoptosis 
induced by B cell-activating factors like CD40L, or other signals from the microenvironment 
70. Similar to ibrutinib and SYK inhibitors, also idelalisib inhibits CLL cell chemotaxis towards 
CXCL12 and CXCL13, and induces downregulation of chemokine secretion. CAL-101 was 
shown to inhibit BCR- and chemokine-receptor-induced AKT phosphorylation, ERK activation 
and survival signals 140. In a phase 1 trial idelalisib was evaluated in 54 patients with relapsed/
refractory CLL with various adverse prognostic characteristics including unmutated IGHV 
status (91%), and del17p and/or TP53 mutations (24%) 141. The patients were treated with 
different dosage levels of oral idelalisib and remained on continuous therapy while showing 
clinical improvement. Similar as was shown ex vivo for CLL cells, inhibition of PI3Kδ abolished 
AKT phosphorylation in patient CLL cells, and significantly reduced serum levels of chemokines 
related to CLL such as CCL3, CCL4, CCL17 and CCL22. Idelalisib induced clear reductions in 
lymph node and spleen size and lymphocytosis was observed in the patients already a few 
hours after the initiation of the treatment. The most commonly observed adverse events 
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were pneumonia, neutropenic fever and diarrhea. The ORR was 72%, and a median PFS for 
all patients was 15.8 months, demonstrating the clinical efficacy of idelalisib 141. 
In a multicenter phase 3 study, which was performed in a randomized, double-blind, and 
placebo-controlled manner, the efficacy and safety of idelalisib in combination with rituximab 
was assessed 142. Two-hundred-and-twenty CLL patients were included, with advanced stage 
disease of which a part was in a poor condition with renal dysfunction, previous therapy-
induced reduced bone marrow function, or major coexisting diseases. The patients received 
rituximab and either idelalisib or placebo. PFS at 24 weeks after treatment initiation was 
~93% in the idelalisib treated group and ~46% in the placebo group. Because of this large 
efficacy differences between the two patient groups, the study was stopped before its end 
point was reached. The observed ORR were ~81% in the patients receiving idelalisib versus 
~13% in the placebo group, of which all were considered as partial responses. The idelalisib 
related lymphocytosis which was seen in the phase 1 study 141, appeared to be less profound 
and shorter in duration when combined with rituximab 142, parallel to observations in the 
study in which ibrutinib was combined with rituximab 127. 
Taken together, the reported clinical data convincingly show that idelalisib treatment 
induces an impressive response in CLL patients, without causing significant toxicity, 
particularly in a combination therapy strategy with rituximab. 
So far it is not known whether idelalisib treatment can induce mutations in PI3Kδ or 
other downstream targets, as it is known for ibrutinib where BTK and PLCγ2 mutations were 
identified in relapsed patients. In vitro data in MCL cell lines and primary CLL cases showed an 
synergistic effect by the combined usage of ibrutinib and idelalisib in induction of apoptosis, 
even with lower dosage than used for therapy. This combination might be a good option to 
prevent relapses as can be seen when used as single agents, whilst the usage of a lower dose 
could prevent therapy- induced toxicity 143.
A recent publication compared the pan-PI3K-inhibitor, BKM120 (Yamanouchi 
Pharmaceuticals, Piramed Pharma, and Genentech) with idelalisib with respect to the effect 
on CLL cell function in vitro. It was shown that BKM120 had an almost 4-fold higher toxicity 
for CLL cells than idelalisib. Furthermore, BKM120 induced apoptosis in CLL cells which could 
not be prevented by rescue through signals from stromal cells 144. In line with this, it was 
recently described that in CLL cells BMK120 decreases PIP3 levels, AKT phosphorylation, and 
FOXO3a phosphorylation 145. The latter regulates expression of the pro-apoptotic protein 
BIM, which is indeed upregulated and goes along with increased apoptosis in CLL cells These 
results show that BKM120 could have clinical impact for treatment of CLL, which should be 
further investigated in vivo. A phase 1 study for usage of BMK120 in patients with advanced 
stage solid tumors, showed that the use of this inhibitor is safe and that it is well tolerated, 
although dose-limiting toxicities were reported; furthermore a clinical response leading to 
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stable disease was seen in ~58% of included patients 146. This appears a good starting point 
to investigate the effect of BMK120 in CLL patients. 
Src-family tyrosine kinase inhibitor (dasatinib)
The Src-family tyrosine kinase inhibitor, dasatinib (Sprycell, Bristol-Myers Squibb), is 
derived from an aminothiazole, and was found to bind Abl tyrosine kinase with an affinity 
>100-fold that of imatinib mesylate. Therefore it was initially developed as therapeutic agent 
for chronic myeloid leukemia (CML) 147. After successful clinical trials, dasatibib received 
FDA approval in 2006 for the treatment of imatinib-resistant CML. Additionally, dasatinib 
appeared to be a potent inhibitor of LYN, and was found to induce apoptosis in CLL cells 
with a higher sensitivity for U-CLL 148. Targeting LYN with dasatinib in a transplantable mouse 
model with Eμ-TCL1-derived CLL-lice cells delayed CLL progression 149. In a phase 2 clinical 
trial for dasatinib treatment in relapsed/refractory CLL, only partial responses were observed 
in three of fifteen treated patients, and nodal responses (~50% reduction) together with 
lymphocyte responses (>50% reduction) were observed in four of these fifteen patients. 
This indicated some effectiveness in patients with relapsed/refractory CLL, however the 
majority of patients included showed no clinical response 150. In another phase 2 study, in 
which dasatinib was given in combination with fludarabine, twenty fludarabine-refractory 
CLL patients were enrolled 151. From these, eighteen patients were assessable for response, 
and although the ORR was ~18%, three patients showed a partial response, with nodal 
responses and a reduction in lymphocyte count, and twelve patients showed stable disease. 
In ~61% of the patients lymphocytosis was observed shortly after treatment initiation. So, 
in fludarabine refractory CLL patients, a combination of fludarabine with dasatinib shows 
no obvious clinical efficacy 151. These results indicate that to date dasatinib is not a very 
promising treatment option in CLL.
 
AKT inhibitor (perifosine)
The alkylphospholipid perifosine (Aeterna Zentaris) inhibits the phosphorylation of AKT by 
preventing membrane localization of AKT and thereby interfering in the interaction between 
PI3K and AKT 152. In vitro assays showed cytotoxicity in CLL cells induced by perifosine in a 
dose-dependent manner. In a phase 2 clinical trial perifosine was evaluated as monotherapy 
for CLL 152. All sixteen included patients had aggressive form of disease. Although initially 
perifosine mainly stabilized disease in the heavily pretreated and highly refractory population 
of CLL patients studied, the median overall survival was 9.7 months. Remarkably, AKT 
phosphorylation in CLL lymphocytes from treated patients was not correlated with response. 
Thus, despite the in vitro induced cytotoxicity, there was no clinical response observed in 
CLL patients by perifosine 152. However, perifosine may have potential as part of combination 
regimen as was shown in a phase 1/2 study where it was investigated in combination with 
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proteasome inhibitor, bortezomib, and with or without dexamethasone in patients with 
relapsed or refractory multiple myeloma. From the 84 patients enrolled in this study, 73 
were evaluable for response of which 41% showed an ORR with 4%, 19% and 18% showing 
a complete response, median response, or partial response, respectively 153. Taken together, 
compared with other novel inhibitors perifosine monotherapy currently does not appear a 
good treatment option for treatment of CLL patients. Nevertheless, it remains possible that 
subgroups of patients may benefit from perifosine in combination therapy strategies.    
CONCLUSIONS AND PERSPECTIVE
Targeting of kinases with essential roles in signaling pathways have shown impressive 
efficacy as therapeutic option for CLL in various clinical trials. These studies also confirm 
that BCR and particularly chemokine receptor signaling are critical for CLL. The BTK inhibitor, 
ibrutinib, SYK inhibitors, fostamatinib and entospletinib, and PI3K inhibitor, idelalisib, have 
shown significant effects when used as single-agent therapy. Currently a large number of 
clinical trials are ongoing to investigate efficacy of these inhibitors in combination therapy 
strategies. This might circumvent the induction of mutations that either alter the binding 
site of the inhibitor or cause gain-of-function of other signaling molecules, thus leading to 
resistance, as has already been described for ibrutinib 125. To date, the frequency of such 
events is not known but may be quite low inferred from the low number of cases described 
so far. 
Given the various targets of these novel therapies, choosing the right treatment regimen 
for a given CLL patient has become a task that requires experience, a good clinical assessment 
of the patients, as well as careful evaluation of the responses and resistance development in 
CLL patient subgroups in the ongoing clinical trials. Because the individual kinase inhibitors 
are in different stages of clinical evaluation, it is currently difficult to make fair comparisons 
and to establish if one inhibitor should be preferred over another. Moreover, the design of 
new treatment strategies will depend on detailed analyses of clinical responses, resistance 
development, toxicity and quality of life for individual inhibitors in combination therapies in 
relation to CLL patient subgroups. Furthermore, effective CLL treatment should take notice 
of the disease complexity that depends on signaling within the microenvironment, where 
targeted drugs need to act against. Also, based on the rapidly increasing knowledge on 
biological variation in human CLL, it will become important to select the correct subgroups 
of CLL patients that would benefit from a particular drug combination. In this context, next-
generation sequencing analyses will provide information about genetic heterogeneity in CLL 
that is invaluable to optimize treatment regimens for individual CLL patients. Future pre-
clinical research, both in animal models and in human in vitro cell systems, should provide 
Chapter 2
53
the necessary (new) mechanistic insights to understand the interaction of CLL cells with 
their microenvironment. It is expected that these novel agents will translate into innovative 
therapies that will eventually take control of a thus far incurable disease.
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ABSTRACT
On the basis of somatic hypermutation status of their B-cell antigen receptor (BCR) genes, 
chronic lymphocytic leukemia (CLL) patients can be divided into unmutated CLL (U-CLL) or 
mutated CLL (M-CLL). Approximately 30% of CLL patients express a stereotypic BCR, which 
may indicate that specific antigenic stimulation is driving CLL pathogenesis. Recently it was 
reported that BCRs from CLL cells are capable of antigen-independent, cell-autonomous 
signaling, through recognition of an internal framework 2 (FR2) BCR epitope. We hypothesized 
that the level of cell-autonomous signaling may differ between CLL subgroups. Therefore, we 
analyzed Ca2+ signaling in a series of primary stereotypic or heterogeneous U-CLL and M-CLL 
(n=68) and healthy controls (n=14). We confirmed that basal Ca2+ signaling in CLL cells is 
higher than in normal B cells. Interestingly, we found that basal signaling was particularly 
increased in M-CLL. The degree of basal signaling did not correlate with membrane Ig levels, 
HCDR3 characteristics, or FR2 / FR3 sequence. We conclude that the level of basal Ca2+ 
signaling is not uniformly enhanced in CLL B cells, but is associated with CLL IGHV mutational 
status, reflecting a distinct cellular origin and possibly a different anergic state induced by 
repetitive or continuous antigen binding in vivo.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by monoclonal expansion of 
mature CD5+ CD19+ B lymphocytes, and is the most common type of leukemia in the elderly 
in the Western world1. On the basis of the somatic hypermutation status (SHM) of the 
immunoglobulin heavy chain V (IGHV) genes, CLL can be divided in unmutated CLL (U-CLL) 
and mutated CLL (M-CLL). This division is clinically relevant because U-CLL has an unfavorable 
prognosis, with a more aggressive disease course and shorter time to first treatment, while 
M-CLL represents a more indolent form of the disease with a more favorable prognosis2, 3.
Over 30% of all CLL cases can be grouped on the basis of their restricted IGHV/IGHD/
IGHJ gene usage, similarities of the length and amino acid sequence of the complementarity 
determining region 3 (CDR3)4. These so-called stereotypic B cell receptors (BCR) are 
found in different CLL patients. This stereotypy indicates involvement of similar antigens, 
thus implicating antigenic stimulation and BCR specificity in CLL pathogenesis4. Indeed, 
several lines of evidence support the important role of antigen-driven BCR signaling in the 
pathogenesis of CLL. In general, most U-CLLs express polyreactive, low affinity BCRs, which 
recognize self- and non-self antigens, such as DNA, insulin, LPS, apoptotic cells, vimentin, 
myosin heavy chain 2A (MYH2A), and phosphorylcholine-containing antigens like oxidized 
LDL5, 6, 7, 8.
For several of the major stereotypic subsets the target antigen has been identified. Many 
of these are poly- or autoreactive and bind to antigens expressed by apoptotic cells. BCRs from 
stereotypic subset #1 are found to target oxidized LDL6, 8, 9. Stereotypic subset #2 is able 
to bind to protein L, a cell-wall protein of the commensal gut bacterium Peptostreptococcus 
magnus10 and cofilin 18. Recent reports demonstrated that two stereotypic M-CLL subsets 
have rheumatoid factor activity and show specificity for the Fc-tail of IgG11, 12. Stimulation 
of these stereotypic CLL cells with IgG results in proliferation11. Another recent study 
describes a stereotypic M-CLL subset with IGHV3-7 usage with an extremely short CDR3, 
which is highly specific for β-(1,6)-glucan. This is a potent antigenic factor found in yeast and 
filamentous fungi that induces proliferation of CLL cells expressing this particular stereotypic 
BCR13. Collectively, these data support an important role of antigen-driven BCR signaling in 
the pathogenesis of CLL.
Contrary to these studies, Dühren – von Minden et al. showed that CLL BCR can be 
stimulated independent of external antigens, because their CDR3 regions recognize an 
internal epitope in framework 2 (FR2) of IGHV14. This recognition induces a higher level 
of antigen-independent, basal or ‘autonomous’ signaling of the BCR as demonstrated by 
increased cytoplasmic Ca2+ levels. These observations were primarily made in an in vitro 
assay using triple knockout (TKO) cells, which are BCR-free, conditionally signaling-competent 
mouse B-lineage cells. Upon transfection of human CLL-derived BCRs (or CDR3s) higher basal 
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Ca2+ signaling was observed, while other B cell lymphoma-derived BCRs needed crosslinking 
for signaling14. Recently, another internal epitope in FR3 of both IGHV and light chain V genes 
was identified15.
Collectively, these findings fueled the controversy whether antigen-dependent or 
autonomous stimulation would be important in CLL pathogenesis. We hypothesized that 
these apparently contrasting observations may not be mutually exclusive, as the level of 
cell-autonomous signaling could be different between immunogenetic CLL subgroups. We 
therefore analyzed Ca2+ signaling in a large series of primary CLL samples consisting of U-CLL 
and M-CLL with stereotypic or heterogeneous BCRs.
MATERIALS & METHODS
Patients and healthy controls
Primary patient material was obtained from CLL patients, whilst the material from healthy 
controls (mostly >50 years of age) was obtained via Erasmus MC and via Sanquin blood bank 
(Rotterdam). Diagnostic and control samples were collected upon informed consent and 
anonymized for further use, following the guidelines of the Institutional Review Board, and 
in accordance with the declaration of Helsinki.
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Hypaque (GE 
Healthcare, Little Chalfont, United Kingdom) according to the manufacturer’s instructions, 
and were either stored frozen or used freshly. For Ca2+ flux assays, CLL cells were isolated by 
depleting other cell types from PBMCs using the B-CLL isolation kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) and MACS (Miltenyi Biotec). When enough PBMCs were obtained 
from healthy controls, B cells were isolated using the B cell isolation kit (Miltenyi Biotec); 
alternatively, whole PBMC fractions were used for Ca2+ flux analyses. The purity of both the 
CLL and healthy control B cell samples was >95% as determined by flow cytometry on the 
LSRII (BD Biosciences, San Jose, California, USA). CLL samples were also evaluated for IgM, 
IgD, and IgG expression by flow cytometry. Normal B cells were analyzed for CD5 expression.
IGHV sequence analysis
Genomic DNA was extracted from PBMCs with use of spin-column kits and QIAcube 
(QIAGEN, Valencia, California, USA). Primers and protocols for IGHV mutation status analysis 
were used according to the BIOMED-2 protocol and following ERIC guidelines16, 17. In brief, 
PCR products were analyzed by electrophoresis on polyacrylamide gels for monoclonality, 
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followed by direct sequencing. Sequencing results were analyzed online by use of IMGT/V-
QUEST on the IMGT website (www.imgt.org version 3.2.32).
Phylogenetic analysis of IGHV gene sequences
The phylogenetic relationships of CDR3, FR2, and FR3 IGHV gene sequences were 
estimated based on the pairwise matrix of sequence divergences calculated by the online 
tool Clustal W. using neighbor joining algorithm (http://www.genome.jp/tools/clustalw/)18. 
Visualization of MFI ratio of calcium influx as heatmap was created using the Spotfire analysis 
software19.
Ca2+ flux assay
Intracellular Ca2+ fluxes were measured using the Fluo3-AM and Fura Red-AM fluorogenic 
probes, both purchased from Molecular Probes (Life technologies). In brief, CLL cells and B 
cells or PBMCs from healthy controls were incubated with 5 μM Fluo3-AM and 5 μM Fura 
Red-AM in loading buffer (HBSS medium supplemented with 10 mM HEPES and 5%FCS) at 
30°C for 30 minutes in the dark. To gate B cells in PBMCs from healthy controls, we added 
CD20 APC-H7 and CD3 APC for the final 10 minutes of incubation. Cells were then washed 
and resuspended in buffer (HBSS medium with 10 mM HEPES, 5%FCS and 1 mM CaCl
2
) at 
room temperature. Cells were warmed to 37°C for 5 minutes before acquisition of events. 
Basal intracellular Ca2+ levels were measured for 60 seconds, followed by stimulation of the 
BCR with 35 μg/ml anti-human IgM (Jackson Immunoresearch Laboratories, West Grove, 
Pennsylvania, USA), or 5 μg/ml anti-human IgD, or 10 μg/ml anti-human IgG (both Southern 
Biotec, Birmingham, Alabama, USA). At the end of each Ca2+ measurement, the cells were 
stimulated with 2 μg/ml Ionomycin (Life technologies, Carlsbad, Californa, USA) to measure 
maximum Ca2+ signaling. Data were acquired on an LSRII flow cytometer (BD Biosciences) and 
data analysis was performed with the use of FlowJo software (Tree Star, Ashland, Orlando, 
USA). 
Statistical analyses
Statistical analysis was performed using GraphPad Prism software (San Diego, California, 
USA). For overall subgroup analysis, we used the Kruskal-Wallis test for nonparametric 
testing. When 2 groups were compared, the Mann-Whitney U test for nonparametric testing 
was used. To study the relation between variables we used linear regression analysis.
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RESULTS
Basal Ca2+ signaling is highest in primary M-CLL
CLL-derived BCRs have been demonstrated to induce higher basal Ca2+ signaling than BCRs 
derived from primary B cells14. We wondered if the same phenomenon could be observed 
in a cohort of primary CLL samples. To this end we selected 68 primary CLL cases (Table 1) 
and compared the Ca2+ signaling of the CLL cells with that of peripheral B cells derived from 
healthy controls (n=14). We chose to use the total normal B cell population for the analyses, 
because we did not see any difference in basal Ca2+ signaling between CD27- naive and 
CD27+ memory B cells, nor between CD5- and CD5+ B cells (Figure S1). Many of the primary 
CLL samples contained cells that demonstrated high basal Ca2+ signaling levels (Figure 1A). 
Within the total CLL cohort, both U-CLL (≥98% IGHV germline identity) and M-CLL (<98% 
identity) samples demonstrated significantly higher basal Ca2+ signaling levels than normal 
B cells (Figure 1B). Importantly, M-CLL had significantly higher average basal Ca2+ signaling 
levels than U-CLL (Figure 1B,C).
To identify how basal Ca2+ signaling varied within immunogenetic CLL subgroups, we 
made a further subdivision of U-CLL and M-CLL into stereotypic and non-stereotypic 
(heterogeneous) subgroups. No significant differences in Ca2+ levels were found between 
stereotypic and heterogeneous subgroups (Figure 1D). Basal Ca2+ levels in heterogeneous 
M-CLL samples were significantly higher than in stereotypic U-CLL, whereas the differences 
seen between heterogeneous U-CLL vs M-CLL (stereotypic or heterogeneous) were not 
significantly different. Finally, although some CLLs belonging to the same stereotypic subset 
showed very similar basal Ca2+ levels, no clear correlation was found between individual 
stereotypic CLL subsets and basal Ca2+ signaling levels (Figure 1D). 
Collectively, these results demonstrate that primary CLL cells indeed have higher basal 
Ca2+ signaling levels than B cells from healthy controls, whereby this increase is higher in 
M-CLL than in U-CLL. 
Basal Ca2+ levels are not associated with BCR characteristics or cytogenetic 
aberrations
CLL cells typically show a low level of BCR surface expression, although these levels can 
vary20. Therefore, we analyzed whether cell surface IgM and IgD expression levels correlated 
with the levels of basal Ca2+ signaling in CLL. Despite an overall reduced surface Ig expression 
when compared with normal B cells, we did not find any relation between high or low basal 
Ca2+ signaling levels in CLL and IgM (Figure 2A) or IgD (Figure 2B) surface expression levels. 
Upon exclusion of outliers with relatively high IgM and IgD expression, we did not find any 
correlations either (data not shown). Furthermore, Ig kappa vs Ig lambda light chain usage 
also did not correlate with basal Ca2+ signaling levels (data not shown). 
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Figure 1. Ca2+ flux assays in primary CLL samples and normal human B cells. 
A. Representative dot plots of Ca2+ flux assays of representative samples from a healthy control, U-CLL (sample 
30), and M-CLL (sample 23). BCR stimulation was performed after 60s, and stimulation with ionomycin after 480s 
(indicated with arrows). The duration of the total Ca2+ flux assays was 600s. B. Median fluorescence intensity (MFI) 
kinetics plot of Ca2+ signaling in representative healthy control, U-CLL (sample 30) and M-CLL (sample 23) samples. 
C. Basal Ca2+ signaling in U-CLL (n=34) and M-CLL (n=34) cases compared with B cells from healthy controls (n=14). 
D. Basal Ca2+ signaling in CLL samples from specific immunogenetic subgroups. Overall significance was determined 
with the Kruskal Wallis test. Significance between two groups was determined with the Mann-Whitney U test. ** P 
< 0.01 **** P< 0.0001
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We also investigated whether variation in the degree of surface expression of CD5, a 
transmembrane glycoprotein which down-modulates BCR signaling in B cells, would explain 
differences in basal Ca2+ signaling, but no correlation could be found (Figure 2C). In line with 
this, CD5 surface expression levels did not differ between U-CLL and M-CLL (data not shown).
Several cytogenetic aberrations that have been implicated in CLL pathogenesis and 
prognosis are associated with IGHV mutation status or stereotypic subsets21. However, the 
variations seen in basal Ca2+ signaling levels could not be linked to any specific cytogenetic 
abnormality (Supplementary Figure S2). 
Taken together, these results indicate that variation in basal Ca2+ signaling levels between 
CLL subgroups is a phenomenon that cannot be associated to particular BCR characteristics 
or cytogenetic abnormalities. 
CDR3 sequences and FR2 and FR3 motifs do not explain differences in basal 
Ca2+ levels in primary CLL
Since auto- or polyreactive antibodies are associated with long HCDR3 lengths and a 
positive charge5, 22, we next analyzed whether these HCDR3 characteristics might influence 
basal Ca2+ signaling levels. We found no correlation between basal Ca2+ signaling levels in 
the CLL cases in our cohort and HCDR3 length (Figure 3A) or HCDR3 charge (Figure 3B).
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Figure 2. Basal Ca2+ signaling levels in CLL do not correlate with IgM, IgD and CD5 expression levels. 
Linear regression analysis of basal Ca2+ signaling as a function of IgM (A), IgD (B), and CD5 (C) expression levels. Note 
that IgG expressing CLL cases were excluded from IgM and IgD analysis.
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Furthermore, to evaluate a possible effect of the CDR3 amino acid composition, we 
performed phylogenetic analysis of CDR3 heterogeneity and compared median fluorescence 
intensity (MFI) Ca2+ levels. In accordance with the absence of a correlation of sterereotypic 
CLL subsets and basal Ca2+ signaling values, we also did not observe any correlations between 
phylogenetic clustering of CDR3 amino acid sequences of the heterogeneous U-CLL or M-CLL 
and the MFI values of their basal Ca2+ signaling (Figure 3C). 
Furthermore, to investigate if amino acid changes in the IGHV FR2 or FR3 motifs, which 
has been reported to mediate the cell-autonomous signaling14, 15, would correlate with the 
differences in basal Ca2+ signaling levels that we observed between CLL cases, we evaluated 
the IGHV FR2/FR3 sequences in all our 68 CLL patients. Only one of the sequences contained 
a mutation (V42L in case 29) in this FR2 motif leading to amino acid change with a different 
charge. In addition, only in a single CLL case the YYC FR3 motif was mutated and resulted 
in the Y103F amino acid change (case 34). Because these two particular samples with 
mutated FR2 or FR3 motifs both showed a basal Ca2+ signaling level around the median 
of all CLL samples (data not shown), we conclude that FR2 or FR3 epitopes cannot explain 
the Ca2+ signaling differences we observed between and within CLL subgroups. Moreover, 
phylogenetic clustering analysis of the FR2 and FR3 sequences from our entire CLL cohort – 
plus U-CLL, M-CLL, stereotypic or heterogeneous subsets - did not show a significant relation 
with MFI values (Figure 3D, Figure S3 and data not shown).
Collectively, these data show that the variation in basal Ca2+ signaling levels within CLL 
and between M-CLL and U-CLL subgroups cannot be accounted for by differences in the 
internal epitopes (FR2, FR3) or in the paratopes (CDR3) of their BCR molecules. 
Primary CLL are largely unresponsive to BCR stimulation
In the Ca2+ flux assays we also evaluated the response of primary CLL samples and B 
cells of healthy controls to BCR stimulation. To this end we stimulated the cells with either 
IgM- or IgD-specific antibodies. Whereas the applied antibody concentrations induced a 
clear Ca2+ flux in healthy control B cells, BCR stimulation in primary CLL generally resulted 
only in a limited increase of cytoplasmic Ca2+ levels (Figure 1, Figure 4A,B). Even though the 
response to IgM was mostly low in both CLL subgroups, U-CLL as a whole appeared slightly 
more responsive towards IgM stimulation than M-CLL (Figure 4A), which is exemplified for 
individual cases in Figure 4C. 
Figure 3. Basal Ca2+ signaling in CLL does not correlate with CDR3 and FR2 composition. (see left page) 
A,B. Linear regression analysis of basal Ca2+ signaling as a function of CDR3 length (A) and CDR3 charge (B). Positive 
and negative charge are defined by amino acids K, R, H and D, E, respectively. C,D. Phylogenetic analysis of HCDR3 
(C) and FR2 (D) amino acid sequences combined with heat map analysis of the MFI of basal Ca2+ signaling levels of 
heterogenous CLL samples (C; n= 34) or total CLL samples (D; n=68) depicted in color code, ranging from red (high), 
via gray (median) to blue (low).
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Finally, we analyzed anti-IgG stimulation in CLL cases belonging to subset 4, which are 
known to have undergone IgG class-switch recombination23. Although Ca2+ flux kinetics upon 
IgG stimulation differs from IgM or IgD in healthy controls, the primary IgG CLL cases were 
also unresponsive to BCR stimulation (data not shown).
Our data demonstrate that CLL cells are largely unresponsive to IgM and IgD stimulation, 
irrespective of their membrane Ig expression levels. Despite this unresponsiveness to BCR 
stimulation, the responses to ionomycin demonstrated that Ca2+ mobilization per se was not 
disturbed in primary CLL cases. 
DISCUSSION
In this study we provide evidence that primary CLL cells show a generally higher basal 
Ca2+ signaling level than seen in PB B cells derived from healthy controls. Interestingly, when 
we divide CLL samples on the basis of their IGHV gene SHM status, we found a significantly 
higher basal Ca2+ signaling level in the M-CLL subgroup compared with U-CLL. Because the 
degree of basal Ca2+ signaling did not correlate with other BCR characteristics, including Ig 
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expression level, HCDR3 length, charge, and composition, or with cytogenetic aberrations, 
we conclude that difference in basal Ca2+ signaling seems directed by the SHM status of the 
CLL subgroup and that intrinsic differences in basal Ca2+ signaling would explain the variation 
seen between CLL subgroups. 
Increased basal Ca2+ signaling levels have previously been described in B cells that are 
in an anergic state24. These cells are capable of antigen binding, but are reduced in their 
ability to signal through their BCR and thus to respond to antigenic stimulation. This is a 
strategy of the immune system for silencing autoreactive B cells24. A constant occupancy of 
a proportion of BCRs by self-antigen is required for the maintenance of this increased basal 
signaling24, 25. In several publications it has indeed been described that CLL cells are in an 
anergic state, as indicated by low surface BCR expression and a reduced capability to respond 
to BCR stimulation20, 26, 27. Hence, the observed increased basal signaling in primary CLL might 
be triggered by constant or repetitive antigenic stimulation of the BCRs and thereby lead to 
an anergic state. The higher basal signaling that we observed in M-CLL might thus be due to 
a more efficient route to anergy for M-CLL than for U-CLL, as earlier described by Mockridge 
et al20. They showed that anergy is characterized by a reduced surface IgM signaling capacity, 
and additionally found that it can be recovered in vitro both at the level of surface expression 
of IgM and signaling capacity20. Furthermore, these authors also showed that U-CLL and 
M-CLL differ in their capacity to respond to IgM stimulation. The latter is in line with our 
results showing a small but significant increase in response to IgM in U-CLL but not in M-CLL.
The anergic state might thus explain the high level of basal Ca2+ signaling seen in the M-CLL 
cases, and could be induced by antigen-independent recognition of the FR2 or FR3 motif or 
other unknown intrinsic epitopes, or alternatively by continuous or repetitive occupation of 
the BCR by a specific antigen. Importantly, we did not find a significant association between 
FR2 and FR3 amino acid sequences and the level of basal Ca2+ signaling. Nevertheless, it is 
conceivable that the somewhat higher or lower basal signaling observed in some IGHV genes 
may reflect their occurrence in M-CLL or U-CLL subgroups, respectively. Increased M-CLL BCR 
affinity for its antigen, as it is induced by SHM, might explain the higher state of anergy in these 
cells. The U-CLL subsets that carry a heterogeneous or a stereotypic BCR both showed lower 
basal Ca2+ signaling than M-CLLs. This could be explained by the low affinity binding of these 
unmutated BCRs to their antigen, as most of these are poly- or autoreactive5. An additional 
explanation could be that the U-CLLs actually recognize their cognate antigen within the 
lymphoid tissues. The U-CLL cells that migrate to peripheral blood will not see their antigen 
and as a consequence regain their signaling capacity. When this would be accompanied by 
parallel re-expression of chemokine receptors, this could eventually lead to relocalization to 
proliferation centers and induction of the more aggressive behavior of U-CLLs. 
Several reports have demonstrated that BCR signaling pathways are altered in CLL. 
For instance, LYN and SYK kinases, are overexpressed and constitutively phosphorylated28, 29. 
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SYK expression29 and phosphorylation30 are found to correlate with prognosis, being higher 
in U-CLL than in M-CLL29, 30. BTK expression levels are also increased in CLL31, and even though 
BTK expression cannot be correlated with prognosis31, it is now a novel therapeutic target 
in clinical trials32. Furthermore, increased ZAP70 expression is associated with U-CLL and 
a more aggressive form of the disease33. Further downstream in the BCR signaling cascade 
differences are found in ERK, NF-κB and NFAT activation between M-CLL and U-CLL27, 30. 
Constitutive ERK phosphorylation was found to be associated with NFAT translocation to 
the nucleus and a higher anergic state27. NF-κB activation was found to be higher in U-CLL 
compared with M-CLL30. This factor is associated with increased survival in CLL cells34. So 
it seems likely that downstream BCR signaling is different between U-CLL and M-CLL, and 
therefore could be associated with the more aggressive behavior of U-CLL and the milder 
form as induced by the higher anergic state in M-CLL. Thus, it cannot formally be excluded 
that the observed differences in basal Ca2+ signaling between U-CLL and M-CLL are not 
related to BCR composition or antigenic stimulation, but instead result from differences in 
BCR downstream signaling pathways between U-CLL and M-CLL.
In summary, we demonstrate here that primary CLL cells show increased basal Ca2+ 
signaling levels compared with PB B cells of healthy controls. However, Ca2+ levels differed 
between CLL samples, with M-CLL showing significantly increased Ca2+ levels over U-CLL. We 
therefore conclude that the level of basal Ca2+ signaling is not uniformly enhanced in CLL B 
cells, but is associated with the CLL IGHV mutational status, reflecting a distinct cellular origin 
and possibly a different anergic state induced by repetitive or continuous antigen-binding in 
vivo.
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Figure S1. Ca2+ flux assays in different normal human B cell fractions. 
Representative kinetic plots of CD5+ vs. CD5- B cells (A) and CD27+ vs. CD27- B cells (B) from healthy controls. BCR 
stimulation was performed after 60s, and stimulation with ionomycin after 480s (indicated with arrows). The dura-
tion of the total Ca2+ flux assays was 600s.
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Figure S2. Correlation of basal Ca2+ signaling with cytogenetic aberrations. 
No significant association with well-known cytogenetic aberrations was established, as determined with the Kruskal 
Wallis test. Comparisons between 2 groups were performed with the Mann-Whitney U test. 
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Figure S3.
Phylogenetic analysis of FR3 amino acid sequences from the total group of CLL (n=68) combined with heat map 
analysis of the MFI of basal Ca2+ signaling levels depicted in color code, ranging from red (high), via gray (median) 
to blue (low).
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ABSTRACT
Chronic lymphocytic leukemia is a heterogeneous disease based on clinical and biological 
characteristics. Differences in Ca2+-levels among cases, both basal and upon B-cell receptor 
(BCR) stimulation may reflect heterogeneity in the pathogenesis due to cell-intrinsic factors. 
Our aim is to elucidate cell-intrinsic differences between BCR responsive and unresponsive 
cases.
Therefore the BCR responsiveness was determined ex vivo based on Ca2+-influx upon 
α-IgM stimulation of purified CLL cell fractions of 52 patients. Phosphorylation levels of 
various B-cell receptor signaling molecules, and expression of activation markers were 
assessed by flow cytometry. Transcription profiling of responsive (n=6) and unresponsive 
cases (n=6) was performed by RNA sequencing. RQ-PCR was used to validate transcript level 
differences in a larger cohort. 
In 24 cases an α-IgM response was visible by Ca2+-influx which was accompanied by 
higher phosphorylation of PLCγ2 and Akt after α-IgM stimulation in combination with a 
higher surface expression of IgM, IgD, CD19, CD38 and CD43 compared to the unresponsive 
cases (n=28). Based on RNA sequencing analysis several components of the canonical NF-κB 
pathway especially related to NF-κB inhibition were higher expressed in unresponsive cases. 
Moreover, upon α-IgM stimulation, the expression of these NF-κB pathway genes (especially 
genes coding for NF-κB pathway inhibitors but also NF-κB subunit REL) are upregulated in 
B-cell receptor responsive cases while for the unresponsive cases the level did not change 
compared to basal levels. 
These findings suggest cells from chronic lymphocytic leukemia cases with an enhanced 
NF-κB signaling are associated with a lower responsive capacity towards B-cell receptor 
stimulation. 
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy that is characterized 
by a monoclonal expansion of mature B cells with a homogeneous morphology and a 
characteristic immunophenotype. 1 CLL is the most common type of leukemia in the Western 
world and affects mainly the elderly. 1 Based on the somatic hypermutation (SHM) status of 
the immunoglobulin heavy chain (IGHV) gene, CLL can be divided in unmutated CLL (U-CLL) 
and mutated CLL (M-CLL), with U-CLL generally having a more aggressive form of the disease 
and M-CLL a more indolent form. 2, 3 Around 30% of all cases can be grouped into subsets 
based on so-called stereotypic B-cell receptors (BCRs), which are identified by their restricted 
IGHV/IGHD/IGHJ gene usage plus similarities in length and amino acid sequence of their 
complementarity-determining region 3 (CDR3). 4
The BCR stereotypy would be indicative for the involvement of similar specific antigens and 
underlines the importance of antigenic stimulation and BCR specificity in the pathogenesis. 4 
In general, most U-CLLs express a BCR that is polyreactive and recognizes self- and non-self-
antigens with low-affinity binding. 5, 6, 7, 8 In addition, for some stereotypic CLL subsets the 
antigens recognized by their BCRs have been identified. 9, 10, 11, 12, 13 
However, it was previously also shown that the BCR from CLL cells could be stimulated 
independently of external antigens, as the CDR3 regions are able to recognize an internal 
epitope in framework 2 (FR2) of the IGHV domain. 14 This induces a higher level of antigen-
independent autonomous BCR signaling, since these cells exhibit a higher Ca2+ level in their 
cytoplasm as demonstrated in vitro using a triple knock out (TKO) cell system. 
14
We previously demonstrated that primary CLL cells generally have higher basal Ca2+ levels 
compared with peripheral B cells from healthy individuals (HI). 15 Basal Ca2+ levels correlated 
with the IGHV mutational status, as we found on average higher basal Ca2+ levels in M-CLL 
than in U-CLL. 14, 15 However, our data also showed large variation within the subgroups, as 
cases with high and low basal Ca2+ levels could be found in both M-CLL and U-CLL groups. 
15 Since there was no correlation with BCR characteristics (i.e. Ig expression level, HCDR3 
length, charge and composition) or with cytogenetic aberrations, it is conceivable that high 
basal Ca2+ levels are partly directed by the SHM status and that cell-intrinsic differences 
caused by cell anergy can explain the variation. 15
Anergy is an immune state in which the cell is silenced upon low-affinity recognition 
of self-antigens. 16 Anergy has been linked to CLL based on low surface BCR expression, 
their reduced responsive capability, 17, 18 and their increased basal Ca2+ levels. 15 Especially 
M-CLL shows this increased basal Ca2+ levels in combination with a poorer response to BCR 
stimulation 15 which is in line with other studies showing that the α-IgM response is associated 
with the IGHV mutational status and with the surface expression of progression markers, like 
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CD38. 18, 19 Moreover, high surface IgM is associated with a clinically aggressive form of the 
disease, which has potential impact as diagnostic parameter for disease progression. 20
However, Ca2+ levels, both basal and upon BCR stimulation vary within the U-CLL and 
M-CLL groups. We therefore hypothesize that this heterogeneity in BCR responsiveness 
could reflect a diverse disease pathogenesis involving cell-intrinsic differences. Here, we aim 
to elucidate potential cell-intrinsic differences underlying the observed differences in Ca2+ 
levels between CLL cases.
METHODS
Study population
Fifty-two patients were included of which 30 patients (58%) are U-CLL and 22 patients 
(42%) are M-CLL as determined by the IGHV SHM status (Supplementary Methods). All 
patient characteristics are shown in Supplementary Table 1. The majority of the included 
patients (n=41, 79%) were treatment-naive. Purified CLL cells were isolated (Supplementary 
Methods) upon informed consent and anonymized for further use, following the guidelines 
of the institutional review board (METC-2015-741) and in accordance with the declarations 
of Helsinki.
Flow cytometry
Flow cytometry was used to assess the responsive capacity upon α-IgM stimulation 
by measuring Ca2+ levels (Supplementary Methods) and to determine the expression of 
activation markers by using antibodies listed in Supplementary Table 2. 
Phospho-flow analysis was done to study the phosphorylation of Spleen tyrosine kinase 
(Syk) and Phopholipase Cγ2 (PLCγ2) and Protein kinase B (Akt) upon α-IgM stimulation. 
(Supplementary Methods). 
Cell culture and retroviral transduction of TKO cells
Triple knockout (TKO) cells, derived from a signaling-competent mouse pre-B cell line 
lacking the expression of endogenous pre-BCRs due to inactivation of RAG2 and λ5 genes 
(21), and Phoenix cells (ATCC CRL-3214) were both cultured as described by Meixlsperger 
et al. 21 The protocol used for the transduction of TKO cells was also documented before by 
Meixlsperger et al. 21 
RNA sequencing
Twelve cases from our cohort were selected based on their responsiveness upon 
α-IgM stimulation (6 responsive, 6 unresponsive) and RNA was sequenced. The RNA was 
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extracted using Allprep DNA/RNA/miRNA Universal (QIAGEN, Hilden, Germany) according 
to manufacturer’s instructions. RNA sequencing was performed on a TruSeq (Illumina, San 
Diego, CA, USA) platform at the Human Genome Facility (HuGeF), Department of Internal 
Medicine (Erasmus MC, Rotterdam). Reads were extracted from the raw sequencing data 
using CASAVA 1.8.2 (Illumina) and aligned to the human reference genome (UCSC’s hg19) 
using the STAR (2.5.0c) splice aware aligner using gencode v19 transcriptome annotations 
as additional template. The BAM files were processed using various tools from the picard 
software suite (v1.90), as well as tools from the Genome Analysis ToolKit (GATK, v3.5). QC 
metrics were collected at various steps using picard and evaluated, along with coverage 
metrics using GATK. Read counts per exon/gene were then determined by the featureCounts 
function of the subread package (v1.4.6-p1) using the gencode v19 annotation as markers. 
The raw read counts were normalized through the FPKM methodology, normalizing for 
library yield and gene size.
For classification analysis, the calculated Spearman correlation as a distance (1/similarity) 
measurement and Ward.D2 for the unsupervised clustering was applied to the used samples. 
The R (version 3.4.4) packages were used for the differential expression analysis and to create 
plots for visualization. We analyzed the samples fitting, with edgeR, the gene wise negative 
binomial generalized linear models for contrast. 
To validate transcript level differences in a larger cohort, RNA was synthesized to cDNA 
and RQ-PCR was performed (Supplementary Methods and Supplementary Table 2).
RESULTS
U-CLL cases are generally more responsive to α-IgM stimulation than M-CLL 
cases
To determine whether high basal Ca2+ levels are BCR dependent or caused by cell-intrinsic 
factors, we selected a small series of CLL samples with known high (n=3) or low (n=6) basal 
Ca2+ levels from our previous study of 2015 15, and cloned their BCR into TKO cells as described 
by Dühren-von Minden et al. 14
Even though we could detect Ca2+ signaling by the BCR in TKO cells for all analyzed CLL-
derived BCR expressed as IgM, we could not detect any correlation (R2=0.014, p=0.764) 
between the Ca2+ signal in CLL and that in TKO cells (Figure 1B) indicating that high basal Ca2+ 
levels as seen in some CLL samples would result from cell-intrinsic changes rather than from 
BCR-dependent autonomous signaling.
To determine which cell-intrinsic differences might cause the heterogeneity in Ca2+ 
signaling at basal level and upon BCR stimulation, we established a new cohort of patients 
(n=52, Supplementary Table 1). CLL cells were isolated from peripheral blood and immediately 
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used for further analysis. First, basal Ca2+ levels were assessed (Figure 1B). Similar to the 
previous study, basal Ca2+ levels were heterogeneous for both U-CLL and M-CLL. 15
Next, we examined the responsive capacity of the CLL samples upon BCR stimulation. 
In Figure 1D, two flowcytometric examples are provided. In line with our previous study 
15, we found that U-CLL cells in general respond significantly (p=0.049) better upon α-IgM 
stimulation compared with M-CLL cells (Figure 1E). Although no differences were found in 
the response after α-IgD stimulation (Figure 1F), a strong correlation existed between the 
relative response towards α-IgM and α-IgD stimulation (Figure 1G; R2=0.508, p<0.0001). 
Based on this, we further define CLL subgroups based on BCR responsiveness upon α-IgM 
stimulation. Twenty-four cases were classified as responsive (MFI ratio response/basal signal: 
1.1-6.5; n=17 U-CLL and n=7 M-CLL) and 28 cases were unresponsive (MFI ratio response/
basal signal: <1.1; n=13 U-CLL and n=15 M-CLL).
Higher phosphorylation of PLCγ2 and Akt in CLL correlated with 
responsiveness upon BCR stimulation
In order to better understand BCR responsive capacity, as defined by Ca2+-influx, we 
examined phosphorylation of the Syk, PLCγ2 and Akt upon α-IgM stimulation. First, we 
evaluated differences basal phosphorylation levels of Syk (pSyk), PLCγ2 (pPLCγ2) and Akt 
(pAkt) (Figure 2A). The responsive cases showed a significantly (p=0.0013) higher basal 
pPLCγ2 level than unresponsive cases but no differences were found in basal pSyk and 
pAKT levels (Figure 2B). Next we examined the relative response of kinase phosphorylation 
upon BCR stimulation. Even though no difference in relative response of pSYK after α-IgM 
stimulation was found, the responsive patients had a higher relative response of pPLCγ2 and 
pAkt upon α-IgM stimulation (Figure 2C). 
Figure 1. Ca2+ signaling in CLL cells
A. Flowcytometric analysis of Ca2+ flux (ratio Indo-1/Indo-1) after the addition of 4-hydroxytamoxifen (4-OHT) to 
TKO cells expressing the BCR from two representative M-CLL (left) and two U-CLL (right) samples. B. From 9 CLL 
cases (6 U-CLL, black dots and 3 M-CLL, open dots) of which the basal Ca2+ level (x-axis) was assessed earlier, the 
BCR was cloned into TKO cells to determine the autonomous Ca2+ signal (y-axis). Linear regression was performed 
and the R2 and p-value is shown. C. Basal Ca2+ level (MFI ratio FI3/FR) was determined in a new cohort of 52 CLL 
samples (freshly isolated) consisting of 30 U-CLL and 22 M-CLL cases. D. Responsive capacity upon BCR stimulation. 
Flowcytometric analysis of a representative CLL sample showing no Ca2+ influx (ratio FL3/FR) upon α-IgM stimulation 
(left) and a representative CLL sample with an increase in Ca2+ influx (ratio FL3/FR) upon α-IgM stimulation (right). 
Based on this analysis the responsive capacity upon α-IgM stimulation (E) and α-IgD stimulation (F) was determined 
in the 30 U-CLL and 22 M-CLL cases. Individual plots and medians (grey bars) are shown. Mann-Whitney U-test was 
performed for statistical analysis between the groups of patients (* = p<0.05). G. Linear regression analysis between 
the relative response after α-IgM and α-IgD stimulation and both R2 and p values are shown.
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Figure 2. Phosphorylation of Syk, PLCγ2 and Akt.
A. The level of pSyk, pPLCγ2 and pAkt was determined at basal level and upon stimulation with α-IgM and correlated 
with the α-IgM response as determined by Ca2+ signaling. Representative examples of the analysis in an unrespon-
sive CLL case (upper histograms) and a responsive CLL case (lower histograms) are shown. After single viable cell 
selection, the level of pSyk, pPLCγ2 and pAkt was determined, both as basal level (black line) and upon stimulation 
with α-IgM (grey line). B. Differences in basal level of pSYK, pPLCγ2 and pAKT (x-axis) between α-IgM unresponsive 
and responsive samples. C. The relative response after α-IgM stimulation for pSYK, pPLCγ2 and pAKT (x-axis) in the 
two patient groups. Individual plots and medians (grey bars) are shown. Mann-Whitney U-test was performed for 
statistical analysis between the groups of patients (** = p<0.01).
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Taken together, the α-IgM response as determined by Ca2+-influx is consistent with a 
higher phosphorylation of pPLCy2 and pAkt upon α-IgM stimulation
CLL cases showing good BCR responsiveness have a more activated 
phenotype 
Next we examined whether the expression of activation markers associates with the 
response to α-IgM. As expected, CLL cells from responsive cases displayed a significantly 
(p=0.0002) higher expression of surface IgM compared to the unresponsive cases, IgD 
(p=0.036), CD19 (p=0.029), CD38 (p=0.035), and CD43 (p=0.047) expression levels were also 
higher compared to unresponsive cases (Figure 3A). No differences were found in CD20, 
CD21, CD27, CD69, CD80, CD86 and CXCR4 expression. (Supplementary Figure S1). 
To determine if the α-IgM responsiveness within the responsive cases correlates with the 
expression level of these markers, we compared surface expression and relative response. 
The relative response did correlate with surface IgM (R2=0.322, p=0.0038) and CD21 
(R2=0.469, p=0.0002) expression levels (Figure 3B). 
Particularly IκB-related genes are differentially expressed between BCR 
responsive and unresponsive cases
Twelve cases from our cohort were selected to evaluate cell-intrinsic differences based 
on RNA sequencing of total RNA from MACS-purified (>95%) CLL cells. Six patients were 
classified based on Ca2+ levels as responders upon α-IgM stimulation and were compared to 
another 6 patients who were unresponsive. (Supplementary Table 3) First, RNA expression 
profiles of the 12 cases were compared to each other via Spearman’s correlation (Figure 4A). 
Based on these results the patients could be divided into three major clusters, which did not 
correlate with BCR responsiveness (blue label) or SHM status (green label). In addition, when 
comparing the variation in total gene expression levels between the samples, as shown 
by Z-scores in a heat map (Supplementary Figure S2), no clear division of responsive and 
unresponsive cases was found either, probably reflecting the biological heterogeneity of CLL 
samples, even when classified as BCR responsive and unresponsive. 
Next, we therefore focused on genes involved in BCR signaling using QIAGEN’s Ingenuity 
Pathway Analysis (IPA). As illustrated by the volcano plot, responsive cases demonstrated a 
significantly higher EBF1, FCGR2A, SYK and FYN expression (positive logFC values), whereas 
the non-responders showed a significantly higher NFKBID, NFKB2, CAM2KA, NFKBIE, RAF1, 
NFKBIB, NFKB1, RPS6K1, PLCG1 and BCL3 expression (negative logFC values) (Figure 4B 
and Supplementary Figure S2). Interestingly, the NFKBIB, NFKBID and NFKBIE genes are all 
encoding inhibitors of NF-κB (IκBs), while NFKB1, NFKB2 and BCL3 are genes coding for NF-κB 
components that are associated with inhibition. 22 
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BCR unresponsive CLL have a higher expression of genes expressing 
regulatory molecules of NF-κB signaling
Additional samples were selected (n=13 unresponsive, n=15 responsive) to validate 
the differences in transcript levels NF-κB genes (NFKB1, NFKB2, BCL3, NFKBIB, NFKBID and 
NFKBIE) using RQ-PCR. RQ-PCR results (displayed as 2-deltaCT values) indeed confirmed that 
responding cases have a significantly lower expression of NFKB1 and NFKB2 (Figure 5A) 
NFKBIB and NFKBIE (Figure 5B). Furthermore, we found a trend towards a lower NFKBID 
expression, but no difference in BCL3 expression between the subgroups (Figure 5B). 
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Figure 3. Surface expression of activation-associated markers.
The surface expression of several activation-associated markers were measured in 52 patients with CLL. 
A. Surface expression level (X-axis) of IgM, IgD, CD19, CD38 and CD43 in α-IgM unresponsive and α-IgM respon-
sive cases. Individual plots and medians (grey bars) are shown. Mann-Whitney U-test was performed for statistical 
analysis between the groups of patients (* = p<0.05). B. Relative response upon α-IgM stimulation (x-axis) is plotted 
against the surface expression (Median Fluorescence Intensity (MFI)) expression level of IgM and CD21. Linear re-
gression analysis was performed and R2 and p values are shown.
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In addition, we further examined if the transcriptional levels of these NF-κB pathway genes 
also correlated with basal Ca2+ levels (Supplementary Figure S3). A significant correlation 
could only be found between basal Ca2+ levels and NFKB1 (R2=0.163, p=0.033) and NFKBIE 
(R2=0.234, p=0.0091) transcript levels (Supplementary Figure S3).
Since loss of IκBε (encoded by NFKBIE as caused by an identical 4-bp frameshift deletion 
in the first exon), has been associated with a progressive form of CLL 23, we examined if 
patients in our cohort with a low NFKBIE expression would carry this identical deletion. Upon 
sequencing of the first exon of NFKBIE, this 4-bp deletion was not observed (data not shown).
Expression levels of genes coding for NF-κB regulators (NFKB1 and NFKB2) and coding for 
IκBs that were lower expressed in responsive cases appeared to correlate with each other 
(Supplementary Figure S4), implying that unresponsive patients show higher expression of 
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Figure 4. Differential expression analysis based on RNA sequencing data.
A. Results of the Spearman correlation of the RNA expression analysis in different CLL samples (n=6 responsive vs. 
n=6 unresponsive CLL cases). The color scale indicates the degree of correlation varying from blue (low correlation) 
to red (high correlation). The two panels at the left end indicate the responsiveness (orange=unresponsive, blue=-
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differences in transcript levels of genes involved in the BCR signaling pathway as determined using QIAGEN’s Ingenu-
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Figure 5. Validation of transcriptional differences of NF-κB related genes
RQ-PCR validation of NFKB1, NFKB2 (A) NFKBIB, NFKBID, NFKBIE, BCL3 (B) and TNFAIP3 (C) expression in an extend-
ed cohort of unresponsive (n=13) and responsive (n=15) CLL cases. 2-deltaCT values were determined for each sample 
and individual data plots and the median are shown. Comparison between the two groups was done using the 
Mann-Whitney U-test (* = p<0.05, ** = p<0.01).
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multiple NF-κB inhibitors. Even though we could not detect statistically significant differences 
in expression levels of genes coding for the NF-κB subunits RELA, RELB and REL between 
the two subgroups (data not shown), we did observe clear correlations between expression 
levels of genes associated with NF-κB inhibition and expression levels of RELA and REL 
(Supplementary Figure S5), both involved in the canonical NF-κB. No correlations between 
inhibitor levels and levels of the non-canonical NF-κB subunit RELB were found (data not 
shown).
Besides the IκBs genes, we also found a difference in expression of tumor necrosis 
factor-α induced protein 3 (TNFAIP3; logFC=-1.70, 10log(Pvalue)=2.24) based on RNA 
sequencing analysis. TNFAIP3 encodes for protein A20 that is induced by TNF-α and functions 
as a negative regulator through inhibition of NF-κB signaling. 24 In addition, RQ-PCR showed 
a significantly (Figure 5C; p=0.017) higher expression of TNFAIP3 in unresponsive cases 
compared to responsive patients. 
Collectively, these results illustrate that unresponsive cases have higher basal gene 
expression of several regulatory molecules of canonical NF-κB pathway signaling.
Upregulation of NF-κB pathway genes upon α-IgM stimulation in BCR 
responsive cases. 
To further study expression of the NF-κB genes upon stimulation, frozen PBMCs of 21 
cases (unresponsive CLL; n=11 and responsive CLL; n=10) were thawed, after which CLL 
cells were MACS-isolated and stimulated for 2.5 hours with α-IgM (optimal stimulation was 
defined using normal B-cells, data not shown). The 2-deltaCT values obtained after incubation 
(α-IgM stimulated and unstimulated) were normalized by subtraction of the basal 2-deltaCT 
value to calculate the fold differences in expression between the patient groups (Figure 6). 
BCR responsive cases showed a significant upregulation of NFKB2, REL, NFKBID, NFKBIE and 
TNFAIP3 after stimulation compared with unresponsive cases for which the expression of the 
NF-κB genes remained roughly equal. 
In summary, α-IgM unresponsive cases had a high basal transcription of especially NF-κB 
inhibitory components, whereas the responsive cases showed a clear upregulation of NF-κB 
inhibitory components, including TNFAIP3 and NF-κB subunit REL, upon stimulation. 
DISCUSSION
Here we aimed to study cell intrinsic differences between unresponsive and responsive 
CLL that may underlie differences in Ca2+ levels upon α-IgM stimulation. Based on RNA 
sequencing analysis several components of the canonical NF-κB pathway, especially related 
to NF-κB inhibition, were higher expressed in unresponsive cases. Besides these inhibitors, 
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the TNFα-induced NF-κB inhibitor A20 was also significantly higher expressed in the BCR 
unresponsive cases. Lastly we showed that upon α-IgM stimulation, the expression of these 
NF-κB pathway genes (especially genes coding for NF-κB pathway inhibitors but also NF-κB 
component REL) are upregulated in BCR responsive cases while for the unresponsive cases the 
transcriptional level did not change compared to basal levels, indicating that NF-κB signaling 
is an important pathway for CLL cells in their ability to respond upon BCR stimulation. 
Based on the lack of correlation between basal Ca2+ levels and autonomous signaling 
in TKO cells (14),we then aimed to gain more insight into possible cell-intrinsic differences, 
although formally we cannot exclude that Ca2+ levels could also (partly) be high due to 
previous antigenic stimulation in our ex-vivo samples. Using a new cohort, Ca2+ signaling 
was now determined in freshly isolated cells instead of thawed cells, which on average 
resulted in lower basal Ca2+ levels (data not shown). This might be, in combination with the 
heterogeneity in basal Ca2+ levels, an underlying explanation for the fact that in this cohort 
the basal Ca2+ levels were not different between M- and U-CLL cases. Further building on the 
study of Mockridge et al. 18, who also showed differences in responsiveness to BCR stimulation 
between CLL cases, we therefore divided our patient cohort based on the responsive capacity 
to BCR stimulation. In both M- and U-CLL groups, there were cases showing a clear α-IgM 
response based on Ca2+ influx, while others did not show such a response, indicating that the 
level of anergy is independent of the IGHV SHM status of the BCR. 
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Figure 6. Transcriptional levels of NF-κB related genes upon α-IgM stimulation
Upon α-IgM stimulation, RQ-PCRs were performed to examine the transcriptional level of multiple NF-κB pathway 
genes (NFKB1, NFKB2, REL, NFKBIB, NFKBID, NFKBIE and TNFAIP3) that were differently expressed at basal level 
between responsive and unresponsive CLL cases. The 2-deltaCT value upon α-IgM stimulation was subtracted by the 
2-deltaCT value at basal level and divided by the 2-deltaCT value of the unstimulated condition corrected by the 2-deltaCT value 
at basal level to calculate the net increase or decrease upon α-IgM stimulation. α-IgM unresponsive CLL cases (n=11, 
white bar) were compared to α-IgM responsive CLL cases (n=10, black bar) and statistics was performed using the 
Mann-Whitney U-test (* = p<0.05, **p<0.01). 
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The anergic nature of unresponsive CLL was partly confirmed by the marker profile. IgM 
responders co-express higher surface IgM and IgD expression, which explains the response 
to α-IgM as well as α-IgD stimulation. The higher expression of the prognostic marker CD38 
by the responsive cases is also in line with findings of Mockridge et al 18 suggesting that 
responsive patients in general have a poor prognosis. 2 Striking is the sharp correlation 
between CD21 expression and the responsive capacity upon α-IgM stimulation. In other 
immune related diseases like rheumatoid arthritis, common variable immunodeficiency 25 
and Sjögren syndrome 26, patients had increased populations of CD21low B cells compared 
to HI. 25 These CD21low B cells were found to represent unresponsive cells expressing 
autoreactive BCRs which failed to respond based on Ca2+ levels upon BCR stimulation. 25, 26 
CD21low CLL cells were not found to be autoreactive and are associated with a poor prognosis. 
27 Unfortunately we had no access to longitudinal patient data and were therefore unable to 
evaluate progression of the CLL.
RNA sequencing analysis showed that especially genes coding for regulatory molecules 
involved in NF-κB inhibition are differentially expressed between BCR responsive and 
unresponsive cases. Several studies have reported that CLL cells have higher basal NF-κB 
levels compared to normal B cells and are continuously activated. 28 In addition, it has been 
shown that NF-κB signaling is important for preventing apoptosis by multiple mechanisms, 
including CD40L mediated signaling. 28, 29, 30
We found that the unresponsive cases have higher basal gene expression of several 
components of the canonical NF-κB pathway, especially those involved in the inhibition. 
Genes coding for the p105/p50 (NFKB1) and p100/p52 (NFKB2) subunits are higher 
expressed in unresponsive CLL. Both are potential inhibitors and allow functional NF-κB 
activation in which p105/p50 is involved in the canonical NF-κB pathway and p100/p52 in 
the alternative (non-canonical) NF-κB pathway. 31 In addition, we found that genes coding 
for IκBs were higher expressed in unresponsive cases. IκBε (coded by NFKBIE), which is an 
important regulator of B-cell proliferation 32, was found to be mutated in patients with CLL. 
23, 33 Especially a recurrent 4-basepair-frameshift deletion resulting in functional loss of IκBε 
and leading to continuous NF-κB activation was detected in progressive CLL forms 23 as well 
as in other B-cell malignancies. 34 However, we could not identify this identical deletion as a 
possible cause for the lower NFKBIE gene expression in the responsive cases. 
Besides BCR stimulation, the canonical NF-κB pathway can be activated by TNF receptor 
stimulation. 31 It might thus be that NF-κB signaling in BCR unresponsive cases is more 
dependent on TNF-mediated activation. Higher TNFAIP3 expression, a negative feedback 
regulator of NF-κB signaling induced by TNFα, as we noticed in unresponsive cases provides 
basis for this theory. From B-cell lymphoma patients it is known that increased and sustained 
NF-κB activation of especially proto-oncogene c-REL, promotes TNFα-induced cell survival. 
35 Through this feedback loop mechanism, secretion and uptake of TNFα might result in 
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NF-κB induced survival of (anergic) CLL cells, independently from BCR signaling. Foa et al. 
36 reported that CLL cells continuously produce TNFα, especially cells from patients with an 
indolent form compared to patients with a progressive form. 36 
Genomic aberrations in the TNFAIP3 gene resulting in the loss of A20 are linked with 
autoimmune disease with a humoral component as well as several B-cell lymphomas. 37 In B 
cells from aged mice it was demonstrated that selective loss of A20 increases the activation 
threshold and enhances proliferation and survival of B cells causing an inflammatory 
condition and inducing autoimmunity. 38 Such loss of A20 caused by genetic aberrations of 
TNAIP3 has not been associated with human CLL. 39
Even though the focus of our study has mostly been on those genes that were higher 
expressed in unresponsive cases, multiple genes were found to be higher expressed in 
responsive cases, such as SYK. Although SYK was differently expressed based on the RNA 
sequencing analysis between the two groups of patients in the extended cohort of patients 
with CLL, we could not confirm this difference on SYK protein level (by phospho-Flow analysis; 
data not shown). Another gene that strikingly came out of our analysis to BCR signaling genes 
is Early B-cell Factor 1 (EBF1), a transcription factor important in B-cell differentiation that 
was higher expressed by the responsive cases. 40 Earlier it was shown by Seifert et al. 41 that 
compared to conventional B cells, EBF1 was significantly downregulated in patients with CLL. 
41 It was suggested that the low expression of EBF1 might result in reduced levels of B-cell 
signaling and might contribute to an anergic phenotype of CLL cells. 41 Our results showing 
a lower level of EBF1 transcripts for unresponsive cases would support this theory. Future 
studies would have to elucidate the importance of EBF1 in CLL pathogenesis.
In summary, our results are showing that responsive CLL cases, irrespective of the IGHV 
SHM status, have a more activated phenotype and a reduced basal expression of several 
regulatory molecules of the canonical NF-κB pathway including those associated NF-κB 
inhibition. Upon α-IgM stimulation these responsive cases showed upregulation of NF-κB, 
including NF-κB inhibitors, whereas transcriptional levels of NF-κB signaling pathway 
components remained unaltered in unresponsive cases. Our findings suggest that enhanced 
basal NF-κB inhibition may be strongly associated with a lower responsive capacity of CLL 
cells to BCR stimulation and for the survival of anergic CLL cells.
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SUPPLEMENTARY METHODS
IGHV sequence analysis
Genomic DNA was extracted from PBMCs via spin-column kits and QIAcube (Qiagen, 
Valencia, CA, USA). Primers and protocols for IGHV mutation status analysis were according 
to the BIOMED-2 protocol and following ERIC guidelines. 1, 2 In brief, PCR products were 
analyzed by electrophoresis on polyacrylamide gels for monoclonality, followed by direct 
sequencing. Sequencing results were analyzed online by use of IMGT/V-QUEST (www.imgt.
org).
Isolation of CLL cells
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Hypaque (GE, 
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions. The obtained 
PBMC fractions were sorted via magnetic-activated cell sorting (MACS), using the B-CLL 
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). For RNA sequencing, a minimum 
of 5x106 isolated CLL cells was resuspended in RLT buffer (Qiagen) supplemented with 1% 
2-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, the Netherlands) and stored at -80°C. To 
check purities, a small fraction of the isolated cells was stained with phycoerythrin (PE)-Cy7 
labelled CD19, Allophycocyanin (APC)-H7 labelled CD3, together with APC-labelled CD5 (CLL 
cases only). All fractions had a purity of more than 95% CD19+ cells. 
Ca2+ flux assay
Intracellular Ca2+ fluxes were measured using Fluo-3AM and Fura Red-AM probes (both 
from Life Technologies, Carlsbad, CA, USA).  Briefly, isolated CLL cells were incubated with 
5 mM Fluo3-AM and 5 mM Fura Red-AM in loading buffer (Hank’s balanced salt solution 
medium (HBSS) supplemented with 10 mM HEPES and 5% fetal calf serum) at 37°C for 30 
min in the dark. Cells were washed and resuspended in 1 ml loading buffer. Before FACS 
measurements, cells were warmed to 37°C for 10 min. Basal intracellular Ca2+ levels were 
measured for 60 seconds, followed by stimulation of the BCR with 20 µg/ml anti-human 
IgM F(Ab`)
2
 (Southern Biotech, Birmingham, USA) or with 20 µg/ml anti-human IgD F(Ab`)
2
 
(Southern Biotech). After stimulation cells were acquired for 360 seconds on the LSRII flow 
cytometer (BD Biosciences, Erembodegem, Belgium). Data analysis was performed using 
FlowJo software (Tree Star, Ashland, OR, USA). 
For Ca2+ influx analysis in TKO cells, 1 × 106 transduced TKO cells were loaded with Indo-1 
(Invitrogen, Carlsbad, California, USA) with use of Pluronic (Invitrogen, Carlsbad, California, 
USA). Induction of ERT2–SLP65 to allow signaling was performed by the addition of 2 µM 
4-hydroxy tamoxifen (4-OHT; Sigma-Aldrich, Saint Louis, Missouri, USA). As controls for BCR 
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crosslinking 10 µg/ml Goat anti-mouse IgM F(Ab`)
2
 (10 µg/ml; Southern Biotech) and 10 µg/
ml Goat anti-mouse IgD F(Ab`)
2
 (Southern Biotech) were used.
Phospho-flow cytometry
Isolated CLL cells with 20 µg/ml anti-human IgM F(Ab`)
2
 (Southern Biotech) at 37°C for 1 
minute to measure phosphorylation of Syk and PLCγ2. To measure phosphorylation of Akt, 
stimulation was done for 10 minutes. After stimulation, the cells were fixated for 10 minutes 
using cytofix (BD Biosciences). Before intracellular staining, cells were permeabilized by 
adding Perm III buffer (BD) at -20°C for 30 minutes. After washing, the cells were stained 
with either PE labelled pSyk (pY348; clone: I120-722), APC-Alexa fluor (AF)-647 labelled 
pPLCγ2 (pY759; clone: K86-689.37) or with PE-labelled pAkt (pY473; clone: M89-61). Data 
was acquired on the LSRII flow cytometer (BD Biosciences). Data analysis was performed 
using FlowJo software (Tree Star, Ashland, OR, USA). 
Gene mutation sequencing
To examine a previously reported 4-bp deletion in the first exon of the NFKBIE 
gene, as described by Mansouri et al. 3, this region was sequenced. 3 In brief, first DNA 
(10 ng/μl) was amplified by hot-start PCR (35 cycles, Tm=60°C) by addition of Gold 
buffer (10x; Thermo Fisher), MgCl
2
 (25 mM; Applied Biosystems Life Technologies), 
dNTPs (20 mM; GE Healthcare), Taq Gold polymerase (5U/μl; Thermo Fisher), forward 
primer (10 pmol/μl; 5’-CCTCAAAAGTGGGCTGAG-3’) and reverse primer (10 pmol/μl; 
5’-CAAGGAACCACAGGAGAAGG-3’). Two μl of the amplified DNA was used and mixed with 
Big Dye® Terminator (BDT; Thermo Fisher), 5x sequencing buffer (Thermo Fisher) together 
with the forward and reverse primers (separately). After amplification, the sequence run was 
performed on an ABI Prism® 3130xl Genetic Analyzer (Thermo Fisher). Analysis was done 
using the program CLC Main Workbench 7 (Qiagen). 
cDNA synthesis and Real-time Quantitative PCR (RQ-PCR)
cDNA was synthesized from isolated RNA by adding reverse transcriptase Superscript II 
(Invitrogen Life Technologies, Waltham, MA, USA), 10x CA buffer (0.2 M Tris pH 8.3, 0.5 M 
KCl), dNTP (GE Healthcare, Cleveland, OH, USA), dithiotreitol (Invitrogen Life Technologies), 
MgCl
2
 (Applied Biosystems Life Technologies), recombinant RNAsin (Promega, Fitchburg, WI, 
USA) and random primers (Invitrogen Life Technologies). The reaction mixture was incubated 
for 45 minutes at 42°C and the reaction was stopped by a 2 minute incubation at 99°C. 
Real-time Quantitative PCR (RQ-PCR) assays were designed with the Roche Universal 
Probe Library (Roche, Basel, Switzerland) (Supplementary Table 4). TaqMan Universal 
PCR master mix (2x; Applied Biosystems) was used for the reaction mix and the run was 
performed on the StepOne Plus instrument (Thermo Fisher, Waltham, MA, USA). Ct values 
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of the samples of each target gene were normalized to the Ct value of the ABL housekeeping 
gene (ΔCT) and the relative quantification (2-ΔCT) was performed. 4
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Table S1. Patient characteristics
Total number of CLL patients 52
• U-CLL 30 (58%)
• M-CLL 22 (42%)
Heterogeneous CLL 44 (85%)
Stereotypic CLL 8 (15%)
• U-CLL #1 2
• U-CLL #3 1
• U-CLL #5 1
• U-CLL #6 1
• U-CLL #64B 2
• M-CLL #2 1
Cytogenic abberations
• none 9 (17%)
• trisomy 12 8 (15%)
• del 11q (including partial) 8 (15%)
• del 17p 5 (10%)
• del13q isolated 15 (29%)
• del13q combined 11 (21%)
• unknown 5 (10%)
Age in years 66.3 (38-88)#
Female 20 (38%)
Male 32 (62%)
# = mean with range
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Antibody Clone Conjugate Supplier
CD3 Sk7 APC-H7 BD Biosciences
CD5 UCHT2 APC BD Biosciences
CD19 J3-119 PC7 Beckman Coulter
CD20 2H7 BV606 BioLegend
CD21 B-ly4 BV711 BD Biosciences
CD27 M-T271 BV421 BD Biosciences
CD38 HB7 AF750 BD Biosciences
CD43 IG10 FITC BD Biosciences
CD69 FN50 BV711 BD Biosciences
CD80 L307.4 PE BD Biosciences
CD86 HA5.2B7 PE Beckman Coulter
CD184 (CXCR4) 12G5 APC BD Biosciences
IgD 1A6-2 PE-CF594 BD Biosciences
IgM MHM-88 BV-510 BD Biosciences
Table S2. Antibodies used for phenotyping
Table S3. Selected CLL cases for RNA sequencing
Patient ID SHM status α-IgM response
(FL3/FR ratio)
Un
re
sp
on
siv
e 
CL
L c
as
es
KL2007-155 M-CLL 0.95
KL2016-348 M-CLL 0.94
KL2016-198 M-CLL 1.00
KL2016-359 U-CLL 0.98
KL2015-485 U-CLL 0.98
KL2016-075 U-CLL 0.96
Re
sp
on
siv
e 
CL
L c
as
es
KL2014-108 M-CLL 1.40
KL2009-080 M-CLL 1.43
KL2015-509 M-CLL 1.44
KL2016-090 U-CLL 5.15
KL2013-264 U-CLL 6.46
KL2015-488 U-CLL 4.24
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Gene Sequence forward primer Sequence reverse primer1 Probe2
NFKB1 CCTGCTCCTTCCAAAACACT CGGTGTAGCCCATTTGTCTC 22
NFKB2 CTCGTGTCTGTCCACCTGTC GAGCATCTGCGAGCATACAG 74
BCL3 ACATCCTGAGGGGGAAGG TGATGCGGAGAGAAGACCA 38
NFKBIB CCCTTCATTTGGCAGTGG CTGCCCTCAGGAGAAGCTC 27
NFKBID ATTTCTCCCTCCCCCAGA GAACCCACAGTCTCCGAGTG 90
NFKBIE TGCTGTGTACCGACTGAAGC CCAGACTGGCTCTCTTCCAC 63
REL TGAACATGGTAATTTGACGACTG ACACGACAAATCCTTAATTCTGC 69
RELA CTGGGAATCCAGTGTGTGAA AAGGGGTTGTTGTTGGTCTG 1
RELB GCTCTACTTGCTCTGCGACA GGCCTGGGAGAAGTCAGC 79
TNFAIP3 AATTTCCTCCAGGTCACCTAAAC GGGGACCTTGGTTCTAGCTT 68
TNFα CAGCCTCTTCTCCTTCCTGAT GCCAGAGGGCTGATTAGAGA 40
1. Reverse complementary primers. 
2. Probe numbers according to the Roche Universal Probe Library.
Table S4. Primers and probes from Roche Universal Probe Library for RQ-PCR design.

Chapter 5
Both related and diverse BCR usage across 
siblings within CLL families
  
Alice F. Muggen1, Ingrid L.M. Wolvers-Tetteroo1, Berna H. Beverloo2, Nikos Darzentas3, 
Rudi W. Hendriks4, Jacques J.M. van Dongen1,5, Anton W. Langerak1
1Dept. Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, The Netherlands,
2Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
3Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 
4Department Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands. 
5Present Address: Department Immunohematology and Blood Transfusion, Leiden University
Medical Center, Leiden, The Netherlands.
 
 
 
 
Manuscript in preparation
Chapter 5
117
ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common type of hematological 
malignancy in elderly in the Western world. As key processes in the onset of disease chronic 
antigenic activation via the B cell receptor (BCR), signals from the microenvironment, and 
genetic alterations in mature B cells are mentioned. Known risk factors for CLL are aging and 
European ancestry, but the etiology of CLL is still largely unknown. Previous epidemiological 
studies indicated that inherited factors play a role in disease onset, and relatives of CLL 
patients were found to have an 8.5-fold increased risk of developing CLL. Familial CLL is 
defined by having at least two affected relatives within one family. Here, we describe three 
families with two or more siblings affected with CLL. We hypothesized that similarities BCR 
composition and/or chromosomal aberrations cause familial CLL occurrence. Therefore, we 
determined whether there are parallels in the BCR heavy and light chains in the CLL clones of 
the siblings of these families. Furthermore, we also investigated if similarities in known CLL-
associated chromosomal aberrations are present within the three families by using single 
nucleotide polymorphism (SNP) array analysis. 
We found that the three families represented three main CLL subgroup, with family 1 
consisting of two brothers and two sisters being M-CLL cases, and family 2 consisting of two 
brothers being U-CLL cases. Additionally, family 3 consisting of two brothers and two sisters 
form a CLL#2-like family with subject 3C being a CLL#2 case and subject 3B a CLL#2-related 
CLL#169 case, and all four having a CLL#2-light chain. Furthermore, based on SNP array 
analysis several known chromosomal aberrations, which have prognostic significance, were 
detected for all siblings of a CLL family. In families 1 and 3 11q14.2-11q14.3 deletions were 
detected, and both family 2 members had trisomy 12. Also, other minor losses, previously 
associated with CLL, were detected for all siblings in these respective families. 
With the exception of family 3 being a CLL#2-like family, we found no relationship in BCR 
gene usage in our CLL families. As we found similarities in known CLL-associated chromosomal 
aberrations within our families, this might indicate a shared path of CLL development, which 
requires further investigation.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common type of hematological malignancy 
in elderly in the Western world, with a prevalence of 4.2 per 100000 between 1975 and 
20091, 2. Chronic antigenic activation, either self or non-self, via the B cell receptor (BCR), 
signals from the microenvironment, and genetic alterations of mature B cells are mentioned 
as key processes in the onset of disease3. 
The BCR has an important role in the development of CLL, which is why its downstream 
signaling pathway is nowadays an attractive target for therapies. In addition, the BCR is of 
significant prognostic value, since the presence of somatic hypermutations (SHM) in the 
immunoglobulin heavy variable (IGHV) gene is generally associated with an indolent form 
of the disease, known as mutated CLL (M-CLL), while the absence of SHM is associated with 
a more aggressive form, known as unmutated CLL (U-CLL)4. The importance of the BCR in 
CLL is corroborated by the fact that about one-third of the CLL cases carry a very restricted 
BCR repertoire, leading to further segregation of CLL into so-called stereotypic BCR subsets. 
Stereotypic BCR are defined by a restricted IGHV, IGH diversity (IGHD), and IGH joining (IGHJ) 
gene usage, with restricted complementarity determining region 3 (HCDR3) length and amino 
acid usage5. In addition, also the immunoglobulin light chain (IGL) shows stereotypy. This 
restricted usage of BCRs in CLL suggests a selection for particular BCR that might be causal 
in the development of the disease. Apart from the biological implications, these stereotypic 
subsets also have clinical impact. This is probably best exemplified by the largest stereotypic 
CLL subset, CLL#2, (characterized by IGHV3-21 in combination with IGHJ6, a short HCDR3 of 9 
amino acids, and a light chain consisting of IGLV3-21 in combination with IGLJ3 with a LCDR3 
length of 12 amino acids), which defines a prognostically poor CLL subgroup5.
Next to the BCR configuration, several genetic aberrations are found to have prognostic 
value. Deletions of chromosomal regions 17p, 11q, or 13q, and trisomy of chromosome 12 
can be detected in about 80% of CLL cases. These chromosomal deletions are associated 
with the loss of the tumor suppressor genes TP53 and ATM, and with miR15a and miR16-1 
microRNA genes, respectively 6, 7 8. Deletion of 17p and deletion of 11q are associated with an 
aggressive form of CLL, while 13q deletion as a single event is associated with a milder form 
and thereby a more favorable prognosis. Trisomy 12 was recently found to be associated with 
altered nuclear factor of activated T cells (NFAT) signaling and immune checkpoint molecule 
CD739, and additionally has an intermediate disease outcome8.
Although advanced age and European ancestry are known risk factors, the etiology of CLL 
is still largely unknown. Epidemiological studies indicate that inherited factors would play a 
role in disease onset10. Relatives of CLL patients have an 8.5-fold increased risk of developing 
CLL, and additionally have an increased risk in developing other types of B cell malignancies 
11. Familial CLL is defined by the presence of at least two affected relatives within one family. 
Chapter 5
119
It was estimated in a Swedisch cohort that first degree relatives of CLL have a 3.05% life time 
risk to develop CLL, while this is 0.41% in the normal population, as was based on a 7.52 
increased relative risk for relatives of CLL cases12. Previous linkage studies in familial CLL did 
not reveal major susceptibility loci. However, GWAS studies in CLL identified many single 
nucleotide polymorphisms (SNPs) with small effects, which can add up in the etiology of 
familial CLL 13, 14, 15. Twin studies for lymphomas showed that monozygotic twins have a 100-
fold higher risk for Hodgkin lymphoma, with no increased risk in dizygotic twins, comparable 
with normal population16. For non-Hodgkin lymphomas, monozygotic twins of a patient were 
found to have a 23-fold increased risk in developing NHL, while dizygotic twins have a 14-fold 
increased risk17. 
In this report, we describe three families with two or more siblings affected with CLL. We 
hypothesize that similarities in chromosomal aberrations and/or immunogenic configuration 
(i.e. BCR composition) would underlie familial CLL occurrence. To this end, we determined 
whether there are parallels in the heavy and light chains of the BCR in the CLL clones of 
the siblings of these families. Furthermore, we also investigated if similarities in known CLL-
associated chromosomal aberrations are present within the three families by using SNP array 
analysis. 
MATERIALS & METHODS
Samples
Peripheral blood was obtained from CLL patients of three families (for details see Figure 
1) in accordance with the declaration of Helsinki. The study was approved by the hospital 
medical ethics committee under number METC2015-741. By use of STR analysis, the familial 
connection was confirmed for the siblings of these three families.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll Paque (GE Healthcare, 
Little Chalfont, UK) gradient centrifugation. CLL cells and T cells were sorted from PBMC 
using a FACSAria cell sorter (BD Biosciences, San Jose, CA, USA). Immediately after sorting, 
cells were lysed in RLT+ buffer (Qiagen, Valencia, CA, USA) complemented with β-mercapto-
ethanol and stored in -80°C until further processing. DNA was isolated with the DNA/RNA/
miRNA easy kit (Qiagen) according to the manufacturer’s protocol. In case DNA was isolated 
from total PBMC, spin-column kits and the QIAcube (Qiagen) were used. 
IGHV-IGHD-IGHJ gene rearrangement analysis
IGH and IGV gene rearrangements were amplified from 100 ng DNA of total PBMC in 
a multiplex PCR using BIOMED-2 IGH primers and Vκ-Jκ and Vλ-Jλ light chain consensus 
primers, following ERIC guidelines18, 19. Clonal PCR products were separated by heteroduplex 
5Immunogenetics in familial CLL
120
gel electrophoresis, and were purified by gel extraction. Rearrangements were determined 
through Sanger sequencing by an ABI 3130xl instrument (ThermoFischer, Waltham, MA, 
USA). Sequencing results were analyzed using the IMGT/V-QUEST tool on the IMGT website 
(www.imgt.org, version 3.3.1).
SNP array analysis
Single nucleotide polymorphism (SNP) array analysis was performed using the Illumina 
Human OmniExpress Beadchip (Illumina, San Diego, CA, USA). Data were analyzed with 
Beadstudio software (Illumina). The log R ratio and B allele frequency data were analyzed 
with the software program Nexus Copy Number (Nexus BioDiscovery, El Segundo, CA, USA). 
The results were compared with a database of known copy number variations (Department 
of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands) and a public copy number 
variations dataset containing approximately 3500 healthy controls (dataset of genomic 
variants). The affected locations detected, were analyzed in Ensembl Genome Browser 95 
(https://www.ensembl.org/index.html). 
RESULTS AND DISCUSSION
The BCR configuration of CLL cells is highly similar between siblings within 
each CLL family 
In family 1 (Figure 1A) four (out of the total ten) siblings, i.e. two brothers and two sisters, 
suffered from CLL, were diagnosed at advanced age (85 (1A), 86 (1B), 79 (1C), and 60 (1D)) 
and were followed until late age (98, 91, 84 and 82 years, respectively)20. Patient 1A was 
treated with chlorambucil due to increased leukocytosis and thrombocytopenia, twelve 
years after diagnosis20. Further follow-up data were unfortunately not available. 
Based on the IGHV sequence analysis all four siblings in this family appeared to carry a 
somatically hypermutated BCR (below 98% identity cut-off with germline IGHV gene) and 
thus should be considered as M-CLL, which are mostly associated with an indolent form of 
the disease. IGHV-IGHD-IGHJ and IGKV-IGKJ/IGLV-IGLJ gene usage were very diverse in this 
family (Figure 1A). Family members 1A and 1C both showed only one IGH rearrangement, 
in addition to two in-frame Ig light chain rearrangements. In family member 1B we could 
detect two productive IGH rearrangements, but only one in-frame rearranged IGL gene 
plus an unproductive (out-of-frame) IGK rearrangement. Family member 1D appeared to 
have bi-clonal CLL, as evidenced from the Igκ positive and Igλ positive CLL clones in flow 
cytometry. Indeed, we could detect the Ig light chain rearrangements for both CLL clones, 
and found three productive IGH rearrangements. Although, CLL is generally characterized 
by a monoclonal lymphoproliferation, multiple productive IGH rearrangements have been 
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Figure 1. Family trees and BCR characteristics of familial CLL cases. 
A. Family 1 consisting of two brothers and two sisters being M-CLL cases. B. Family 2 consisting of two brothers be-
ing U-CLL cases. C. Family 3 consisting of two brothers and two sisters and forming a CLL#2-like family with subject 
3C being a true CLL#2 case and subject 3B a CLL#2-related CLL#169 case, and all four having a CLL#2-light chain.
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observed in around 2% of CLL cases 18. These can arise from a single CLL clone (so-called 
biallelic IGH configuration) caused by a failure of allelic exclusion, or reflect biclonal CLL 
disease. Additionally, CLL with multiple partner clones were also reported in around 2% of 
cases (5 of 198), being all M-CLL cases, as based on single cell PCR analysis 21. Interestingly, 
within M-CLL family 1, member 1D appeared to have biclonal CLL consisting of a SmIgκ+ 
and a SmIgλ+ CLL clone in flow cytometry (data not shown). Since we detected 3 productive 
IGH rearrangements, one of these CLL clones seems biallelically rearranged. In addition, 
family member 1B also appeared to have biallelic productive IGH rearrangements with only 
one rearranged Ig light chain gene. Previously, multiple additional IGH bands were reported 
for these family members in Southern blot analysis20, but these were now all found to be 
unproductive. 
The two brothers of family 2 were diagnosed with CLL at age 77 (2A) and 71 (2B) years. 
They both carried an unmutated IGHV gene in their CLL clone (U-CLL), and used an IGHV4 
gene member in combination with the IGHJ6 gene, and a rearranged IGK light chain gene 
(Figure 1B). 
Family 3 also consisted of two brothers and two sisters with CLL, being diagnosed in the 
age range from 64 until 81 years. Three siblings showed M-CLL, with members 3C and 3D 
carrying a BCR with a clearly mutated IGHV gene, while member 3A showed a borderline 
mutated IGHV gene. The fourth sibling, family member 3B, was found to have a borderline 
U-CLL with a SHM status of 98.2%. Of note, family member 3C showed a stereotypic #2 
BCR, consisting of IGHV3-21 in combination with IGHJ6, with the typical 9 amino acids short 
HCDR3. This particular stereotypic receptor is generally combined with an IGL light chain, 
consisting of IGLV3-21 and IGLJ3 with a LCDR3 length of 12 amino acids. Remarkably, subject 
3B was found to have a stereotypic CLL#2-like receptor, CLL#169, with use of IGHV3-48, 
IGHD4-23, and IGHJ4, with a CDR3 length of 9 amino acids. Interestingly, this CLL#2-like 
IGH chain was found in combination with the typical CLL#2 IGL light chain in this case. The 
respective IGH genes of these stereotypic CLL subsets, IGHV3-21 and IGHV3-48, are 97% 
identical, and both show an aspartic acid at position 107 in the HCDR3 and use similar IGL 
chains5. Stereotypic CLL#2 is the most common stereotypic subset, with almost 3% of all CLL 
cases expressing this BCR5. This subset is associated with an aggressive type of disease with 
a time to first treatment (TTFT) of 1 to 6 years after diagnosis22. Preliminary data from the 
European Research Initiative on CLL (ERIC) comparing CLL#2 with CLL#169, illustrate striking 
similarities in cytogenetic aberrations and TTFT for both subsets. For CLL#169 family member 
3B, we know that treatment with Fludarabine was needed. Unfortunately, we do not have 
additional follow-up data from this patient, nor from the other family 3 siblings.
Furthermore, also family members 3A and 3D carried a CLL#2 IGL light chain, albeit with 
distinct IGH chains (Figure 1C and Table 1). Existence of stereotypic BCR usage in CLL is 
thought to be induced by chronic stimulation involving a common antigen. Up to now there 
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is no clear evidence for a common antigen in CLL#2 cases, but Menici et al. showed with a 
crystal structure of the CLL#2-BCR that inter-BCR interactions play a role and that these are 
mediated by this particular IGL chain, similar to a BCR binding its antigen. The IGLV3-21 light 
chain gene encodes two Asp residues at position 50 and 52 in the VL CDR2 regions, which 
interacts with an Arg110 light chain residue produced by a G to C nucleotide substitution 
caused by SHM in the linker region between the variable and constant region of the light 
chain. This Arg110 L was detected in the CLL#2 BCR in a cohort of 17 patients23. We noticed 
the presence of the Asp 50 and 52 residues in the CLL clones of our family 3 members, but 
we could not detect the Arg110 residue as it is outside the analyzed region (data not shown). 
With the exception of the BCR usage of family 3, which have remarkable similarities, the 
other families are alike in being all M-CLL cases in family 1 and both family 2 cases being 
U-CLL. In a large cohort of 327 CLL patients from 214 families the IGHV gene usage was 
analyzed and compared with sporadic CLL cases24. In this study, it was found that there was 
no relationship in IGHV gene usage between CLL patients of a family. This suggests that 
familial CLL is generally comparable with sporadic CLL based on the BCR, and makes a genetic 
predisposition more supportive for being the basis of familial CLL 24. 
SNP array-based chromosome alterations are overlapping between and 
within families with CLL
Several genetic alterations are common in CLL disease onset or clonal evolution. 
Accumulation of passenger mutations in normal counterpart cells can be an initiating event 
in leukemogenesis 25, where after subsequent driver aberrations can induce the next steps 
in clonal evolution and are generally found throughout the CLL patient population. Deletion 
of the short arm of chromosome 13 (del13q), trisomy 12, and mutations in the MYD88 gene, 
encoding a signaling molecule acting downstream of Toll-like receptors, are examples of such 
driver aberrations in CLL25, 26. Clonal evolution is frequently directed by subclonal mutations 
which result in increased proliferation and decreased apoptosis over other CLL cells 25, 27. 
Such alterations include gain-of-function mutations in NOTCH1, SF3B1, and RAS genes and 
loss-of-function mutations in ATM, a protein that functions in DNA double strand break (DSB) 
repair, and TP53 involved in inducing apoptosis, or loss of chromosomal arms where these 
genes are located, i.e. del11q and del17p respectively 25, 26. 
Family member Stereotypic BCR HCDR3 LCDR3
3A - ARAWSSAWKYYFDY QVWDSGSDHPWV
3B CLL#169 ARDGVGAPY QVWDSGTDHPWV
3C CLL#2 ARDQNGMDV QVWDSSSDHPWV
3D - ARDGGPCGDCYQ LVWDSGSDHPYV
Table 1. HCDR3 and LCDR3 amino acid composition in members of CLL family 3
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To see whether there are common genetic alterations at the chromosomal and allelic 
level uniformly present in familial CLL, all our familial CLL cases were analyzed by means of a 
SNP array. Notably, the most common chromosomal aberration in CLL, the 13q14.2-13q14.3 
allelic deletion, was detected in all siblings of families 1 and 3 (Table 2). In contrast, the 
siblings of family 2 did not show this deletion, but both were found to contain the trisomy 
12 aberration, albeit that in family member 2B this aberration was only found in part of 
the CLL cells (Table 2 and data not shown). So we could detect the CLL–associated driver 
genetic aberrations, i.e. del13q in families 1 and 3, and trisomy 12 in family 2. Interestingly, 
in family member 3C an additional deletion of 11q21-11q24 was found (Table 2). Previously 
CLL#2 subset has been associated with a higher incidence of 11q22-q23 deletions and SF3B1 
mutations 28, 29. Since family member 3C was found to have this particular 11q deletion, 
additional mutation analysis might shed light on the existence of SF3B1 mutations in the CLL 
clone of this individual.
We then focused on less known and smaller chromosomal alterations (reviewed in 30) 
occurring in all CLL family members within one family (Table 3 + Supplementary tables). 
Deletion of one allele or loss of heterozygosity (LOH) of chromosome region 11q22.3, where 
the ATM gene is located, was detected in the members of family 1. 11q22.3 LOH was also 
seen in family 2, albeit that this was in an adjacent location, not including ATM. Interestingly, 
in both families 2 and 3 also 11q23.1 LOH was seen. Chromosome 17p13.1 deletion, which 
is associated with loss of the TP53 gene, we did not identify this loss in one of our families, 
although in family 1 we did detect LOH of the adjacent cytoband 17p13.2. Besides looking 
at these most common deletions, we also evaluated whether other known chromosomal 
aberrations for CLL30 could be found in these CLL families. Although we could not detect other 
known copy number gains for CLL in our families, we did observe losses that have earlier 
been described in CLL. LOH in chromosome region 3p21.31 was seen in families 2 and 3, LOH 
of 4p15.2 (associated with del11q and del17p) in family 3, and LOH of 9q12-q21.11 (earlier 
described as the 9q13-q21.11 region) in families 1 and 2. We detected LOH of the 10q24.33 
Table 2. Chromosomal aberrations as observed in the different members of the three families with CLL
Chromosomal aberration Family member
Family 1
13q14.2-13q14.3 del 1A, 1B, 1C, 1D
2q34-2q35 del 1C
Family 2
Trisomy 12 2A, 2B
Family 3
13q14.2-13q14.3 del 3A, 3B, 3C, 3D
11q21-11q24 del 3C
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region in family 3, which is adjacent to the 10q24.32 region that was earlier described in 
association with the NFKB2 gene. Loss of 14q24.1-32.3 was previously found in association 
with trisomy 12 in CLL, and in line with this finding we found LOH of 14q32.2-q32.33 in family 
2. In addition we detected 14q31.1 LOH for family 3. Finally, loss of 15q15.1 with designated 
candidate gene MGA, was detected in family 1 (15q15.1-15.3) and family 2 (15q15.1). Of 
note, the affected location did not contain the MGA gene. In fact in family 1, the LOH region 
involved the DNA damage repair gene TP53BP, whereas in family 2 it involved the RAD51 
gene, also known to be important for DSB repair. 
Finally, it would be of interest to determine using whole genome or whole exome next-
generation-sequencing approaches whether there are shared mutations in the non-CLL cells 
within each of these families, as this could point to predisposing events in CLL development. 
Additionally, using next-generation-sequencing methodology it would be relevant to evaluate 
whether comparable patterns of clonal evolution can be detected in the CLL clones within 
each family. 
SUMMARY
The three families with siblings with CLL, as described in this study, illustrate that both 
immunogenetic and chromosomal similarities exist within these families in a disease that is 
known to be quite heterogeneous. Interestingly, from the immunogenetic standpoint these 
families represent three completely different groups of CLL, i.e. M-CLL (family 1), U-CLL (family 
2) and CLL#2-like CLL (family 3), with member 3C being a true CLL#2 case and member 3B a 
closely related CLL#169 case. Additionally, several common chromosomal aberrations, which 
have been shown to be of prognostic significance, could be detected for all siblings of a CLL 
family. In families 1 and 3 this concerned 11q14.2-11q14.3 deletions, whereas both family 2 
members had trisomy 12. Also, other minor losses, which have previously been associated 
with CLL, could be detected for all siblings within the respective families. Further analysis at 
Table 3. Loss of heterozygosity observed in three families with CLL
Chromosomal aberration - Loss of heterozygosity Family
3p21.31 1, 2
4p15.2 3
9q12-q21.11 1, 2
10q24.33 3 (associated with NFκB2 gene)
11q22.3 1 (region incl ATM), 2 (region not including ATM)
14q24.1-32.3 2
15q15.1 1 (region incl TP53BP), 2 (region incl RAD51)
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the gene level (e.g. whole exome or whole genome sequencing) is required to identify the 
relevant genes that are involved in CLL pathogenesis in the members of each of these three 
families.
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SUPPLEMENTARY DATA
SNP analysis 
Family 1 
Region
Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chr5:104,431,051-104,505,444 74393 q21.2 - q21.3 CN Loss 1 0 100.0
chr13:50,594,028-50,977,946 383918 q14.2 - q14.3 CN Loss 6 2 100.0
chrY:2,655,180-3,274,356 619176 p11.31 - p11.2 CN Loss 4 0 100.0
chrY:6,088,397-6,453,668 365271 p11.2 CN Loss 14 0 100.0
chrY:6,614,711-9,974,735 3360024 p11.2 CN Loss 41 0 100.0
chrY:13,504,884-19,567,718 6062834 q11.21 - q11.221 CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - q11.223 CN Loss 55 0 100.0
chr1:35,379,026-36,172,748 793722 p34.3 LOH 10 0 100.0
chr1:49,217,100-50,594,083 1376983 p33 LOH 5 0 100.0
chr1:72,554,899-74,232,322 1677423 p31.1 LOH 2 0 100.0
chr1:102,892,857-103,489,911 597054 p21.1 LOH 1 0 100.0
chr1:185,560,304-186,155,434 595130 q25.3 - q31.1 LOH 3 0 100.0
chr2:27,997,621-28,600,002 602381 p23.2 LOH 7 1 100.0
chr2:74,468,875-74,969,186 500311 p13.1 LOH 24 0 100.0
chr2:110,471,451-111,450,478 979027 q13 LOH 27 3 100.0
chr2:175,584,886-176,424,238 839352 q31.1 LOH 5 1 100.0
chr2:198,143,796-198,956,120 812324 q33.1 LOH 12 0 100.0
chr2:203,634,425-204,414,782 780357 q33.2 LOH 8 0 100.0
chr3:52,269,021-52,817,501 548480 p21.2 - p21.1 LOH 25 2 100.0
chr3:74,696,073-75,246,290 550217 p12.3 LOH 0 0 100.0
chr3:138,121,037-138,843,786 722749 q22.3 - q23 LOH 12 0 100.0
chr4:33,464,268-34,721,840 1257572 p15.1 LOH 1 0 100.0
chr4:47,707,595-48,228,024 520429 p12 - p11 LOH 8 0 100.0
chr4:48,353,699-50,400,000 2046301 p11 - q11 LOH 7 0 100.0
chr4:52,697,856-53,310,666 612810 q11 - q12 LOH 4 0 100.0
chr5:61,459,189-61,990,246 531057 q12.1 LOH 5 0 100.0
chr5:109,640,022-110,385,094 745072 q22.1 LOH 2 1 100.0
chr5:121,046,612-121,490,403 443791 q23.1 - q23.2 LOH 4 0 100.0
chr5:176,900,534-177,083,853 183319 q35.3 LOH 8 0 100.0
chr6:27,812,754-28,325,491 512737 p22.1 LOH 23 0 100.0
chr6:34,488,013-35,366,938 878925 p21.31 LOH 12 0 100.0
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Region
Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chr6:63,145,180-63,856,600 711420 q11.1 - q12 LOH 0 0 100.0
chr6:83,969,883-84,940,602 970719 q14.2 - q14.3 LOH 7 0 100.0
chr6:121,193,332-121,721,042 527710 q22.31 LOH 1 0 100.0
chr6:128,530,979-129,060,850 529871 q22.33 LOH 1 0 100.0
chr8:42,468,283-43,570,212 1101929 p11.21 - p11.1 LOH 10 1 100.0
chr8:47,002,900-49,782,743 2779843 q11.1 - q11.21 LOH 10 0 100.0
chr8:50,041,266-50,281,380 240114 q11.21 LOH 0 0 100.0
chr9:40,714,011-44,887,313 4173302 p13.1 - p11.2 LOH 29 0 100.0
chr9:65,629,772-69,410,435 3780663 q12 - q21.11 LOH 19 3 100.0
chr10:22,097,219-22,778,784 681565 p12.31 - p12.2 LOH 8 0 100.0
chr11:107,836,378-
108,377,055
540677 q22.3 LOH 7 0 100.0
chr12:88,346,583-89,141,109 794526 q21.32 - q21.33 LOH 5 0 100.0
chr12:112,090,689-
112,870,613
779924 q24.12 - q24.13 LOH 15 3 100.0
chr13:19,967,131-20,479,141 512010 q12.11 LOH 4 0 100.0
chr15:42,628,517-44,360,693 1732176 q15.1 - q15.3 LOH 39 1 100.0
chr15:44,506,807-45,093,361 586554 q15.3 - q21.1 LOH 9 0 100.0
chr15:50,035,265-50,193,311 158046 q21.2 LOH 1 0 100.0
chr16:21,980,261-22,674,107 693846 p12.2 LOH 11 0 100.0
chr16:66,914,076-67,031,763 117687 q22.1 LOH 7 0 100.0
chr17:4,838,934-5,399,205 560271 p13.2 LOH 25 2 100.0
chr17:58,047,835-58,826,484 778649 q23.1 - q23.2 LOH 14 1 100.0
chr18:18,556,505-19,485,452 928947 q11.1 - q11.2 LOH 10 3 100.0
chrX:18,940,301-19,514,138 573837 p22.13 - p22.12 LOH 4 0 100.0
chrX:27,457,880-28,033,736 575856 p21.3 LOH 4 0 100.0
chrX:35,866,731-36,448,757 582026 p21.1 LOH 5 0 100.0
chrX:36,867,611-37,648,093 780482 p21.1 - p11.4 LOH 6 0 100.0
chrX:41,238,580-41,814,194 575614 p11.4 LOH 4 0 100.0
chrX:47,515,770-48,056,381 540611 p11.23 LOH 13 0 100.0
chrX:53,158,285-55,189,679 2031394 p11.22 - p11.21 LOH 28 5 100.0
chrX:70,879,864-71,616,164 736300 q13.1 LOH 16 0 100.0
chrX:78,609,014-80,019,624 1410610 q21.1 LOH 5 0 100.0
chrX:84,031,249-85,101,938 1070689 q21.1 - q21.2 LOH 6 1 100.0
chrX:93,231,600-95,058,136 1826536 q21.32 - q21.33 LOH 0 1 100.0
chrX:96,413,763-96,929,550 515787 q21.33 LOH 2 0 100.0
chrX:100,866,801-102,191,205 1324404 q22.1 LOH 22 0 100.0
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Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chrX:104,464,158-104,950,968 486810 q22.3 LOH 2 0 100.0
chrX:109,569,422-111,390,962 1821540 q23 LOH 13 0 100.0
chrX:113,769,528-114,561,241 791713 q23 LOH 12 6 100.0
chrX:116,605,263-117,608,772 1003509 q24 LOH 3 1 100.0
chrX:120,222,656-122,317,172 2094516 q24 - q25 LOH 0 1 100.0
chrX:129,624,961-130,779,855 1154894 q26.1 - q26.2 LOH 5 0 100.0
chrX:135,586,894-136,176,088 589194 q26.3 LOH 9 1 100.0
chrX:138,457,383-139,132,961 675578 q27.1 LOH 6 1 100.0
chrX:153,183,036-154,918,789 1735753 q28 LOH 92 8 100.0
Family 2
Region
Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chr12:31,240,839-
31,407,801
166962 p11.21 Allelic 
Imbalance
1 0 100.0
chrY:7,464,715-10,077,460 2612745 p11.2 Allelic 
Imbalance
38 0 100.0
chr12:0-256,127 256127 p13.33 CN Gain 4 0 100.0
chr12:3,302,395-3,340,081 37686 p13.32 CN Gain 1 0 100.0
chr12:9,219,050-9,272,773 53723 p13.31 CN Gain 2 0 100.0
chr12:17,525,916-
17,639,517
113601 p12.3 CN Gain 0 0 100.0
chr12:19,414,992-
20,922,051
1507059 p12.3 - p12.2 CN Gain 5 0 100.0
chr12:21,447,001-
21,464,915
17914 p12.1 CN Gain 1 0 100.0
chr12:31,240,839-
31,407,801
166962 p11.21 CN Gain 1 0 100.0
chr12:33,846,842-
35,800,000
1953158 p11.1 - q11 CN Gain 1 0 100.0
chr12:52,960,073-
53,010,650
50577 q13.13 CN Gain 4 0 100.0
chr12:54,385,273-
54,687,878
302605 q13.13 CN Gain 19 3 100.0
chr12:59,459,881-
62,137,864
2677983 q14.1 CN Gain 2 0 100.0
chr12:64,324,996-
64,409,482
84486 q14.2 CN Gain 1 0 100.0
chr12:69,513,557-
69,542,929
29372 q15 CN Gain 0 0 100.0
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Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chr12:71,249,238-
71,388,234
138996 q15 CN Gain 1 0 100.0
chr12:71,482,919-
71,570,918
87999 q15 - q21.1 CN Gain 1 0 100.0
chr12:72,728,822-
73,077,229
348407 q21.1 CN Gain 1 0 100.0
chr12:73,343,040-
74,402,940
1059900 q21.1 CN Gain 1 0 100.0
chr12:74,850,958-
75,015,653
164695 q21.1 CN Gain 1 0 100.0
chr12:76,636,821-
76,941,675
304854 q21.2 CN Gain 2 0 100.0
chr12:77,215,437-
77,398,066
182629 q21.2 CN Gain 2 0 100.0
chr12:77,722,882-
78,269,390
546508 q21.2 CN Gain 1 0 100.0
chr12:78,508,794-
81,089,543
2580749 q21.2 - q21.31 CN Gain 8 1 100.0
chr12:82,537,785-
82,976,126
438341 q21.31 CN Gain 2 0 100.0
chr12:83,147,536-
85,410,579
2263043 q21.31 CN Gain 3 0 100.0
chr12:85,920,682-
87,533,262
1612580 q21.31 - q21.32 CN Gain 4 0 100.0
chr12:98,207,772-
98,487,513
279741 q23.1 CN Gain 1 2 100.0
chr12:99,196,800-
99,229,824
33024 q23.1 CN Gain 1 0 100.0
chr12:101,194,298-
101,379,071
184773 q23.1 CN Gain 1 0 100.0
chr12:126,738,610-
126,881,735
143125 q24.32 CN Gain 0 0 100.0
chr12:127,850,708-
128,208,987
358279 q24.32 CN Gain 1 0 100.0
chr12:128,406,449-
128,522,391
115942 q24.32 CN Gain 1 0 100.0
chr12:129,171,957-
129,247,690
75733 q24.32 CN Gain 1 0 100.0
chr12:129,459,964-
129,530,498
70534 q24.33 CN Gain 1 0 100.0
chr12:129,808,003-
129,870,681
62678 q24.33 CN Gain 1 0 100.0
chr12:130,808,601-
130,911,986
103385 q24.33 CN Gain 2 0 100.0
chr12:131,557,897-
131,654,487
96590 q24.33 CN Gain 2 0 100.0
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Region 
Length
Cytoband  
Location Event Genes miRNAs Frequency %
chrY:5,893,803-6,088,397 194594 p11.2 CN Gain 0 0 100.0
chr1:111,927,724-
111,939,188
11464 p13.2 CN Loss 1 0 100.0
chr8:9,054,811-9,063,535 8724 p23.1 CN Loss 1 0 100.0
chr15:21,903,815-
22,701,317
797502 q11.2 CN Loss 15 4 100.0
chr19:24,378,791-
24,629,285
250494 p12 - p11 CN Loss 0 0 100.0
chrX:2,699,012-58,483,247 55784235 p22.33 - p11.1 CN Loss 460 34 100.0
chrX:61,719,290-
154,918,789
93199499 q11.1 - q28 CN Loss 802 82 100.0
chrY:2,655,180-3,205,097 549917 p11.31 - p11.2 CN Loss 4 0 100.0
chrY:6,088,397-10,077,460 3989063 p11.2 CN Loss 55 0 100.0
chrY:12,500,000-19,567,718 7067718 q11.1 - q11.221 CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
CN Loss 55 0 100.0
chrY:27,390,536-28,817,458 1426922 q11.23 - q12 CN Loss 7 0 100.0
chr1:4,016,259-4,717,365 701106 p36.32 LOH 2 0 100.0
chr1:5,786,633-7,123,793 1337160 p36.31 LOH 26 2 100.0
chr1:35,380,394-36,653,079 1272685 p34.3 LOH 20 0 100.0
chr1:52,444,299-53,314,329 870030 p32.3 LOH 14 0 100.0
chr1:102,715,763-
103,228,130
512367 p21.1 LOH 0 0 100.0
chr1:108,754,355-
109,260,195
505840 p13.3 LOH 6 0 100.0
chr1:146,982,244-
150,273,115
3290871 q21.1 - q21.2 LOH 72 2 100.0
chr1:155,198,085-
155,856,049
657964 q22 LOH 20 1 100.0
chr1:184,919,131-
185,321,452
402321 q25.3 LOH 6 0 100.0
chr1:189,878,840-
189,917,632
38792 q31.1 LOH 0 0 100.0
chr1:196,931,277-
197,833,592
902315 q31.3 LOH 6 0 100.0
chr1:248,578,156-
249,250,621
672465 q44 LOH 18 1 100.0
chr2:72,400,279-73,127,289 727010 p13.2 LOH 2 0 100.0
chr2:83,038,741-83,445,915 407174 p12 - p11.2 LOH 1 0 100.0
chr2:115,582,560-
116,803,204
1220644 q14.1 LOH 2 0 100.0
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Cytoband  
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chr2:120,415,435-
121,073,997
658562 q14.2 LOH 5 0 100.0
chr2:122,321,522-
122,501,276
179754 q14.2 - q14.3 LOH 3 0 100.0
chr2:135,596,163-
137,047,657
1451494 q21.3 - q22.1 LOH 15 2 100.0
chr2:144,680,114-
145,603,608
923494 q22.3 LOH 6 0 100.0
chr2:155,651,456-
156,421,270
769814 q24.1 LOH 1 0 100.0
chr2:162,934,383-
163,694,830
760447 q24.2 LOH 7 0 100.0
chr2:188,885,530-
189,739,668
854138 q32.1 - q32.2 LOH 3 1 100.0
chr2:189,767,583-
189,845,650
78067 q32.2 LOH 3 2 100.0
chr2:189,881,782-
190,945,244
1063462 q32.2 LOH 11 1 100.0
chr2:196,447,589-
197,139,484
691895 q32.3 LOH 5 0 100.0
chr2:197,302,186-
197,467,881
165695 q32.3 - q33.1 LOH 1 0 100.0
chr2:209,680,376-
211,378,875
1698499 q34 LOH 10 0 100.0
chr2:229,364,088-
229,901,642
537554 q36.3 LOH 1 0 100.0
chr2:235,193,356-
235,982,045
788689 q37.1 - q37.2 LOH 2 0 100.0
chr3:17,217,661-17,919,247 701586 p24.3 LOH 1 0 100.0
chr3:37,814,046-38,362,894 548848 p22.2 LOH 12 1 100.0
chr3:46,703,041-47,652,726 949685 p21.31 LOH 20 0 100.0
chr3:47,940,266-49,361,616 1421350 p21.31 LOH 53 10 100.0
chr3:50,442,701-52,012,422 1569721 p21.31 - p21.2 LOH 27 1 100.0
chr3:57,214,270-57,963,559 749289 p14.3 LOH 8 0 100.0
chr3:58,698,805-59,262,425 563620 p14.2 LOH 2 0 100.0
chr3:74,874,137-75,688,849 814712 p12.3 LOH 4 2 100.0
chr3:81,189,382-82,269,480 1080098 p12.2 LOH 1 0 100.0
chr3:84,962,866-85,519,268 556402 p12.1 LOH 2 1 100.0
chr3:89,144,116-91,000,000 1855884 p11.1 - q11.1 LOH 1 0 100.0
chr3:93,537,290-95,152,163 1614873 q11.1 - q11.2 LOH 6 0 100.0
chr3:96,453,404-97,451,705 998301 q11.2 LOH 1 0 100.0
chr3:98,769,252-99,361,262 592010 q12.1 LOH 2 0 100.0
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chr3:123,211,813-
123,963,648
751835 q21.1 - q21.2 LOH 8 1 100.0
chr3:126,569,921-
127,473,759
903838 q21.3 LOH 11 2 100.0
chr3:128,693,984-
129,687,483
993499 q21.3 - q22.1 LOH 22 1 100.0
chr3:130,562,656-
131,149,371
586715 q22.1 LOH 6 0 100.0
chr3:140,221,000-
141,453,382
1232382 q23 LOH 8 0 100.0
chr3:145,338,487-
149,232,963
3894476 q24 - q25.1 LOH 20 0 100.0
chr3:152,307,615-
153,017,777
710162 q25.2 LOH 2 0 100.0
chr3:159,254,869-
159,905,509
650640 q25.33 LOH 6 0 100.0
chr3:160,406,601-
161,139,545
732944 q25.33 - q26.1 LOH 4 0 100.0
chr3:162,439,405-
163,241,531
802126 q26.1 LOH 1 0 100.0
chr3:175,115,958-
175,670,087
554129 q26.31 LOH 3 0 100.0
chr3:191,064,673-
191,594,905
530232 q28 LOH 3 0 100.0
chr3:197,316,962-
198,022,430
705468 q29 LOH 11 1 100.0
chr4:35,689,092-36,299,203 610111 p15.1 - p14 LOH 3 0 100.0
chr4:43,195,130-43,767,034 571904 p13 LOH 0 0 100.0
chr4:48,333,953-50,400,000 2066047 p11 - q11 LOH 7 0 100.0
chr4:62,631,861-63,335,182 703321 q13.1 LOH 2 0 100.0
chr4:65,630,867-66,146,740 515873 q13.1 LOH 1 0 100.0
chr4:66,344,312-67,206,875 862563 q13.1 - q13.2 LOH 2 1 100.0
chr4:74,980,499-75,654,445 673946 q13.3 LOH 5 0 100.0
chr4:81,205,180-81,957,891 752711 q21.21 LOH 3 0 100.0
chr4:86,692,130-88,310,459 1618329 q21.23 - q22.1 LOH 12 2 100.0
chr4:88,431,819-89,285,296 853477 q22.1 LOH 9 0 100.0
chr4:96,733,414-97,648,466 915052 q22.3 LOH 1 0 100.0
chr4:109,875,222-
110,630,257
755035 q25 LOH 5 1 100.0
chr4:131,100,989-
131,641,353
540364 q28.3 LOH 0 0 100.0
chr5:23,723,195-24,810,874 1087679 p14.2 - p14.1 LOH 1 0 100.0
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chr5:26,389,096-27,810,897 1421801 p14.1 LOH 2 0 100.0
chr5:32,650,154-33,521,774 871620 p13.3 LOH 3 0 100.0
chr5:45,484,737-46,399,093 914356 p12 - p11 LOH 1 0 100.0
chr5:54,320,927-54,862,001 541074 q11.2 LOH 14 4 100.0
chr5:70,305,696-70,970,864 665168 q13.2 LOH 7 0 100.0
chr5:74,285,356-74,925,970 640614 q13.3 LOH 6 0 100.0
chr5:79,007,849-79,602,200 594351 q14.1 LOH 6 0 100.0
chr5:87,783,396-87,789,234 5838 q14.3 LOH 0 0 100.0
chr5:100,083,616-
100,606,712
523096 q21.1 LOH 1 1 100.0
chr5:102,102,192-
102,829,017
726825 q21.1 - q21.2 LOH 4 0 100.0
chr5:109,614,961-
110,388,292
773331 q22.1 LOH 2 1 100.0
chr5:151,905,383-
152,471,313
565930 q33.1 LOH 1 0 100.0
chr5:162,737,230-
174,289,546
11552316 q34 - q35.2 LOH 67 9 100.0
chr6:27,643,618-27,874,755 231137 p22.1 LOH 18 0 100.0
chr6:46,150,913-47,007,505 856592 p21.1 - p12.3 LOH 12 0 100.0
chr6:63,757,593-64,355,373 597780 q12 LOH 3 0 100.0
chr6:69,303,495-69,864,787 561292 q12 LOH 2 0 100.0
chr7:33,017,558-33,554,811 537253 p14.3 LOH 4 0 100.0
chr7:83,947,969-84,714,347 766378 q21.11 LOH 2 0 100.0
chr7:97,657,477-98,297,659 640182 q21.3 - q22.1 LOH 6 0 100.0
chr7:98,784,554-
100,218,724
1434170 q22.1 LOH 70 5 100.0
chr7:118,350,126-
120,161,811
1811685 q31.31 LOH 1 0 100.0
chr7:127,977,707-
128,521,335
543628 q32.1 LOH 15 0 100.0
chr7:132,895,740-
133,740,061
844321 q33 LOH 3 1 100.0
chr8:33,198,980-33,976,120 777140 p12 LOH 5 0 100.0
chr8:50,400,061-51,371,902 971841 q11.21 LOH 1 0 100.0
chr8:57,801,924-58,414,726 612802 q12.1 LOH 5 0 100.0
chr8:60,941,817-61,544,883 603066 q12.1 LOH 3 0 100.0
chr8:71,466,636-72,016,193 549557 q13.3 LOH 4 0 100.0
chr8:91,245,848-91,831,782 585934 q21.3 LOH 4 0 100.0
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chr8:104,452,240-
105,466,077
1013837 q22.3 LOH 4 0 100.0
chr8:106,768,766-
107,381,279
612513 q23.1 LOH 3 0 100.0
chr8:111,232,782-
112,194,918
962136 q23.2 - q23.3 LOH 2 0 100.0
chr8:112,612,536-
114,668,761
2056225 q23.3 LOH 2 1 100.0
chr8:120,030,797-
120,562,718
531921 q24.12 LOH 3 1 100.0
chr9:30,118,918-30,824,061 705143 p21.1 LOH 1 0 100.0
chr9:40,714,011-44,887,313 4173302 p13.1 - p11.2 LOH 29 0 100.0
chr9:65,629,772-69,410,435 3780663 q12 - q21.11 LOH 19 3 100.0
chr9:75,135,868-75,708,218 572350 q21.13 LOH 3 0 100.0
chr10:57,392,918-
58,341,005
948087 q21.1 LOH 1 0 100.0
chr10:73,795,084-
75,737,378
1942294 q22.1 - q22.2 LOH 37 1 100.0
chr10:86,442,005-
86,501,917
59912 q23.1 LOH 0 0 100.0
chr11:109,811,640-
109,865,601
53961 q22.3 LOH 0 0 100.0
chr11:111,340,514-
111,968,864
628350 q23.1 LOH 20 2 100.0
chr12:29,907,850-
30,500,007
592157 p11.22 LOH 1 0 100.0
chr12:42,351,506-
42,874,797
523291 q12 LOH 5 1 100.0
chr12:43,974,715-
44,929,120
954405 q12 LOH 5 0 100.0
chr12:75,048,084-
75,666,423
618339 q21.1 LOH 1 0 100.0
chr12:79,922,622-
80,624,751
702129 q21.2 - q21.31 LOH 3 0 100.0
chr12:81,344,005-
81,863,060
519055 q21.31 LOH 4 1 100.0
chr12:87,806,746-
88,346,583
539837 q21.32 LOH 1 0 100.0
chr12:88,816,482-
89,327,106
510624 q21.32 - q21.33 LOH 1 0 100.0
chr12:90,267,231-
91,258,064
990833 q21.33 LOH 0 0 100.0
chr12:92,064,462-
92,680,637
616175 q21.33 - q22 LOH 2 0 100.0
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chr13:65,384,770-
66,338,879
954109 q21.31 - q21.32 LOH 0 0 100.0
chr13:71,977,167-
72,478,934
501767 q21.33 LOH 1 0 100.0
chr13:77,540,443-
78,197,615
657172 q22.3 LOH 5 0 100.0
chr13:87,041,530-
87,732,973
691443 q31.1 - q31.2 LOH 0 0 100.0
chr14:37,447,823-
38,100,171
652348 q13.3 - q21.1 LOH 4 0 100.0
chr14:40,341,881-
42,311,608
1969727 q21.1 LOH 2 0 100.0
chr14:42,557,388-
43,094,022
536634 q21.1 LOH 0 0 100.0
chr14:56,527,831-
57,247,713
719882 q22.3 LOH 2 0 100.0
chr14:63,291,869-
63,898,582
606713 q23.2 LOH 4 0 100.0
chr14:98,891,530-
107,349,540
8458010 q32.2 - q32.33 LOH 195 70 100.0
chr15:28,179,087-
29,424,997
1245910 q13.1 LOH 20 2 100.0
chr15:29,734,810-
30,296,926
562116 q13.1 LOH 2 0 100.0
chr15:35,445,410-
35,952,899
507489 q14 LOH 4 1 100.0
chr15:40,641,754-
41,146,399
504645 q15.1 LOH 19 0 100.0
chr15:42,993,637-
43,542,417
548780 q15.2 LOH 8 0 100.0
chr15:50,035,265-
50,726,076
690811 q21.2 LOH 8 1 100.0
chr15:52,356,004-
53,014,853
658849 q21.2 - q21.3 LOH 9 1 100.0
chr15:53,904,718-
54,591,907
687189 q21.3 LOH 2 0 100.0
chr16:25,071,876-
25,594,081
522205 p12.1 LOH 5 0 100.0
chr17:18,910,214-
19,595,331
685117 p11.2 LOH 22 1 100.0
chr17:27,923,227-
28,562,673
639446 q11.2 LOH 8 2 100.0
chr17:58,042,824-
58,907,819
864995 q23.1 - q23.2 LOH 14 1 100.0
chr18:36,365,993-
36,985,148
619155 q12.2 LOH 1 0 100.0
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chr18:61,126,522-
61,655,577
529055 q21.33 - q22.1 LOH 11 0 100.0
chr18:72,077,495-
72,739,391
661896 q22.3 LOH 5 0 100.0
chr19:21,166,576-
22,086,094
919518 p12 LOH 11 0 100.0
chr19:22,687,065-
23,378,095
691030 p12 LOH 10 0 100.0
chr19:42,740,369-
43,427,508
687139 q13.2 - q13.31 LOH 20 1 100.0
chr19:55,412,185-
56,428,148
1015963 q13.42 - q13.43 LOH 54 5 100.0
chr19:56,776,801-
57,604,668
827867 q13.43 LOH 17 0 100.0
chr20:21,754,925-
22,266,532
511607 p11.22 LOH 2 0 100.0
chr20:24,792,689-
26,293,985
1501296 p11.21 - p11.1 LOH 21 1 100.0
chr20:30,631,997-
31,187,852
555855 q11.21 LOH 10 1 100.0
chr20:32,848,215-
33,418,434
570219 q11.22 LOH 9 1 100.0
chr22:22,556,516-
23,267,314
710798 q11.22 LOH 10 2 100.0
chr22:32,026,214-
32,550,766
524552 q12.2 - q12.3 LOH 8 0 100.0
chrX:2,699,012-58,483,247 55784235 p22.33 - p11.1 LOH 460 34 100.0
chrX:61,719,290-88,460,879 26741589 q11.1 - q21.31 LOH 151 14 100.0
chrX:92,364,640-
154,918,789
62554149 q21.32 - q28 LOH 647 68 100.0
chrY:14,368,629-19,567,718 5199089 q11.21 - q11.221 LOH 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
LOH 55 0 100.0
Family 3
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chr2:117,777,567-117,937,434 159867 q14.1 Allelic 
Imbalance
0 0 100.0
chr2:117,777,567-117,942,955 165388 q14.1 CN Gain 0 0 100.0
chr4:64,131,761-64,152,984 21223 q13.1 CN Loss 0 0 100.0
chr13:50,565,275-50,977,946 412671 q14.2 - q14.3 CN Loss 8 3 100.0
chr13:69,250,062-69,279,507 29445 q21.33 CN Loss 0 0 100.0
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chrY:2,655,180-2,915,938 260758 p11.31 CN Loss 4 0 100.0
chrY:6,088,397-6,453,668 365271 p11.2 CN Loss 14 0 100.0
chrY:6,614,711-9,974,735 3360024 p11.2 CN Loss 41 0 100.0
chrY:13,504,884-19,567,718 6062834 q11.21 - 
q11.221
CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
CN Loss 55 0 100.0
chrY:27,390,536-28,817,458 1426922 q11.23 - q12 CN Loss 7 0 100.0
chr1:12,867,459-13,894,497 1027038 p36.21 LOH 47 0 100.0
chr1:35,380,394-36,583,527 1203133 p34.3 LOH 18 0 100.0
chr1:44,011,963-44,541,978 530015 p34.2 - p34.1 LOH 13 1 100.0
chr1:52,420,352-52,948,569 528217 p32.3 LOH 9 0 100.0
chr1:87,017,898-87,586,244 568346 p22.3 LOH 5 0 100.0
chr1:88,988,945-89,520,321 531376 p22.2 LOH 7 0 100.0
chr1:92,884,038-93,471,407 587369 p22.1 LOH 6 0 100.0
chr1:151,791,836-152,310,313 518477 q21.3 LOH 14 0 100.0
chr1:155,198,085-156,023,132 825047 q22 LOH 30 2 100.0
chr2:72,267,907-74,122,284 1854377 p13.2 - p13.1 LOH 22 0 100.0
chr2:125,743,710-126,273,043 529333 q14.3 LOH 0 0 100.0
chr2:135,279,341-136,833,450 1554109 q21.3 - q22.1 LOH 15 2 100.0
chr2:152,675,099-152,869,334 194235 q23.3 LOH 2 0 100.0
chr2:197,309,620-198,041,313 731693 q32.3 - q33.1 LOH 7 0 100.0
chr3:46,754,908-47,652,726 897818 p21.31 LOH 18 0 100.0
chr3:48,626,312-48,655,179 28867 p21.31 LOH 2 0 100.0
chr3:51,977,348-52,538,540 561192 p21.2 - p21.1 LOH 27 2 100.0
chr3:58,202,231-58,491,150 288919 p14.3 LOH 6 0 100.0
chr3:96,423,966-96,696,356 272390 q11.2 LOH 1 0 100.0
chr3:96,926,055-97,232,093 306038 q11.2 LOH 1 0 100.0
chr4:8,677,677-9,825,907 1148230 p16.1 LOH 90 1 100.0
chr4:60,857,979-61,358,488 500509 q13.1 LOH 0 0 100.0
chr4:81,208,622-81,877,198 668576 q21.21 LOH 2 0 100.0
chr4:93,607,879-94,116,170 508291 q22.1 - q22.2 LOH 1 0 100.0
chr4:131,595,687-131,791,265 195578 q28.3 LOH 0 0 100.0
chr4:170,151,499-170,647,296 495797 q33 LOH 3 0 100.0
chr5:12,010,729-12,593,544 582815 p15.2 LOH 1 0 100.0
chr5:54,523,599-55,036,332 512733 q11.2 LOH 8 1 100.0
chr5:63,165,056-63,742,557 577501 q12.2 - q12.3 LOH 2 0 100.0
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chr5:109,605,654-110,086,128 480474 q22.1 LOH 2 1 100.0
chr5:130,146,514-130,560,692 414178 q23.3 LOH 2 0 100.0
chr6:15,255,688-15,743,928 488240 p22.3 LOH 2 0 100.0
chr6:48,524,782-49,353,062 828280 p12.3 LOH 0 0 100.0
chr6:97,645,281-98,180,734 535453 q16.1 LOH 3 0 100.0
chr6:116,177,802-117,079,925 902123 q22.1 LOH 16 0 100.0
chr6:128,530,979-129,060,850 529871 q22.33 LOH 1 0 100.0
chr7:77,104,498-77,606,655 502157 q11.23 - q21.11 LOH 5 0 100.0
chr7:98,820,525-99,465,188 644663 q22.1 LOH 21 0 100.0
chr7:104,620,677-105,143,060 522383 q22.3 LOH 5 0 100.0
chr7:123,012,750-123,448,271 435521 q31.32 LOH 7 0 100.0
chr8:66,456,396-67,089,473 633077 q13.1 LOH 7 0 100.0
chr8:145,085,554-145,567,655 482101 q24.3 LOH 22 5 100.0
chr10:32,701,399-33,354,991 653592 p11.22 LOH 3 0 100.0
chr10:103,471,966-
103,879,746
407780 q24.32 LOH 8 0 100.0
chr11:14,341,632-14,895,559 553927 p15.2 LOH 4 0 100.0
chr11:84,843,246-85,386,644 543398 q14.1 LOH 4 0 100.0
chr11:111,390,064-
111,983,755
593691 q23.1 LOH 17 0 100.0
chr12:33,444,058-35,800,000 2355942 p11.1 - q11 LOH 2 0 100.0
chr12:37,876,400-39,325,273 1448873 q11 - q12 LOH 2 0 100.0
chr12:50,686,641-51,147,777 461136 q13.12 LOH 3 0 100.0
chr14:55,308,648-55,883,645 574997 q22.2 - q22.3 LOH 10 1 100.0
chr14:81,065,439-81,747,472 682033 q31.1 LOH 5 0 100.0
chr15:43,256,833-43,905,857 649024 q15.2 - q15.3 LOH 16 0 100.0
chr15:56,785,467-57,254,721 469254 q21.3 LOH 3 0 100.0
chr15:64,312,554-64,970,632 658078 q22.31 LOH 9 0 100.0
chr15:67,463,337-68,238,646 775309 q22.33 - q23 LOH 9 0 100.0
chr15:72,104,485-73,332,708 1228223 q23 - q24.1 LOH 17 1 100.0
chr15:76,540,526-77,232,177 691651 q24.2 - q24.3 LOH 5 1 100.0
chr16:21,738,928-22,674,107 935179 p12.2 LOH 13 0 100.0
chr16:28,328,430-28,825,827 497397 p11.2 LOH 18 2 100.0
chr16:30,556,442-31,010,980 454538 p11.2 LOH 25 2 100.0
chr16:32,151,873-34,231,404 2079531 p11.2 LOH 16 0 100.0
chr17:27,890,925-29,303,662 1412737 q11.2 LOH 25 2 100.0
chr17:30,106,603-30,612,412 505809 q11.2 LOH 8 0 100.0
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chr17:58,321,300-58,826,484 505184 q23.2 LOH 6 0 100.0
chr18:38,845,074-39,409,691 564617 q12.3 LOH 1 0 100.0
chr19:42,803,185-43,392,144 588959 q13.2 LOH 16 1 100.0
chr20:21,553,601-21,754,925 201324 p11.22 LOH 3 0 100.0
chrX:18,882,933-19,538,442 655509 p22.13 - p22.12 LOH 5 0 100.0
chrX:19,703,881-20,334,542 630661 p22.12 LOH 9 1 100.0
chrX:20,537,739-21,689,798 1152059 p22.12 LOH 2 0 100.0
chrX:36,799,171-37,772,276 973105 p21.1 - p11.4 LOH 7 0 100.0
chrX:49,104,417-50,534,869 1430452 p11.23 - p11.22 LOH 79 8 100.0
chrX:53,909,369-54,497,617 588248 p11.22 LOH 5 0 100.0
chrX:64,420,830-67,003,457 2582627 q11.2 - q12 LOH 9 1 100.0
chrX:70,483,328-71,301,116 817788 q13.1 LOH 16 0 100.0
chrX:71,844,251-73,542,576 1698325 q13.2 LOH 31 5 100.0
chrX:73,648,249-73,662,587 14338 q13.2 LOH 1 0 100.0
chrX:73,791,519-77,370,364 3578845 q13.2 - q21.1 LOH 18 2 100.0
chrX:84,167,819-84,961,903 794084 q21.1 - q21.2 LOH 6 0 100.0
chrX:98,465,617-99,154,899 689282 q22.1 LOH 1 0 100.0
chrX:99,253,470-99,765,160 511690 q22.1 LOH 1 0 100.0
chrX:110,110,735-111,200,966 1090231 q23 LOH 8 0 100.0
chrX:111,657,286-111,856,925 199639 q23 LOH 1 0 100.0
chrX:126,962,408-127,595,158 632750 q25 LOH 1 0 100.0
chrX:132,567,373-133,181,878 614505 q26.2 LOH 1 0 100.0
chrX:134,612,278-134,797,939 185661 q26.3 LOH 2 0 100.0
chrX:151,278,776-151,798,204 519428 q28 LOH 7 3 100.0
chrX:153,063,333-154,918,789 1855456 q28 LOH 96 8 100.0
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chr5:104,431,051-104,505,444 74393 q21.2 - q21.3 CN Loss 1 0 100.0
chrY:2,655,180-3,274,356 619176 p11.31 - p11.2 CN Loss 4 0 100.0
chrY:6,088,397-6,453,668 365271 p11.2 CN Loss 14 0 100.0
chrY:6,614,711-9,974,735 3360024 p11.2 CN Loss 41 0 100.0
chrY:13,504,884-19,567,718 6062834 q11.21 - q11.221 CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - q11.223 CN Loss 55 0 100.0
chr4:48,353,699-50,400,000 2046301 p11 - q11 LOH 7 0 100.0
chr8:47,002,900-49,782,743 2779843 q11.1 - q11.21 LOH 10 0 100.0
chr9:40,714,011-44,887,313 4173302 p13.1 - p11.2 LOH 29 0 100.0
chr9:65,629,772-69,410,435 3780663 q12 - q21.11 LOH 19 3 100.0
chrX:53,158,285-55,189,679 2031394 p11.22 - p11.21 LOH 28 5 100.0
chrX:120,222,656-122,317,172 2094516 q24 - q25 LOH 0 1 100.0
CLL Family 2
Region
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Length
Cytoband 
Location Event Genes
miR-
NAs Frequency %
chr12:31,240,839-31,407,801 166962 p11.21 Allelic 
Imbalance
1 0 100.0
chr12:0-256,127 256127 p13.33 CN Gain 4 0 100.0
chr12:3,302,395-3,340,081 37686 p13.32 CN Gain 1 0 100.0
chr12:9,219,050-9,272,773 53723 p13.31 CN Gain 2 0 100.0
chr12:17,525,916-17,639,517 113601 p12.3 CN Gain 0 0 100.0
chr12:19,414,992-20,922,051 1507059 p12.3 - p12.2 CN Gain 5 0 100.0
chr12:21,447,001-21,464,915 17914 p12.1 CN Gain 1 0 100.0
chr12:31,240,839-31,407,801 166962 p11.21 CN Gain 1 0 100.0
chr12:33,846,842-35,800,000 1953158 p11.1 - q11 CN Gain 1 0 100.0
chr12:52,960,073-53,010,650 50577 q13.13 CN Gain 4 0 100.0
chr12:54,385,273-54,687,878 302605 q13.13 CN Gain 19 3 100.0
chr12:59,459,881-62,137,864 2677983 q14.1 CN Gain 2 0 100.0
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Region
Region 
Length
Cytoband 
Location Event Genes
miR-
NAs Frequency %
chr12:64,324,996-64,409,482 84486 q14.2 CN Gain 1 0 100.0
chr12:69,513,557-69,542,929 29372 q15 CN Gain 0 0 100.0
chr12:71,249,238-71,388,234 138996 q15 CN Gain 1 0 100.0
chr12:71,482,919-71,570,918 87999 q15 - q21.1 CN Gain 1 0 100.0
chr12:72,728,822-73,077,229 348407 q21.1 CN Gain 1 0 100.0
chr12:73,343,040-74,402,940 1059900 q21.1 CN Gain 1 0 100.0
chr12:74,850,958-75,015,653 164695 q21.1 CN Gain 1 0 100.0
chr12:76,636,821-76,941,675 304854 q21.2 CN Gain 2 0 100.0
chr12:77,215,437-77,398,066 182629 q21.2 CN Gain 2 0 100.0
chr12:77,722,882-78,269,390 546508 q21.2 CN Gain 1 0 100.0
chr12:78,508,794-81,089,543 2580749 q21.2 - q21.31 CN Gain 8 1 100.0
chr12:82,537,785-82,976,126 438341 q21.31 CN Gain 2 0 100.0
chr12:83,147,536-85,410,579 2263043 q21.31 CN Gain 3 0 100.0
chr12:85,920,682-87,533,262 1612580 q21.31 - 
q21.32
CN Gain 4 0 100.0
chr12:98,207,772-98,487,513 279741 q23.1 CN Gain 1 2 100.0
chr12:99,196,800-99,229,824 33024 q23.1 CN Gain 1 0 100.0
chr12:101,194,298-101,379,071 184773 q23.1 CN Gain 1 0 100.0
chr12:126,738,610-126,881,735 143125 q24.32 CN Gain 0 0 100.0
chr12:127,850,708-128,208,987 358279 q24.32 CN Gain 1 0 100.0
chr12:128,406,449-128,522,391 115942 q24.32 CN Gain 1 0 100.0
chr12:129,171,957-129,247,690 75733 q24.32 CN Gain 1 0 100.0
chr12:129,459,964-129,530,498 70534 q24.33 CN Gain 1 0 100.0
chr12:129,808,003-129,870,681 62678 q24.33 CN Gain 1 0 100.0
chr12:130,808,601-130,911,986 103385 q24.33 CN Gain 2 0 100.0
chr12:131,557,897-131,654,487 96590 q24.33 CN Gain 2 0 100.0
chrY:5,893,803-6,088,397 194594 p11.2 CN Gain 0 0 100.0
chr1:111,927,724-111,939,188 11464 p13.2 CN Loss 1 0 100.0
chr8:9,054,811-9,063,535 8724 p23.1 CN Loss 1 0 100.0
chr15:21,903,815-22,701,317 797502 q11.2 CN Loss 15 4 100.0
chr19:24,378,791-24,629,285 250494 p12 - p11 CN Loss 0 0 100.0
chrX:2,699,012-58,483,247 55784235 p22.33 - p11.1 CN Loss 460 34 100.0
chrX:61,719,290-154,918,789 93199499 q11.1 - q28 CN Loss 802 82 100.0
chrY:2,655,180-3,205,097 549917 p11.31 - p11.2 CN Loss 4 0 100.0
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Region
Region 
Length
Cytoband 
Location Event Genes
miR-
NAs Frequency %
chrY:6,088,397-10,077,460 3989063 p11.2 CN Loss 55 0 100.0
chrY:12,500,000-19,567,718 7067718 q11.1 - 
q11.221
CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
CN Loss 55 0 100.0
chrY:27,390,536-28,817,458 1426922 q11.23 - q12 CN Loss 7 0 100.0
chr1:146,982,244-150,273,115 3290871 q21.1 - q21.2 LOH 72 2 100.0
chr14:98,891,530-107,349,540 8458010 q32.2 - q32.33 LOH 195 70 100.0
chr3:145,338,487-149,232,963 3894476 q24 - q25.1 LOH 20 0 100.0
chr4:48,333,953-50,400,000 2066047 p11 - q11 LOH 7 0 100.0
chr5:162,737,230-174,289,546 11552316 q34 - q35.2 LOH 67 9 100.0
chr8:112,612,536-114,668,761 2056225 q23.3 LOH 2 1 100.0
chr9:40,714,011-44,887,313 4173302 p13.1 - p11.2 LOH 29 0 100.0
chr9:65,629,772-69,410,435 3780663 q12 - q21.11 LOH 19 3 100.0
chrX:2,699,012-58,483,247 55784235 p22.33 - p11.1 LOH 460 34 100.0
chrX:61,719,290-88,460,879 26741589 q11.1 - q21.31 LOH 151 14 100.0
chrX:92,364,640-154,918,789 62554149 q21.32 - q28 LOH 647 68 100.0
chrY:14,368,629-19,567,718 5199089 q11.21 - 
q11.221
LOH 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
LOH 55 0 100.0
chrY:7,464,715-10,077,460 2612745 p11.2 LOH 38 0 100.0
CLL Family 3
Region
Region 
Length
Cytoband 
Location Event Genes
mi-
RNAs Frequency %
chr2:117,777,567-117,942,955 165388 q14.1 CN Gain 0 0 100.0
chr4:64,131,761-64,152,984 21223 q13.1 CN Loss 0 0 100.0
chr13:50,565,275-50,977,946 412671 q14.2 - q14.3 CN Loss 8 3 100.0
chr13:69,250,062-69,279,507 29445 q21.33 CN Loss 0 0 100.0
chrY:2,655,180-2,915,938 260758 p11.31 CN Loss 4 0 100.0
chrY:6,088,397-6,453,668 365271 p11.2 CN Loss 14 0 100.0
chrY:6,614,711-9,974,735 3360024 p11.2 CN Loss 41 0 100.0
chrY:13,504,884-19,567,718 6062834 q11.21 - 
q11.221
CN Loss 12 0 100.0
chrY:20,812,848-25,201,107 4388259 q11.222 - 
q11.223
CN Loss 55 0 100.0
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Region
Region 
Length
Cytoband 
Location Event Genes
mi-
RNAs Frequency %
chrY:27,390,536-28,817,458 1426922 q11.23 - q12 CN Loss 7 0 100.0
chr12:33,444,058-35,800,000 2355942 p11.1 - q11 LOH 2 0 100.0
chr16:32,151,873-34,231,404 2079531 p11.2 LOH 16 0 100.0
chrX:64,420,830-67,003,457 2582627 q11.2 - q12 LOH 9 1 100.0
chrX:73,648,249-73,662,587 14338 q13.2 LOH 1 0 100.0
chrX:73,791,519-77,370,364 3578845 q13.2 - q21.1 LOH 18 2 100.0
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ABSTRACT
Background
Aging is known to induce immunosenescence, resulting in alterations in both the innate 
and adaptive immune system. Here we evaluated the effects of aging on B cell subsets in 
peripheral blood of 155 immunologically healthy individuals in four age categories (range 
20-95y) via multi-parameter flow cytometry. Furthermore, we studied the naive and antigen-
experienced B cell receptor (BCR) repertoire of different age groups and compared it to the 
clonal BCR repertoire of chronic lymphocytic leukemia (CLL), a disease typically presenting 
in elderly individuals.
Results
Total numbers and relative frequencies of B cells were found to decline upon aging, 
with reductions in transitional B cells, memory cell types, and plasma blasts in the 70+y 
group. The BCR repertoire of naive mature B cells and antigen-experienced B cells did not 
clearly alter until age 70y. Clear changes in IGHV gene usage were observed in naive mature 
B cells of 70+y individuals, with a transitional pattern in the 50-70y group. IGHV gene usage 
of naive mature B cells of the 50-70y, but not the 70+y, age group resembled that of both 
younger (50-70y) and older (70+y) CLL patients. Additionally, CLL-associated stereotypic BCR 
were found as part of the healthy control BCR repertoire, with an age-associated increase in 
frequency of several stereotypic BCR (particularly subsets #2 and #5).
Conclusion
Composition of the peripheral B cell compartment changes with ageing, with clear 
reductions in non-switched and CD27+IgG+ switched memory B cells and plasma blasts 
in especially the 70+y group. The BCR repertoire is relatively stable until 70y, whereafter 
differences in IGHV gene usage are seen. Upon ageing, an increasing trend in the occurrence 
of particular CLL-associated stereotypic BCR is observed. 
Keywords: aging, B-lymphocyte, BCR repertoire, CLL, stereotypic BCR
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BACKGROUND
Changes in the immune system related to aging generally lead to increased susceptibility 
to infections, poor responses to new and evolving pathogens, poor vaccination responses, 
and higher incidence of autoimmune disorders and malignancies 1, 2. This decline in function 
of the immune system, also referred to as immunosenescence, is the result of alterations 
occurring in both innate and adaptive immunity 3. 
Age-related changes in humoral immune responses have generally been ascribed to 
defects in the T cell compartment and a lack of T cell help for B cell function 3. Nevertheless, 
mouse studies do provide evidence for changes in the B cell compartment itself during aging. 
Although total B cell numbers did not alter much, shifts in the distribution of functional 
subsets were apparent with old age. In fact, in old mice nearly 100% of splenic B cells 
exhibited an antigen-experienced phenotype 4 and circulating immunoglobulins (Ig) were 
predominantly derived from post-germinal center B cells, as deduced from the presence of 
somatic hyper mutations (SHM) 5. 
In human, age-related alterations in peripheral blood (PB) B cell subset distribution 
have also been reported, with circulating CD19+ B cells declining in absolute numbers and 
frequencies 6, 7, 8, 9, 10. In some studies numbers and percentages of CD27+ memory B cells 
were found to decline 7, 8, whereas others showed an increase of these cells 10, 11, 12. Similarly, 
numbers and percentages of naive CD27-IgD+ B cells were found to decrease by some studies 
9, 10, 12, whereas others reported an increase 7, 8. These inconsistent results may be explained 
by different B cell subset definitions and/or by large inter-individual variations in the studied 
age groups 11, 13. 
Changes in B cell subsets during aging will likely also impact on B cell receptor (BCR) 
repertoire diversity. Indeed, in several mouse models age-related changes in the naive BCR 
repertoire were reported 14. In some elderly humans, Ig heavy chain (IGH) complementarity 
determining region 3 (HCDR3) spectratyping analysis of PB B cells revealed a significant loss 
of diversity, which was associated with poor health status and poor survival 13. Conflicting 
data, however, were reported on SHM in IGHV genes of the memory B cell compartment 
upon aging, varying from increased mutation rates in IgG+ but not in IgM+ PB memory B 
cells, to increased mutation rates in IgM+ memory B cells but not in other tonsillar subsets 
15, 16.
Introduction of next generation sequencing (NGS) technologies has opened new 
possibilities to analyze the aging BCR repertoire, particularly in the light of immune diseases 
that typically arise in elderly. One category of immune diseases with a higher change to 
develop in elderly humans are B cell malignancies, with chronic lymphocytic leukemia (CLL) 
being the most common type. Notably, in about one-third of CLL patients, quasi-identical 
(stereotypic) BCRs are observed, which are characterized by restricted IGHV, IGHD, and IGHJ 
Chapter 6
151
gene usage plus similarities in HCDR3 length and amino acid sequence 17. One study reported 
on stereotypic BCRs within the normal IGHV1-69-IGHJ6 repertoire 18. Little is known however 
about the overall existence of CLL-associated stereotypic BCRs in the normal BCR repertoire 
of different age groups. We hypothesize that these CLL-associated stereotypic BCR could be a 
reflection of changes in B cell subset distribution and the normal BCR repertoire upon aging. 
In this study we determined absolute numbers and relative distribution of PB B cell subsets 
in healthy individuals of different age categories. Additionally, we used NGS to investigate 
the BCR repertoire of naive mature B cells and different types of antigen-experienced B 
cells in healthy individuals upon aging. Finally, we compared IGHV gene usage of the normal 
BCR repertoire of different age groups with that of CLL leukemic cells and evaluated the 
occurrence of CLL-associated stereotypic BCR in the aging normal BCR repertoire. 
RESULTS
Alterations in peripheral blood B cell subpopulations are minor upon aging
To study B cell dynamics during aging, we performed extensive flow cytometric 
immunophenotyping of peripheral blood (PB) cells in a cohort of 155 immunologically 
healthy individuals of 20-95 years [<50 (n=47), 50-60 (n=31), 60-70 (n=45), and 70+ (n=32)].
To validate our cohort, we first evaluated age-related dynamics of the total white blood 
cells and lymphocyte subpopulations (Figure 1; Figure S1). White blood counts (WBC) 
remained stable across the age groups (Figure 1A). Although differences were not significant, 
there was a trend that the absolute numbers of lymphocytes was lower in the 50-60y and 
60-70y groups than in the <50y group (Figure S1). Both absolute and relative numbers of 
naive CD8+ T cells significantly declined >50y of age, whereas absolute and relative numbers 
of CD8+ effector (TemRA) T cells clearly increased with increasing age and CD8+ effector 
memory (TemRO) T cells remained stable (data not shown). CD4+ T cell and NK cell numbers 
did not alter between the age groups (Figure S1). These data are in line with previously 
reported data on T and NK cells 19, thus supporting the validity of our cohort for evaluating 
B cell aging effects.
Next, we focused on the composition of the B cell compartment (see Methods, Table S1, 
Figure S2) in the different age groups. The total B cell numbers and relative frequencies of B 
cells (as fraction of total lymphocytes) slightly declined during aging, resulting in a significant 
difference between the <50y and 70+y groups (Figure 1B-C). More specifically, we observed 
a significant reduction in absolute numbers of transitional B cells in the 70+y group, as well 
as reductions in the non-switched and CD27+IgG+ switched memory B cell populations, and 
plasma blasts in the two oldest age categories (Figure 1D-M). For naive mature B cells and 
all other types of memory B cells no clear alterations in absolute numbers were noted upon 
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aging (Figure 1D-M). The overall PB B cell subset distribution displayed only minor shifts 
between different age groups (Figure 1N), which was mainly reflected by the significantly 
lower frequencies of non-switched memory B cells and plasma blasts upon increasing age 
(Figure S3).
We then looked into CD5+CD43+ chronically activated B cells, as these have been 
associated with CLL and CLL-like MBL that typically appear in elderly 20, 21, 22. We noted a 
small but significant increase in relative frequencies of CD5+CD43+ B cells in the 70+y group 
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Figure 1. B cells and B cell subpopulations in peripheral blood upon aging. 
A. WBC counts. B-C. Analysis of total cell numbers (B) and relative frequencies (C) of B cells. D-N. Total numbers of 
different B cell subpopulations (D-M), and relative distribution of B cell subpopulations (N). Data were evaluated 
for four age categories: <50 (n=47), 50-60 (n=31), 60-70 (n=45), and >70 (n=32). Statistical significance between 
age groups was determined using the Mann-Whitney U test; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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(when compared with the 60-70y age group), together with a trend towards increased 
absolute numbers of these cells (Figure 2A-B). Next, we also evaluated CD21low B cells, as 
high numbers of these cells have been associated with autoimmune disease 23. Notably, a 
significant increase of CD21low cell numbers and relative frequencies was seen between the 
50-60y and 60-70y groups, which normalized again in the 70+y group (Figures 2C-D). 
Taken together, our B cell subpopulation analysis mostly showed a decline in transitional 
B cells, non-switched and CD27+IgG+ switched memory B cells, and plasma blasts in elderly. 
The frequency of CD21low B cells appeared to be increased in 60-70y group.
Composition of the BCR repertoire of naïve mature B cells is stable until 70y 
but shows changes in the 70+y group 
Our next aim was to see which differences occur in the BCR repertoire of healthy donors 
during aging. To this end, we first sorted antigen-inexperienced naive mature B cells of 
healthy controls in the <50y, 50-70y, and 70+y groups (n=4-5 per age group) and analyzed 
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Figure 2. CD43+CD5+ B cells and CD21low B cells in peripheral blood upon aging.
Analysis of total cell numbers (A,C) and relative frequencies (B,D) of CD5+CD43+ B cells and CD21low B cells, re-
spectively. Data were evaluated for four age categories: <50 (n=47), 50-60 (n=31), 60-70 (n=45), and >70 (n=32). 
Statistical significance between age groups was determined using the Mann-Whitney U test; *, p<0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001.
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unique IGHV-IGHD-IGHJ sequences and their HCDR3 regions (Table S2). Despite slight 
variations in the mean HCDR3 lengths between the <50y (53.0 nucleotides), 50-70y (54.5 
nucleotides), and 70+y (46.1 nucleotides) groups, the overall HCDR3 profiles showed no 
significant differences (Figure 3A). 
When evaluating gene usage, differences in IGHV subgroup usage between the <50y and 
50-70y groups appeared limited, but we did find a marked increase in IGHV1 and IGHV5 
subgroup usage and a decrease in IGHV4 subgroup usage in the 70+y donors (Figure 3B). 
Upon further examination of IGHV gene usage, significant differences were mostly noted 
in the 70+y age group, with IGHV1-18, IGHV1-46, IGHV1-69, and IGHV5-51 gene usage 
being significantly higher, and IGHV4-34, IGHV4-39, and IGHV4-59 usage being significantly 
lower (Figure 3C), which could not be explained by small clonal proliferations. That said, the 
most commonly used IGHV gene in all three age groups appeared to be the IGHV3-23 gene, 
followed by IGHV3-21 (Figure 3B). We did not detect clear differences in IGHD and IGHJ gene 
usage between any of the three age groups.
Collectively, our data from healthy controls of different age groups suggest that the BCR 
repertoire of naive mature B cells is relatively stable until 70y. In contrast, in the 70+y group 
IGHV gene usage does differ, which most probably should be interpreted as an aging effect, 
since there were no other indications that can explain this difference.
Differences in BCR repertoire of memory B cell subpopulations are minor 
between <50y and 50-70y age groups
To evaluate age effects in the antigen-selected BCR repertoire, we then focused on 
non-switched, IgM-only, and CD27+IgG+ switched memory B cells, which are all antigen-
experienced cells though arising via distinct activation routes. Some of the memory B cell 
populations are so small that they can only be sorted from buffy coats of healthy donors (n= 
4-5 per age group); unfortunately blood donors are only allowed to give blood until 70y, so 
we could not the study the 70+y age group. Mean HCDR3 lengths did not differ significantly 
between the <50y and 50-70y age groups (Figure S4). IGHV, IGHD, and IGHJ gene usage 
and combined IGHV / IGHJ patterns of non-switched, IgM-only, and CD27+IgG+ memory B 
cells did not show significant differences either between these two age groups (Figure S5). 
Notably, when analyzing SHM frequencies for these memory B cell subpopulations, we did 
detect a higher mutation rate for non-switched and IgM-only memory B cells in the 50-70y 
group, whilst a small reduction in mutation frequency was seen in CD27+IgG+ switched 
memory B cells (Figure S5). 
Collectively these data show that the BCR characteristics of memory B cell subpopulations 
do not differ statistically between the <50y and 50-70y groups.
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Figure 3. BCR repertoire analysis in naive mature B cells upon aging. 
A. Comparison of HCDR3 lengths in <50, 50-70, and 70+y age categories. Statistical significance was determined 
using the Kolmogorov-Smirnov test. B. Circos plots of the combination of IGHV-IGHJ gene usage in <50, 50-70, and 
70+y age categories. C. Differences in IGHV gene usage frequencies upon aging. Statistical significance between 
different age groups was determined using the two-way ANOVA test (with Bonferroni multiple comparisons correc-
tion); *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
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IGHV gene usage in the clonal BCR repertoire of CLL patients is largely 
comparable to IGHV genes in naive mature B cells of 50-70y individuals
As the BCR is known to play an important role in disease onset and prognosis of CLL, 
which normally develops at elderly age (average 70+y), we then asked whether overall IGHV 
gene usage in CLL patients of different age groups would reflect the BCR repertoire of normal 
B cells of the same age groups. To this end we evaluated IGHV gene usage in different B cell 
subsets of healthy controls of different age groups and compared the profiles with Sanger 
sequencing-based data of a cohort of 920 CLL patients (Figure 4). 
Overall IGHV gene usage profiles did not differ significantly between different types 
of normal B cell subpopulations, such as naive mature B cells, non-switched memory B 
cells, and IgM-only memory B cells, in the 50-70y age group (p=0.99-1 in all comparisons). 
Unfortunately, no such comparison was possible in 70+y individuals, due to the lack of 
available data from non-switched and IgM-only memory B cells for this age group. However, 
overall IGHV gene usage profiles in naive mature B cells of healthy individuals did clearly vary 
between the 50-70y and 70+y groups (p=0.005). 
When we next compared overall IGHV gene usage profiles between CLL patients of the 
50-70y and the 70+y groups we did not observe a significant difference (p=0.995). The IGHV 
profiles of naive mature B cells and CLLs in the 50-70y group appeared to look rather similar 
(p=0.574), albeit with a more dominant IGHV1-69 and IGHV4-34 usage in CLL. In contrast, 
naive mature B cell and CLL IGHV gene usage profiles in the 70+y groups were clearly different 
(p<0.0001), while the overall IGHV profile in 70+y CLL was in fact rather similar to that of 
naive mature B cells of the 50-70y age group (p=0.110). Furthermore, overall IGHV profiles in 
the 50-70y group appeared clearly different between CLL and non-switched memory B cells 
(p=0.028) or IgM-only memory B cells (p=0.004).
These data indicate that the overall IGHV gene usage profile in CLL patients, irrespective 
of the age of presentation, is similar to naive mature B cells of especially the 50-70y control 
group. The overall IGHV profile of the 70+y control group is different without obvious 
explanation as mentioned above. 
CLL-associated stereotypic BCR are present in naive mature B cells and 
increase with age
In view of the occurrence of quasi-identical (stereotypic) BCR with similar IGHV / IGHD / 
IGHJ and HCDR3 features in CLL clones of different patients, we then investigated whether 
we could also detect stereotypic BCR in healthy individuals of different age groups. To identify 
CLL-related stereotypic BCRs in the normal repertoire of healthy controls of different age 
groups, a reference database of stereotypic BCR from CLL patients 24 was used for assigning 
individual IGH sequences from healthy controls. With this algorithm we could indeed identify 
CLL-associated stereotypic BCRs based on HCDR3 characteristics in the repertoire of naive 
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Figure 4. Comparison of IGHV gene usage in the normal BCR repertoire of healthy individuals and the clonal CLL 
repertoire of different age groups. 
A-B. IGHV gene usage in naive mature B cells of 50-70y (A) and 70+y (B) healthy controls. C-D. IGHV gene usage in 
non-switched (C) and IgM-only B (D) cells of 50-70y healthy controls. E-F. IGHV gene usage in clones of CLL patients 
of 50-70y (C) and 70+y (D). Statistical analysis was determined using the Fisher’s exact test; see text for details on 
significance levels.
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mature B cells, and also of non-switched, IgM-only, and CD27+IgG+ switched memory B cells 
(Figure 5). The presence of stereotypic BCR receptors in naive mature B cells showed an 
increasing trend with age and was most apparent in the 70+y group (Figure 5A). In naive 
mature B cells, the most prominent stereotypic BCR belonged to CLL subsets #2, #5, and 
#64B (Figure 5B). In non-switched memory B cells the most frequently found stereotypic 
BCRs concerned CLL subsets #2 and #14 (Figure 5C). The CLL#14 BCR also appeared most 
prominent in IgM-only and CD27+IgG+ switched memory B cells, especially in the 50-70y 
category (Figure 5D-E). 
From these findings we conclude that CLL-associated stereotypic BCRs are present in the 
normal BCR repertoire during life and that their frequency showed an increasing trend upon 
aging.
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Figure 5. Stereotypic BCR in the normal BCR repertoire of healthy aging individuals.
A. Total frequency of stereotypic BCR in the normal BCR repertoire in naive mature B cells of healthy individuals. 
B-E. Frequency of stereotypic BCR assigned to CLL-associated stereotypic subsets in naive mature (B), non-switched 
(C), IgM-only (D), and CD27+IgG+ switched (E) memory B cells. Statistical significance between different age groups 
was determined using the two-way ANOVA test (with Bonferroni multiple comparisons correction); *, p<0.05; **, 
p<0.01; ***, p<0.001; ****, p<0.0001.
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DISCUSSION
Here we evaluated age-related changes in B cell subset composition as well as BCR 
repertoire with a focus on CLL-associated stereotypic BCR usage. In the most elderly (70+y) 
individuals we observed a decline in absolute numbers of transitional B cells, total memory 
B cells, and plasma blasts. The BCR repertoire of naive mature B cells and distinct memory B 
cell populations was found to be relatively stable until 70y. In naive mature B cells of the 70+y 
group differences were noted, especially with respect to IGHV gene usage. Notably, IGHV 
gene usage in the clonal BCR repertoire in CLL did not differ with the age of presentation 
of the CLL patients, and largely resembled naive mature B cells of the 50-70y group rather 
than the 70+y group. Finally, CLL-associated stereotypic BCR were found as part of the BCR 
repertoire of healthy individuals and their frequencies increased with age.
The observed decline in total B cell numbers in the 70+y group could result from a reduced 
output from the bone marrow 25, 26. An alternative explanation could be the reduction in 
CD27+ antigen-experienced B cell subpopulations. Non-switched and CD27+IgG+ memory 
B cells together make up the majority of the CD27+ memory B cell compartment, and were 
previously described to decline upon aging 6. The decline in non-switched memory B cells 
could underlie the higher vulnerability to diseases caused by encapsulated bacteria like 
Streptococcus pneumoniae in elderly 27. CD27+IgG+ memory B cells are mainly, albeit not 
exclusively, formed in T cell-dependent immune responses and play a role in recall responses 
to previously encountered pathogens 28. The reduction of plasma blasts upon aging is in line 
with earlier observations 29 and fits the lower immunoglobulin levels in the circulation as 
reported in elderly 30. Together these data could, at least partially, explain the reduced effects 
of vaccination and immune responses against infections in elderly. 
Chronically activated B cells express CD5 and CD43 31, 32 and might trigger MBL onset. 33, 
34. MBL are found in healthy adult individuals, with an incidence that increases with age to 
roughly 10% of individuals >65y 35. Based on their phenotypical association with MBL 20 and 
CLL 22, the increase of CD5+CD43+ B cells upon aging might thus correlate with the higher 
risk of MBL and CLL clones in elderly. Another B cell subset related with chronic activation 
concerns CD21low B cells, increased numbers of which can be found in patients showing 
chronic inflammation in the context of autoimmune disease 23. As we excluded individuals 
with inflammatory and (auto)immune disease in our immunologically healthy cohort, 
unfortunately we could not link the higher number of CD21low B cells in the 60-70y group 
to overt autoimmune disease occurrence. Nevertheless, increased numbers of CD21low B 
cells in this age group might reflect an increased incidence of, yet undiagnosed, autoimmune 
diseases upon aging. 
BCR repertoire changes were most apparent in naive mature B cells of the 70+y group. 
Since naive mature B cells are not affected by exogenous antigen, this is most likely the result 
6B cell receptor repertoire in healthy aging.
160
of changes in repertoire development and/or output from the bone marrow. Whilst HCDR3 
length, IGHD, and IGHJ usage remained stable in all three age categories, IGHV gene usage did 
reveal alterations. Interestingly, IGHV4-34 usage, a gene often associated with autoimmunity, 
was found to be reduced upon aging in these healthy individuals. Upon aging we also noticed 
a combined increased usage of IGHV5-51 and IGHV1-69, in line with a previous report 36. 
IGHV1-69 has been associated with broadly neutralizing antibodies against amongst others 
influenza, HIV, hepatitis C, and commensal bacteria antigens in the context of CLL 37.
Remarkably, IGHV gene usage in both the 50-70y and 70+y CLL patient groups most 
closely resembled IGHV gene usage in naive mature B cells of 50-70y, but not 70+y, healthy 
individuals. One could speculate that CLL clones, even the ones in elderly CLL patients (70+y), 
would have developed from B cells with a BCR repertoire of relatively younger age (<70y), 
but it might also reflect selection for IGHV specificities in the younger repertoire that could 
be predisposing for CLL development.
Stereotypic BCR, which are found in roughly one third of CLL clones, have previously 
been documented in RNA from a total lymphocyte pool of three healthy individuals (age 50, 
69, and 69) 38, 39. In this study we show that stereotypic BCR can be found in the normal BCR 
repertoire of both naive mature and antigen-experienced B cells. Interestingly, a frequently 
observed stereotypic BCR was the CLL#2 BCR (IGHV3-21 in combination with IGHJ6 with a 
short HCDR3 length of 9 amino acids), which is the most common stereotypic BCR seen in CLL 
patients and is associated with an aggressive form of CLL 17, 40. Stereotypic CLL#5 BCR (IGHV1-
69, IGHD3-10/3-3, IGHJ6, 20 amino acids HCDR3) as well as stereotypic CLL#64 BCR (IGHV3 
subgroup genes, IGHD2 subgroup genes, IGHJ6, 21 amino acids HCDR3) 17 were relatively 
often detected in naive mature B cells of especially individuals 70+y. In antigen-experienced 
B cells, stereotypic CLL#14 BCR (IGHV4-4, no specific IGHD, IGHJ4, and short 10 amino acids 
HCDR3) was frequently found. The possibility to detect stereotypic BCRs with short HCDR3 
lengths in antigen-experienced B cell subpopulations would be in line with our observation 
that on average the complete memory BCR repertoire shows selection for shorter HCDR3 
lengths in comparison with naive B cells. Notably, other common CLL-associated stereotypic 
BCR, such as CLL#4, CLL#6, and CLL#8 BCR, could not be detected. 
Even though the frequency of stereotypic BCR in healthy B cells shows a trend towards 
increase with age, stereotypic BCR can already be detected in cord blood (data not shown) 
and thus are to be considered as part of the normal BCR repertoire. Moreover, even though 
the increase of CLL-associated stereotypic BCR in the aging normal BCR repertoire might 
imply an increased predisposition for CLL development in elderly, it should be stressed that 
two thirds of CLL show heterogeneous BCR specificities that can also mediate derailment 
of B cells leading to CLL. Investigations into the presence of CLL-associated stereotypic 
BCR in healthy individuals should therefore be extended to larger datasets including more 
healthy individuals of all age groups, as well as to individuals suffering from chronic infection, 
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immunodeficiency, or autoimmune disease. Such studies would allow to define the true 
impact of CLL-associated stereotypic BCR in CLL development.  
CONCLUSION
We analyzed the peripheral B cell compartment and BCR repertoire during human 
ageing. Composition of the peripheral B cell compartment changes with ageing, with clear 
reductions in non-switched and CD27+IgG+ switched memory B cells and plasma blasts in 
especially the 70+y group. The BCR repertoire is relatively stable until 70y age, whereafter 
differences in IGHV gene usage are seen. Upon ageing, an increase in the occurrence of 
particular CLL-associated stereotypic BCR is observed, potentially reflecting the occurrence 
of such BCR in CLL in elderly. 
METHODS 
Sample inclusion
For B cell subpopulation analysis, peripheral blood (PB) of immunologically healthy 
individuals was obtained from pre-surgery patients (Dept. Orthopedics, Erasmus MC) with 
the following exclusion criteria: (auto)immune or inflammatory diseases; malignancies; usage 
of anti-inflammatory or immunosuppressive drugs; surgery in the past 30 days; alcohol and 
drug abuse. To increase the number of subjects per age group, additional samples from the 
SENEX healthy aging cohort (Rheumatology and Clinical Immunology, UMCG, Groningen, 
Netherlands), and samples from co-workers from the department were included. Subjects 
(n=155) were divided into four age categories: <50 (n=47), 50-60 (n=31), 60-70 (n=45), and 
70+ (n=32). For the BCR repertoire study, peripheral blood samples (n=5 per age group) were 
additionally obtained from Sanquin Blood bank (Amsterdam, The Netherlands). Diagnostic 
samples from CLL patients were collected upon informed consent and anonymized for 
further usage. Written consent was obtained in accordance with the Declaration of Helsinki 
after medical ethics committee approval (MEC 2011-409, 2016-202, and 2012375).
Immunophenotyping of B cell subpopulations
Folllowing white blood cell count (WBC) measurement on a Coulter®Ac.T diff analyzer 
(Beckman Coulter, Fullerton, CA, USA), flowcytometry was performed on whole blood [after 
red blood cell lysis with ammonium chloride] using an LSR FortessaTM (BD Biosciences, San 
Jose, CA). Absolute cell counts of monocytes, natural killer (NK) cells, T cells, and B cells 
were calculated from WBC numbers using Infinicyt software (Cytognos, Salamanca, Spain). 
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Lymphocytes were first gated based on FSC / SSC characteristics, and B cells were defined by 
expression of the pan-B cell marker CD19. Further gating was performed for defined CD19+ 
B cell subpopulations, i.e. transitional B cells (CD38hi/CD27-), naive mature B cells (CD38-/
CD27-/IgM+/IgD+), non-switched memory B cells (CD38-/CD27+/IgM+/IgD+), IgM-only B 
cells (CD38-/CD27+/IgM+/IgD-), switched memory B cells (CD38-/CD27+ or -/IgM-/IgD-IgG+ 
or IgA+ or IgE+), plasma blasts (CD38hi/CD27+), CD5+/CD43+ B cells (CD38-/CD5+/CD43+), 
and CD21low B cells (CD38dim/CD21low) according to published data 28 (see also (Table S1), 
using 11-color flowcytometric stainings (Table S3) and FACS DIVA software (BD Biosciences) 
for analysis.
Sorting of B cell subpopulations and DNA isolation
PB mononuclear cells (PB-MNC) were isolated via Ficoll Paque gradient centrifugation. 
Subsequently, B cells were purified with human CD19 MicroBeads via AutoMACS (Myltenyi 
Biotech, Bergisch Gladbach, Germany). Next, several B cell subpopulations (naive mature, 
non-switched memory, IgM only, and CD27+/IgG+) were collected using a FACSAria cell 
sorter (BD Biosciences). Immediately after collection cells were lysed in RLT+ buffer (QIAGEN, 
Valencia, CA) complemented with β-mercapto-ethanol. Cells were used for DNA isolation 
with the DNA/RNA/miRNA Easy kit (QIAGEN) and/or stored in -80°C for later processing. 
NGS-based BCR repertoire analysis of healthy individuals
IGHV-IGHD-IGHJ rearrangements were amplified from 100 ng DNA of sorted B cell 
subpopulations (from n=3-5 healthy controls per age group; see Table S3) using the 
BIOMED-2 IGH multiplex PCR with 6 IGHV primers and 1 IGHJ consensus primers that were 
extended with adapter sequences for NGS. PCR products were purified by gel extraction 
(QIAGEN) and subsequently by Agencourt AMpure XP beads (Beckman Coulter, Brea, CA). 
Concentrations were measured using Quant-iT Picogreen dsDNA assay (Invitrogen, Carlsbad, 
CA). PCR products were sequenced on a 454 GS junior (Roche, Branford, CT), using the GS 
Junior Titanium emPCR, sequencing, and PicoTiterPlate kits (Roche), and partly on a MiSeq 
(Illumina, San Diego, CA) platform. Cross-validation experiments using B cells from healthy 
individuals showed comparability of data from both platforms (unpublished; see Suppl. 
Information). Sequences were demultiplexed based on their multiplex identifier sequence 
and trimmed via the ImmunoGlobulin galaxy (IGGalaxy) pipeline 41. FASTA files were uploaded 
in IMGT/High-V-QUEST (http://www.imgt.org/HighV-QUEST/login.action) and IMGT output 
files were further analyzed in the Antigen Receptor Galaxy pipeline, as described before 42. 
For comparison purposes, a local Erasmus MC cohort of 920 CLL patients (mean 65y) was 
used, in which Sanger sequencing-based IGHV mutation status analysis was performed using 
the BIOMED-2 primers and protocol 43, and following ERIC interpretation guidelines 44. 
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IGHV-IGHJ circos plots were generated via the Circos Table Viewer (http://mkweb.bcgsc.
ca/tableviewer/). CLL-associated stereotypic BCR in healthy control samples were defined 
using the ARResT/AssignSubsets tool (http://tools.bat.infspire.org/arrest/assignsubsets/).
Statistical analysis
Significant differences in relative and absolute numbers of lymphocyte subpopulations 
and IGH SHM levels between age groups were determined using the Mann-Whitney U test. 
Differences in HCDR3 lengths were evaluated using Kolmogorov-Smirnov statistics. Relative 
IGHV gene usage and relative frequencies of stereotyped BCR between different age groups 
were analyzed using a two-way ANOVA with multiple comparisons. Overall IGHV gene usage 
between B cell subpopulations and CLL clones was analyzed using the Fisher’s exact test. A 
p-value <0.05 was considered significant. Statistics were performed in GraphPad Prism v5.0 
(La Jolla, CA). 
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Figure S1. Frequencies and absolute numbers of T cell subsets and NK cells to validate the cohort for evaluating 
peripheral blood B cell subpopulations upon aging. 
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SUPPLEMENTARY TABLES
B cell subpopulation Markers 
transitional B cells CD19+/CD38hi/CD27- 
naive mature B cells CD19+/CD38-/CD27-/IgM+/IgD+ 
non-switched memory B cells CD19+/CD38-/CD27+/IgM+/IgD+ 
IgM-only B cells CD19+/CD38-/CD27+/IgM+/IgD- 
CD27+ or – IgG+ switched memory B cells CD19+/CD38-/CD27+ or -/IgM-/IgD-/IgG+ 
CD27+ or – IgA+ switched memory B cells CD19+/CD38-/CD27+ or -/IgM-/IgD-/IgA+ 
CD27+ or – IgE+ switched memory B cells CD19+/CD38-/CD27+ or -/IgM-/IgD-/IgE+ 
plasma blasts CD19+/CD38hi/CD27+ 
CD5+/CD43+ B cells CD19+/CD38-/CD5+/CD43+ 
CD21low B cells CD19+/CD38dim/CD21low
B cell subpopulation Age group Productive 
sequences 
Unique 
sequences 
naïve mature B cells <50 (n=5) 20507 14257 
50-70 (n=5) 31211 20367 
>70 (n=4) 657 648 
non-switched memory B cells <50 (n=5) 17793 9495 
50-70 (n=4) 16012 10973 
IgM-only B cells <50 (n=5) 26519 10112 
50-70 (n=3) 7248 3200 
switched memory B cells (CD27+IgG+) <50 (n=5) 27606 9329 
50-70 (n=4) 15030 8994 
Panel 1 Panel 2 
Marker Fluorochrome Marker Fluorochrome 
CD27 BV421 CD27 BV421 
IgM BV510 IgM BV510 
CD20 BV605 CD20 BV605 
CD21 BV711 CD21 BV711 
IgE FITC CD43 FITC 
IgA FITC 
IgG PE CD11b PE 
IgA PE 
IgD PE-CF594 IgD PE-CF594 
CD79b PerCP CD11c PerCP 
CD19 PE-Cy7 CD19 PE-Cy7 
CD23 APC CD5 APC 
CD38 APC-H7 CD38 APC-H7 
Table S1. Definition of human B cell subpopulations
Table S2. Overview of productive and unique IGH sequences in NGS analysis
Table S3. Composition of different antibody panels for staining B cell subpopulations
To allow combining data from the two panels. a backbone of markers (indicated in bold) was used.
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Comparison of productive and unique productive sequencess
SUPPLEMENTARY INFORMATION 
Cross-validation between different NGS platforms was performed using DNA from 
8 controls that were used for paired analysis of IGH DNA and RNA/cDNA libraries on 454 
(Roche. Branford. CT) and MiSeq (Illumina. San Diego. CA) platforms and data analysis using 
the ImmunoGlobulin galaxy (IGGalaxy) pipeline (Moorhouse et al.. 2014).
Donor All Productive Unique Productive 
NWK16 454 4363 2849 65% 1539 35% 
NWK214 454 7640 3845 50% 1951 26% 
NWK276 454 8183 6486 79% 4286 52% 
NWK279 454 11111 8517 77% 4716 42% 
NWK31 454 3322 1226 37% 928 28% 
NWK43 454 7868 4994 63% 2669 34% 
NWK53 454 32403 24107 74% 3449 11% 
NWK54 454 4547 2966 65% 1528 34% 
Mean 454 64% 33% 
NWK16 ILLUMINA 29043 21964 76% 9858 34% 
NWK214 ILLUMINA 30202 20884 69% 10790 36% 
NWK276 ILLUMINA 41469 28165 68% 16173 39% 
NWK279 ILLUMINA 36737 24792 67% 13725 37% 
NWK31 ILLUMINA 44931 33886 75% 19209 43% 
NWK43 ILLUMINA 41800 19032 46% 13834 33% 
NWK53 ILLUMINA 44482 35421 80% 11212 25% 
NWK54 ILLUMINA 30746 19682 64% 9498 31% 
Mean ILLUMINA 68% 35% 
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Comparison of junctional region characteristics
Donor Total,Del Total,N Total,P CDR3,Length 
NWK16 454 18.9 11 0.6 15 
NWK214 454 20.2 11.9 0.5 14 
NWK276 454 17.2 12.5 0.6 16 
NWK279 454 17.7 12.8 0.5 16 
NWK31 454 19.8 10.9 0.5 14 
NWK43 454 21.1 11 0.4 14 
NWK53 454 20.8 12.1 0.5 14 
NWK54 454 18.7 11.4 0.4 14 
Mean 454 18.8 11.2 0.5 14.5 
NWK16 ILLUMINA 19.5 12 0.5 15 
NWK214 ILLUMINA 20.9 12.4 0.4 14 
NWK276 ILLUMINA 17.4 11.7 0.6 16 
NWK279 ILLUMINA 17.7 12.3 0.6 16 
NWK31 ILLUMINA 18.9 11.7 0.5 15 
NWK43 ILLUMINA 19.7 11 0.5 14 
NWK53 ILLUMINA 21.5 12.8 0.4 14 
NWK54 ILLUMINA 19 12.5 0.4 14 
Mean ILLUMINA 19.25 12.25 0.45 14.5 
Comparison of V subgroup usage
Donor IGHV1 IGHV2 IGHV3 IGHV4 IGHV5 IGHV6 IGHV7 
NWK16 454 8.77 0.06 65.95 19.75 5.26 0.19 
NWK214 454 8.25 0.46 40.80 47.87 1.90 0.72 
NWK276 454 7.44 1.61 55.27 32.13 2.24 1.31 
NWK279 454 8.69 1.38 54.52 32.46 2.04 0.91 
NWK31 454 14.44 1.62 51.08 30.39 1.94 0.54 
NWK43 454 4.57 1.09 61.22 26.71 3.11 3.18 0.11 
NWK53 454 7.36 0.58 66.98 20.50 3.89 0.70 
NWK54 454 3.93 0.20 69.31 21.34 4.65 0.46 0.13 
Mean 454 7.93 0.87 58.14 28.89 3.13 1.00 0.12 
NWK16 ILLUMINA 19.32 0.87 53.04 22.95 3.62 0.19 
NWK214 ILLUMINA 0.38 0.05 66.29 30.92 1.42 0.94 0.01 
NWK276 ILLUMINA 39.49 1.79 40.75 8.64 8.68 0.64 0.01 
NWK279 ILLUMINA 44.92 1.70 39.81 6.87 5.68 0.98 0.03 
NWK31 ILLUMINA 15.20 2.34 40.05 26.12 14.35 1.38 0.56 
NWK43 ILLUMINA 10.16 2.11 36.29 35.39 12.06 3.43 0.56 
NWK53 ILLUMINA 16.33 1.31 40.90 36.59 4.17 0.67 0.02 
NWK54 ILLUMINA 0.64 0.03 48.96 46.11 3.33 0.93 
Mean ILLUMINA 18.30 1.28 45.76 26.70 6.66 1.14 0.20 
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Comparison of J gene usage
Donor IGHJ1 IGHJ2 IGHJ3 IGHJ4 IGHJ5 IGHJ6 
NWK16 454 1.30 2.86 17.48 45.35 8.77 24.24 
NWK214 454 2.72 3.74 9.33 52.49 15.89 15.84 
NWK276 454 1.33 2.75 11.78 43.89 11.06 29.19 
NWK279 454 1.95 2.84 12.77 43.83 12.13 26.48 
NWK31 454 5.50 4.42 8.19 48.38 14.87 18.64 
NWK43 454 3.33 4.50 12.51 50.88 12.89 15.89 
NWK53 454 2.17 4.03 9.51 53.93 13.31 17.05 
NWK54 454 2.29 2.88 12.30 54.25 11.26 17.02 
Mean 454 2.57 3.50 11.73 49.13 12.52 20.54 
NWK16 ILLUMINA 1.13 3.95 15.56 41.72 11.09 26.56 
NWK214 ILLUMINA 2.80 4.08 9.84 53.20 14.09 16.00 
NWK276 ILLUMINA 1.16 1.28 10.33 37.28 11.21 38.75 
NWK279 ILLUMINA 1.88 1.54 14.70 35.72 10.14 36.02 
NWK31 ILLUMINA 2.76 3.00 12.04 49.73 13.00 19.46 
NWK43 ILLUMINA 2.76 3.79 12.28 51.63 14.03 15.50 
NWK53 ILLUMINA 1.96 3.29 10.60 49.31 15.61 19.23 
NWK54 ILLUMINA 2.10 2.07 12.16 54.32 13.22 16.13 
Mean ILLUMINA 2.07 2.88 12.19 46.61 12.80 23.46 
6B cell receptor repertoire in healthy aging.
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GENERAL DISCUSSION
In this thesis, we studied the role of the B cell receptor (BCR) in chronic lymphocytic 
leukemia (CLL), which is the most common type of leukemia in elderly in the Western world. 
Although the cause of CLL is still not fully clear, the BCR was found to be important in the 
development of the disease. It has been known for a long time that CLL can be separated into 
mutated (M-CLL) and unmutated (U-CLL) subgroups based on the somatic hypermutation 
(SHM) status of the BCR1, 2. An important role of the BCR is further supported by the restricted 
usage of immunoglobulin (Ig) heavy chain variable, diversity, and joining gene (IGHV, IGHD, 
and IGHJ respectively), with a restricted heavy chain determining region 3 (HCDR3) length and 
composition, in combination with a restricted light chain usage, in subsets of CLL patients. 
These so-called stereotypic BCR, which are found in one-third of CLL cases, suggest antigenic 
selection for certain BCRs in the development of CLL3. Most U-CLLs have been found to be 
polyreactive, recognizing self- and non-self-antigens such as DNA, insulin, apoptotic cells, 
LPS, oxidized LDL, and cytoskeletal proteins myosin and vimentin, with low affinity binding4, 
5, 6, 7, 8. For M-CLLs more specific, high-affinity antigen binding is expected, but for only a few 
stereotypic M-CLL receptors the specific antigen has actually been identified. Hoogeboom 
et al. described a stereotypic receptor consisting of the IGHV3-7 containing IGH with an 
extremely short HCDR3 length of 5 or 6 amino acids, in combination with an IGKV2-24-
containing light chain, which recognizes the fungal antigen pustulan (β-1,6-glucan)9. 
To get more insight in the role of the BCR in CLL pathogenesis, in this thesis we explored 
signaling pathways downstream of the BCR and focused on characteristics of the BCR itself, 
especially also in families with CLL patients. Furthermore, as CLL is a disease of the elderly, 
in parallel we evaluated changes in B cell subset distribution and BCR repertoire of healthy 
individuals upon aging.
BCR signaling
The crucial role of the BCR downstream signaling cascade in CLL development is 
thoroughly outlined in our review on signaling pathways in CLL (Chapter 2)10. CLL cells show 
increased basal Ca2+ signaling compared to normal B cells, as we have described in Chapter 
3. We detected an association between the IGHV SHM status of the CLL cases and basal 
Ca2+ signaling levels, being higher in M-CLL compared with U-CLL11. In another CLL cohort 
(described in Chapter 4), we could detect higher basal Ca2+ signaling for CLL in comparison 
with normal B cells, but we could not validate the association with the SHM status of the CLL 
cases. One possible explanation for this difference could be that the samples used for the 
cohort in Chapter 3 were taken from our CLL biobank and these stored, frozen samples were 
thawed for the Ca2+ signaling experiments. In contrast, for the studies described in Chapter 4, 
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fresh CLL samples were used. Nevertheless, when we performed experiments to compare Ca2+ 
signaling in samples from CLL patients both fresh and after freezing and thawing, we noticed 
no major differences in Ca2+ signaling (data not shown). Thawed samples might contain 
more apoptotic cells, which are known to have higher cytosolic Ca2+ levels, but we excluded 
these cells as much as possible from the analysis by stringent gating strategies. Another 
explanation for the difference between the two cohorts could be the heterogeneity between 
CLL patients, which could impact on the mean levels of Ca2+ signaling of the included M-CLL 
and U-CLL samples in the two relatively small cohorts. That notwithstanding, we detected in 
both CLL cohorts (Chapters 3 and 4) that U-CLL are in general more responsive to anti-IgM 
stimulation than M-CLL. For IgD stimulation we did not notice any dissimilarities between 
U-CLL and M-CLL11. Differences in signaling capacity between U-CLL and M-CLL after BCR 
stimulation were also reported previously, whereby U-CLL were more capable to respond to 
IgM stimulation than M-CLL, which was explained by the latter being more anergic12. 
In Chapter 4 we analyzed the phosphorylation status of various signaling molecules 
from the BCR signaling pathway (Figure 1) to further zoom in on BCR responsive and non-
responsive CLL cases. We found a higher basal phosphorylation level of the signaling molecule 
PLCγ2 in the former as compared with the latter. For the signaling molecules SYK and AKT 
we did not find such differences. After anti-IgM-mediated BCR stimulation, responsive CLL 
cases showed an increase in phosphorylation of PLCγ2 and AKT (Figure 1). In addition, CLL 
cells from anti-IgM responsive CLL cases appeared to have higher expression levels of IgM, 
IgD, CD19, CD38, and CD43, and thus a more activated phenotype than unresponsive CLL 
cases. Furthermore, we detected a strong correlation between IgM and CD21 expression and 
the capability of CLL cells to respond to IgM stimulation. CD21 is an important component 
of the BCR co-receptor complex and enhances signaling capacity13. Downregulation of CD21 
is associated with anergy14 and high numbers of CD21 low B cells are often found in patients 
with autoimmune diseases15 and in healthy individuals with increasing age (Chapter 6).
Evaluation of gene expression via RNA sequencing of CLL cells of six BCR responsive and 
six BCR non-responsive CLL cases, showed differential expression of several NF-κB-related 
genes between these CLLs (Chapter 4). Interestingly, in unresponsive CLL cases transcripts of 
several regulators of NF-κB signaling, such as inhibitor of NF-κB (IκB) genes NFKBIB, NFKBID 
and NFKBIE, and NF-κB components NFKB1, NFKB2, and BCL3 were found to be upregulated. 
RQ-PCR confirmed higher expression levels of NFKB1, NFKB2, NFKBIB, and NFKBIE in anti-IgM 
unresponsive CLL samples. Stimulation of known responsive and unresponsive CLL samples 
with anti-IgM, led to a clear upregulation in the expression of NFKB2, NF-κB component 
REL, NFKBID, NFKBIE, and NF-κB regulator TNFAIP3 (A20) in responsive CLL compared with 
unresponsive CLL cases (Figure 1).
These differences in response to BCR stimulation seem to reflect differences in the 
anergic state of the CLL cases. Anergy in B cells is defined by loss of the capacity to respond 
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Figure 1. Differences between BCR signaling in α-IgM responsive CLL versus α-IgM unresponsive CLL.
Schematic overview of BCR signaling pathway in α-IgM responsive CLL versus α-IgM unresponsive CLL. Upon antigen 
binding to the BCR, signaling is initiated by LYN-mediated phosphorylation of ITAMs in the cytoplasmic tail of Igα/β 
and CD19, recruiting SYK and PI3K, respectively. PI3K converts PIP2 into PIP3 to enable membrane recruitment of 
BTK. SYK-induced phosphorylation of SLP65 promotes a docking platform for BTK and PLCγ2, and formation of the 
BCR micro-signalosome, resulting into phosphorylation of PLCγ2 by BTK. This induces an influx of Ca2+ in the cyto-
plasm, finally resulting in activation of the transcription factors NF-κB, NFAT, FOXO, and ELK1/c-Myc10. 
α-IgM unresponsive CLL have higher protein expression levels of IgM, IgD, CD19, CD21, CD38, and CD43, and in 
addition higher basal P-PLCγ2 (indicated in orange). Also, EBF1, FCGR2A, SYK and FYN RNA expression levels are 
increased (orange). Furthermore, unresponsive CLL have higher RNA expression levels of NF-κB-related genes (NFK-
BIB, NFKBID and NFKBIE), and NF-κB components (NFKB1, NFKB2, and BCL3), and in addition TNFAIP3 encoding A20 
(indicated in purple). Upon α-IgM stimulation of responsive CLL-cases P-PLCγ2 and P-AKT levels increase, relative to 
unresponsive cases, while NFKB2, REL, NFKBID, NFKBIE and A20 RNA expression levels are upregulated (indicated 
with orange arrows). 
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to auto-antigenic stimulation via the BCR. As a result, the anergic state prevents the 
B cell to go into apoptosis. Anergic B cells internalize especially their IgM BCR and show 
increased cytosolic Ca2+ levels16, 17. In addition, the anergic cells fail to mobilize Ca2+ 17, and 
do not proliferate upon stimulation18. Several phosphatases and kinases play a role in the 
maintenance of this anergic state. LYN seems to function as a driver for the inhibition of PI3K 
signaling via the inositol phosphatases SHIP and PTEN, which convert PIP3 into PIP218 (Figure 
1). In addition, LYN was found to recruit SHP-1 that dephosphorylates signaling molecules and 
thereby acts as a regulator. This eventually leads to activation of the ERK and Ca2+-calcineurin-
NFAT signaling pathways, without activation of JNK and NF-κB19, 20. Also, anergic CLL cells 
exhibit constitutive activation of ERK1/2 and NFAT221. Recently, it was shown that NFAT2 
is critical in maintaining the anergic phenotype of CLL, whereas loss of NFAT2 expression 
plays a role in CLL transformation (Richter’s syndrome)22. Loss of IκBε, leading to NF-κB 
activation and translocation to the nucleus is associated with a more aggressive type of CLL23. 
In addition, upon IgM stimulation U-CLL have in general higher phosphorylation levels of 
NF-κB and ERK than M-CLL24. It thus seems likely that unresponsive CLL with a more anergic 
phenotype are controlled by Ca2+-calcineurin-NFAT signaling. Moreover, higher basal levels 
of NF-κB regulatory components, and especially of NF-κB inhibitory proteins, could make 
these CLL cells unresponsive and independent of BCR stimulation. In responsive CLL, which 
are less anergic than unresponsive CLL, though more than their normal B cell counterparts, 
NF-κB signaling is required. Based on these findings it would be tempting to speculate that if 
unresponsive CLL shift from control via NFAT signaling towards NF-κB signaling and become 
more responsive, this goes hand in hand with disease progression. 
BCR characteristics
Apart from BCR signaling, we also investigated characteristics of the BCR of CLL cases in 
more detail. In Chapter 5, we studied the BCR characteristics of CLL cells in three families 
with multiple siblings who developed CLL. Whereas in CLL family 1 the four siblings were 
recognized as M-CLL cases, the family 2 siblings could be characterized as U-CLL cases. 
Interestingly, family 3 was identified as a stereotypic subset #2(-like) CLL family, in which all 
siblings expressed the specific CLL#2 λ light chain. One of the family 3 siblings appeared to 
carry the specific CLL#2 BCR, and another was found to have a CLL#169 BCR, which is known 
to be very alike to CLL#2. Three completely different groups of CLL, are represented by these 
families, being M-CLL (family 1), U-CLL (family 2) and CLL#2-like CLL (family 3), with member 
3C being a true CLL#2 case and member 3B a closely related CLL#169 case.
To study the reactivity of the BCRs of the M-CLL familial CLL cases, we attempted to 
clone and express the BCR of the various siblings of family 1. For CLL family member 1A we 
detected by use of ELISA that the recombinant BCR (IgM), which consisted of the IGHV1-3, 
IGHD3-3, and IGHJ3 genes (SHM status 92.9%) in combination with IGKV1-9, IGKJ5 light chain 
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genes, bound to LPS, but did not show affinity for insulin, actin, or fungal antigen pustulan 
(Figure 2). LPS binding by this CLL-BCR could be specific, since this BCR has undergone SHM, 
although it cannot be entirely excluded that this BCR is polyreactive when more antigens 
would have been tested. Unfortunately, as we were not able to test antigen binding of the 
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Figure 2. Evaluation of the binding of recombinant IgM from CLL family member 1A towards different molecules.
By use of ELISA the binding of recombinant IgM of familial case 1A towards different molecules such as LPS (A), 
insulin (B) actin (C) and the fungal antigen pustulan (D), as indicated, were analyzed. 
On the x-axis the titrated concentrations of the soluble recombinant pentameric IgM from familial CLL sibling 1A 
consisting of IGHV1-3/IGHD3-3/IGHJ3 with a HCDR3 length of 19 amino acids combined with IGKV1-9/IGKJ5, and 
two controls. I.e.; CLL57 IgM consisting of IGHV3-30-3/IGHD3-3/IGHJ6 and a HCDR3 length of 25 amino acids in 
combination with IGLV1-51/IGLJ3 is used as a positive control since it is known to be polyreactive, whereas CLL82 
IgM, which consists of IGHV3-7/IGHD2-21/IGHJ5 with a HCDR3 length of 5 amino acids combined with IGKV2-24/
IGKJ2 and which specifically recognizes pustulan (β-1,6-glucan) was used as a negative control9. An antibody was 
considered to be reactive when the absorbance of the titration exceeds the absorbance of the blank mean times 
three (3x Optical density 450 (OD450)) as is shown on the y-axis. 
Method used for production of soluble IgM was described by Bende et al37. ELISA plates were coated overnight 
with actin (Sigma-Aldrich) (3 ug/ml), insulin (Sigma-Aldrich) (3 ug/ml), LPS (E. Coli O55:B5, Sigma-Aldrich) (3 ug/ml) 
or pustulan (10 ug/ml) (Invivogen). This was followed by overnight incubation with titrated concentrations of the 
soluble recombinant pentameric IgM as described before9. Absorbance was measured at 450 nm.
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BCR of the other family 1 members due to the multiple rearrangements of their heavy and 
light chains25, we cannot address if recognition of a common antigen acts as a driving factor 
in this CLL family. Irrespective of the involvement of common antigens, it seems likely that 
the familial CLL occurrence is also impacted by a common genetic predisposition in the three 
families. Our SNP data seem to indicate a shared path of CLL clonal evolution, as we detected 
similarities in known CLL-related chromosomal alterations within our CLL families. Currently, 
genetic predisposition is the topic of further study, exploiting whole genome sequencing on 
paired CLL cell / non-malignant T cell genomic DNA samples of the various siblings.
Additionally, we tested the reactivity of several CLL-derived BCR from the CLL cohort as 
described in Chapter 3 (see Table 1) by expressing their heavy and light chain as IgM in an 
in vitro model system. We took advantage of the triple knock-out (TKO) cell system, which is 
derived from a signaling-competent mouse pre-B cell line lacking expression of endogenous 
pre-BCRs due to inactivation of RAG2 and λ5 genes26, 27. The λ5 gene encodes one of the 
components of the surrogate light chain, which forms the pre-BCR together with the Ig H 
chain27. Upon evaluating antigen recognition through flow cytometry, we found that five 
out of six tested U-CLL recognized one or more auto-antigens, in contrast to only one out 
of four M-CLL. The antigens which bound to the CLL-derived BCR were LPS, LDL, oxidized-
LDL, liposomes, and double-stranded DNA (Figure 3A). Unfortunately, we were not able to 
analyze the BCR response upon stimulation with these antigens. Altogether, our results are 
in line with other reports showing that autoantigen recognition is more common in U-CLL 
than in M-CLL.
In the Eμ-TCL1 transgenic CLL mouse model, it was found that viral infections induced 
expansion of virus-specific B cells, but did not alter leukemogenesis directly nor resulted 
Sample SHM status*) IGHV IGHD IGHJ
CDR3 AA 
length CDR3 AA
2010-135 97.36 IGHV1-2*04 IGHD3-9*01 IGHJ3*02 28 ARSSRPGSRRGLYDILTNYRGEGDAFDI
2011-308 97.76 IGHV3-21*01 IGHD1-14*01 IGHJ4*02 12 VRTTQDVTLFDS
2006-207 96.82 IGHV4-34*01 IGHD3-22*01 IGHJ6*02 20 VRGYPEDTTTRRYYYYGMEV
2009-115 92.73 IGHV4-34*01 IGHD3-16*01 IGHJ6*02 20 VRGfPYDYTTRRYYYYGMDV
2008-022 100 IGHV4-34*01 IGHD3-3*01 IGHJ3*02 19 ARGPYYDFWSGYSRRAFDI
2011-304 100 IGHV3-23*01 IGHD6-13*01 IGHJ6*02 20 AKPLYSSSWYLNYYYYGMDV
2011-467 100 IGHV3-30*01 IGHD3-3*01 IGHJ6*02 27 ARASDFWSGYYKYEDPYGYYYYYGMDV
2006-225 100 IGHV1-69*01 IGHD3-16*02 IGHJ3*02 21 ARGGGYDYVWGSYRPNDAFDI
2006-284 100 IGHV1-69*01 IGHD3-16*02 IGHJ3*02 21 ARGGGYDYIWGSYRSNDAFDI
2009-335 100 IGHV1-69*06 IGHD3-16*02 IGHJ3*02 21 ARGGDYDYIWGSYRPNDAFDI
*) Values represent % identity with germline DNA sequence
Table 1. Characteristics of CLL cases
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in earlier onset or progression of CLL28. When comparing sera from young non-leukemic 
Eμ-TCL1 mice with that of aged CLL-bearing Eμ-TCL1 mice, the former did not show 
autoreactivity, while the latter did recognize a broad range of autoantigens, mostly directed 
via light chain usage28. In line with these findings, it was shown in the IgH.TEμ CLL mouse 
model that the unmutated CLL-BCR repertoire is dependent on B cell-T cell interaction. 
This was explored in vivo using crosses with mice deficient for activation-induced cytidine 
deaminase (AID) expression in B cells or CD40L expression in T cells, as well as antigenic 
stimulation pressure29. Hereby, It was also found that the age of onset was not influenced by 
high expression levels of AID or CD40L29. These observations in mouse CLL models further 
underline the importance of the BCR including the role of (auto)antigens, as well as T-cell 
derived signals in disease onset28, 29. However, it should be further investigated whether this 
is comparable with CLL pathogenesis in human. 
Next to the antigen reactivity concept, over the last years another concept has emerged 
in which the CLL BCR itself can act as an antigen, thus resulting in autonomous stimulation. 
Dühren-Von Minden et al. found that CLL-derived BCR recognized an internal epitope within 
framework 2 of the BCR, which causes cell-autonomous Ca2+ signaling26. This cell-autonomous 
signaling is induced by CLL BCRs expressed as IgM in the above described TKO cell system. 
When expressing the IGH and IGL genes from CLL cases described in Chapter 3 in TKO cells, 
we could indeed confirm autonomous signaling when these CLL BCRs were expressed as 
IgM isotypes. However, no autonomous Ca2+ signaling could be induced when they were 
expressed as IgD isotypes (Figure 3B). IgM can respond to monovalent and polyvalent 
antigens, while IgD requires polyvalent antigens for stimulation. This is found to be dependent 
on the specific hinge region in IgD, because after abrogation of the hinge region IgD can be 
stimulated by monovalent antigens30. Additionally, it was recently published that IgM-BCR 
can be autoreactive, while the same antigen shows less binding to and signaling induction 
in the corresponding IgG-BCR in TKO cells. Furthermore, it was also found that auto-antigen 
binding to soluble IgG, does not automatically correspond with autoantigen binding when 
this is expressed as IgM-BCR or IgG-BCR31. Taken together, these experiments corroborate 
the idea of cell-autonomous signaling in CLL, but also indicate the importance of the IGH 
constant region structure for this phenomenon and as a result perhaps for development of 
CLL.
The importance of the IGH constant region structure has been further shown in the 
publication by Minici et al, who investigated crystal structures of the stereotypic subsets 
CLL#2 and CLL#432. The CLL#4 BCR consists of IGHV4-34, and IGHJ6*02 with a HCDR3 length 
of 20 amino acids, combined with an IGKV2-30/IGKJ2 light chain, and is expressed as IgG. 
For CLL#4 BCRs the class switch to IgG appeared to be required to induce autonomous 
signaling. The authors provided evidence that this is caused by the positively charged residue 
Lys214H, of which the side chain in the IgG CH1 domain forms hydrogen bonds that stabilize 
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Figure 3. Analysis of the binding capacity and Ca2+ influx induction of CLL-derived BCR in TKO cells.
TKO cells were transduced to express a selection of CLL-derived BCR (see table 1 for details) as IgM and IgD as de-
scribed previously26, 27. 
A. Flow cytometric analysis of antigen binding capacity of CLL-derived BCR in TKO cells. 
TKO cells expressing IgM were incubated with biotinylated antigens for antigen-binding analysis; IgG, LPS, oxi-
dized-LDL, LDL, Malondialdehyde (MDA)-BSA, phosphorylcholine-conjugated BSA (PC-BSA), Liposomes, or double 
stranded DNA (from calf thymus), as indicated. Antigen binding was detected by APC-streptadavidin and measured 
by flow cytometry on a LSR-Fortessa. CLL-derived BCR and controls are plotted on the x-axis. Antigen binding is 
shown by mean fluorescence intensity with background subtraction of negative control (delta MFI) on the y-axis 
from 3 separate analysis.
B. Flow cytometric analysis of Ca2+ influx in TKO cells expressing CLL-derived BCR as IgM and IgD. 
TKO cells were incubated with Indo-1 for Ca2+ influx analysis. Autonomous signaling was detected after addition of 
tamoxifen, which allows the cells to signal by release of SLP65, for IgM CLL-BCR and not for IgD CLL-BCR, both in 
M-CLL (upper panels) and U-CLL (lower panels). The shown Ca2+ influx assay plots are representative for all tested 
CLL-derived BCR. Time of measurement in seconds is plotted on the x-axis, Ratio of median fluorescence intensity 
of Indo1/Indo-1 is plotted on thy y-axis.
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self-interaction, and which is not conserved in CH1 domains of IgM and IgE. Furthermore, 
substitution of tyrosine into histidine on position 31L of the IGKV2-30 gene, as caused by 
SHM, proved to be important for the stabilization of the heavy chain-light chain pairing site 
and thereby self-interaction in this CLL#4 BCR32. In addition, Catera et al, showed that CLL#4 
BCR recognize naïve and memory B cells via an aspartic acid at position 66 of FR3 in the 
rearranged IGKV2-30 light chain gene, which is acquired by SHM33. Altering the DNA leading 
to an amino acid change at this position resulted in loss of binding to B cells. What the exact 
target is on the naïve and memory B cells needs to be further determined33. Furthermore, 
BCR-BCR interaction cannot only be induced by the constant domain or variable regions 
of the heavy chain, but also via the light chain. This has been shown for CLL#2 receptors 
which were found to contain an Arg110L residue because of a specific G to C nucleotide 
substitution induced by SHM32. This substituted amino acid was identified in CLL#2 receptors 
from a cohort of 17 CLL patients32. Of note, the primer pairs that we used for our analysis 
did not allow for the detection of this substitution in our subset #2(-like) CLL family 3 cases 
which use CLL#2 BCR light chains (Chapter 5). Hence this would require further investigation. 
In summary, these findings in two independent stereotypic CLL-BCR show the importance 
of the BCR structure in self-recognition, which could also impact on the ‘selection’ of these 
BCR and provide an explanation why these BCR are stereotypic. Chronic activation through 
self-recognition may thus be a key step in the development of stereotypic CLL.
Since CLL is generally considered a disease of elderly, we also investigated the BCR 
repertoire in aging healthy individuals. Our BCR repertoire analysis (Chapter 6) showed that 
are no gross alterations in the repertoire of naïve mature B cells between 20 and 70 years 
of age. After 70y we noted a shift in IGHV gene usage with significantly higher IGHV1-18, 
IGHV1-46, IGHV1-69, and IGHV5-51 gene usage, and significantly lower IGHV4-34, IGHV4-39, 
and IGHV4-59 gene usage. When we compared IGHV gene usage of clones from CLL patients 
with the BCR repertoire in naïve mature B cells of different age groups, we observed that 
the IGHV gene usage in CLL clones is very similar with that of the 50-70y healthy group and 
not the 70+y group. Comparison of the clonal BCR repertoire of CLL patients with other B 
cell subpopulations did not show much resemblance. In addition, we also investigated the 
presence of stereotypic BCR in the BCR repertoire of healthy control B cell subpopulations. 
Interestingly, we could show that CLL-associated stereotypic BCR are present in the BCR 
repertoire in B cell subpopulations of healthy individuals, and that their presence increases 
with age. This might suggest that part of specific IGHV gene usage or CLL-associated 
stereotypic BCR usage can be explained by age-dependent narrowing or skewing in the BCR 
repertoire. In naïve mature B cells, stereotypic BCR belonging to CLL#2, CLL#5, and CLL#64B 
were most frequently detected. In non-switched memory B cells the mostly found stereotypic 
BCRs concerned CLL#2 and CLL#14, the latter also being most prominent in IgM-only and 
CD27+IgG+ memory B cells. Altogether, we observed that stereotypic CLL-associated BCR are 
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part of the normal BCR repertoire. The increase of their presence upon aging might reflect 
a predisposition towards the development of monoclonal B cell lymphocytosis (MBL) or CLL 
clones in elderly, although further research is required.
In addition to the BCR repertoire studies in elderly, we further looked into the distribution 
of B cell subpopulations (Chapter 6). Although B cell subset distribution did not alter 
dramatically with increase of age, our B cell subpopulations analyzed in peripheral blood 
did show a decline in both absolute numbers and proportions of transitional B cells, total 
memory B cells and plasma blasts in elderly. These changes were accompanied with signs 
of relatively increased chronically activated CD5+CD43+ B cell and CD21low B cell populations. 
Chronically activated B cells have been associated with MBL and CLL34, 35, while high numbers 
of CD21low B cells have been associated with autoimmune disease36. Increased numbers of 
CD5+CD43+ B cells upon aging could relate to a higher risk of MBL and CLL development in 
elderly. Higher counts of CD21low B cells in our screened elderly population could point to 
undiagnosed autoimmune phenomena. 
 
SUMMARY OF MAIN FINDINGS AND FUTURE PERSPECTIVES
In summary, in this thesis we studied the B cell populations and BCR repertoire of healthy 
individuals upon aging. We detected a decline in both absolute numbers and proportions 
of transitional B cells, total memory B cells, and plasma blasts in elderly, and noticed signs 
of increased proportions of chronically activated CD5+CD43+ B cells and CD21low B cells. 
Furthermore, we observed that CLL-associated stereotypic BCR are present in the normal 
BCR repertoire from healthy individuals and their usage appeared to increase with age. 
Both immunogenetic and chromosomal similarities were detected within the three CLL 
families in a disease that is known to be quite heterogeneous. Immunogenetically, these 
families represent three known CLL subgroups being M-CLL (family 1), U-CLL (family 2), and 
CLL#2-like CLL (family 3). Common chromosomal aberrations having prognostic value in CLL, 
were found to be present in these families. Deletion of 11q14.2-11q14.3 was found in family 
1 and family 3 members, while trisomy 12 was detected in family 2 members.
Finally, when evaluating basal Ca2+ levels we noted clear differences in BCR signaling in 
CLL patients compared with B cells of healthy individuals, especially upon BCR stimulation. 
We identified a relationship between the basal Ca2+ level and SHM status, with the Ca2+ level 
being higher in M-CLL. Furthermore, we observed striking differences in expression levels of 
several BCR signaling molecules as well as NF-κB-related genes between IgM-responsive and 
IgM-unresponsive CLL cases. 
In future research the role of molecular processes including BCR signaling and the more 
downstream NF-κB signaling should be linked to analysis of clonal evolution of CLL cells. 
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Current research on clonal evolution is mainly focused on the associated genetic alterations. 
We anticipate that combining studies into clonal evolution and BCR downstream signaling 
can shed new light on how CLL progresses and can lead to novel diagnostic tools. This will 
pave the way for personalized medicine in CLL, taking advantage of innovative targeted 
therapies that are currently available or that will be further developed. 
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LIST OF ABBREVIATIONS
AKT  protein kinase B
BCR   B cell receptor
BTK  Bruton’s tyrosine kinase
CDR3  complementarity determining regions
CLL  chronic lymphocytic leukemia
CML  chronic myeloid leukemia
CSR  class switch recombination
DAG  diacylglycerol
DLBCL  diffuse large B cell lymphoma
EBF1  Early B-Cell Factor 1
ERK  extracellular signal-regulated kinase
FCγR2  Fc receptor, IgG, low affinity II
FOXO   forkhead transcription factors
FR   framework
GC   germinal center
Ig  Immunoglobulin
IGH  immunoglobulin heavy chain
IGHD  immunoglobulin heavy chain diversity region
IGHJ  immunoglobulin heavy chain joining region
IGHV   Immunoglobulin heavy chain variable region
IGL  immunoglobulin light chain
IκB  inhibitor of nuclear factor kappa B 
IKK  IκB kinase
ITAM   immunoreceptor tyrosine-based activation motif
LPS  Lipopolysaccharide
LYN  Lck/Yes novel tyrosine kinase
M-CLL   mutated chronic lymphocytic leukemia
MCL   mantle cell lymphoma
MYD88   myeloid differentiation primary response 88
MZ  marginal zone
NFAT   nuclear factor of activated T cells
NF-κB   nuclear factor kappa B 
NHL   non-Hodgkin lymphoma
NGS  next generation sequencing
ORR   overall response rate 
OS   Overall survival
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PFS   progression-free survival
PI3K   phosphatidyl-inositol-3-kinase
PIP  phosphatidyl-inositol phosphate
PIP2  phosphatidyl-inositol 4,5-biphosphate
PIP3  phosphatidyl-inositol 1,3,5-triphosphate
PKC   protein kinase C
PLCγ   phospholipase C γ
SHM   somatic hypermutation
SLL   small lymphocytic lymphoma
SLP65  SH-2 domain leukocyte protein of 65 KD
SNP  single nucleotide polymorphism 
SYK   spleen tyrosine kinase
TKO  triple knock-out
TLR   toll-like receptor
U-CLL  unmutated chronic lymphocytic leukemia
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NEDERLANDSE SAMENVATTING (VOOR NIET INGEWIJDEN) 
Alle levende organismen, inclusief de mens, worden blootgesteld aan ziekteverwekkers 
zoals virussen, bacteriën, schimmels en parasieten gedurende hun leven. Daarom is 
een goed werkend afweersysteem nodig om ons te beschermen tegen ziekten of zelfs 
overlijden veroorzaakt door infecties. Het immuunsysteem bestaat uit cellen die behoren 
tot het aangeboren afweersysteem, dat een eerste verdedigingslinie vormt, en uit cellen 
die behoren tot het verworven afweersysteem, dat een heel specifieke reactie op een 
ziekteverwekker oproept. Een speciaal soort witte bloedcellen zijn de B en T cellen, ook wel 
lymfocyten genoemd. Zij maken deel uit van de verworven afweersysteem en brengen heel 
specifieke receptoren tot expressie, welke gericht zijn tegen eiwitten of andere moleculen 
(antigenen) van ziekteverwekkers. Bij de eerder genoemde B cel worden deze specifieke 
receptoren B-celreceptoren (BCR) genoemd. B cellen hebben verder als heel specifieke 
eigenschap dat ze zich nadat ze een antigeen herkend hebben, gaan delen, zich verder 
ontwikkelen en in staat zijn om deze BCR ook als antistof (ook wel immuunglobuline (Ig) 
genoemd) uit te kunnen scheiden. Er zijn 5 verschillende Ig klassen; IgM, IgD, IgG, IgA en 
IgE. Om alle mogelijke ziekteverwekkende antigenen te kunnen herkennen is een breed 
repertoire van BCR moleculen nodig. Dit is mogelijk door middel van knip- en plakprocessen 
(herschikkingen) in het immuunglobuline DNA waarbij “variable” (V), “diversity” (D), en/of 
“joining” (J) genen aan elkaar gekoppeld worden. Dit vormt samen uiteindelijk een unieke 
BCR. Omdat alle B cellen een unieke BCR tot expressie brengen zorgt dit voor een heel breed 
BCR repertoire en kunnen er onnoemelijk veel antigenen herkend worden. 
Wanneer een antigeen bindt aan de BCR wordt de B cel geactiveerd doordat diverse 
signaalmoleculen achtereenvolgens aangezet worden. Dit wordt BCR signalering genoemd 
(zie hoofdstuk 2, figuur 1). Een deel van deze signaalmoleculen zijn kinases die elkaar 
aanzetten door op een ander signaalmolecuul een fosfaat-groep te zetten (fosforylering). Dit 
zorgt voor het vrijkomen van calcium (Ca2+), wat uiteindelijk zorgt dat ook andere eiwitten 
zoals transcriptiefactoren worden geactiveerd. BCR signalering leidt tot verdere ontwikkeling 
(differentiatie) van de B cel en celdeling (proliferatie). Tijdens de B cel differentiatie kan een 
enzym mutaties in het DNA van het antigeen-herkennende domein van de BCR aanbrengen. 
Dit proces wordt somatische hypermutatie (SHM) genoemd en kan de bindingssterkte 
(affiniteit) voor het antigeen verhogen. Daarnaast kan verandering van immunoglobuline 
klasse van het constante deel van de BCR (class switch recombination, CSR), de affiniteit 
voor een antigeen ook versterken. Op basis van verschillende kenmerken tijdens de 
differentiatiestappen kunnen B cellen gegroepeerd worden. 
Chronische lymfatische leukemie (CLL), het meest voorkomende type leukemie bij 
ouderen, is een monoklonale tumor van B cellen die allen dezelfde BCR hebben. CLL is een 
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heel heterogene ziekte, wat betekent dat het ziekteverloop voor veel patiënten heel mild 
is en zij weinig klachten hebben, maar andere patiënten hebben een agressievere vorm. 
Kenmerken van de BCR zijn een belangrijke indicatie voor de prognose van CLL patiënten. 
Wanneer er SHM van de BCR heeft plaatsgevonden, wordt dit gemuteerde CLL genoemd 
(M-CLL). Dit heeft een gunstige prognose ten opzichte van ongemuteerde CLL (U-CLL), welke 
vorm agressiever is. Verder is het opvallend dat bij een-derde van alle CLL patiënten de CLL 
cellen een BCR hebben die heel erg lijkt op die van CLL cellen in andere patiënten. Dit worden 
stereotype BCR genoemd. CLL patiënten met dezelfde stereotype BCR kunnen ingedeeld 
worden in groepen of stereotype subsets en dit kan ook prognostische waarde hebben. 
Subset CLL#2 is geassocieerd met een agressieve vorm van CLL en subset CLL#4 heeft over 
het algemeen een gunstige prognose. 
In dit proefschrift hebben we de rol van de BCR signalering onderzocht in CLL cellen van 
verschillende groepen CLL patiënten. We hebben onderzocht in hoeverre BCR signalering 
verschilt van normale B cellen en welke verschillen er zijn tussen CLL cellen van verschillende 
patiënten na stimulatie van de BCR. Verder hebben we in 3 families met meerdere CLL 
patiënten de karakteristieken van de BCR onderzocht en daarnaast gekeken naar genetische 
afwijkingen in deze families. Omdat CLL een ziekte is die vooral bij ouderen voorkomt, hebben 
we tenslotte ook de B cel differentiatie en BCR repertoire bij veroudering bestudeerd. 
In hoofdstuk 2 geven we een overzicht van de literatuur over belangrijke immuun-
gerelateerde signaleringspaden die een rol spelen in het ontstaan en de verdere groei 
van CLL en welke tegenwoordig een doelwit zijn voor therapie. Dit zijn BCR signalering, 
chemokine receptor signalering en Toll-like receptor (TLR) signalering. Ook bespreken we 
hier de medicatie die heel specifiek signaleringsmoleculen blokkeren en de effecten daarvan 
op CLL cellen. 
In hoofdstuk 3 hebben we de verschillen in BCR signalering tussen B cellen van 14 gezonde 
personen en CLL cellen van 68 patiënten bestudeerd aan de hand van de hoeveelheid 
intracellulair Ca2+. We vonden dat intracellulair Ca2+ hoger was in CLL cellen dan in normale 
B cellen. Wanneer we deze resultaten vergeleken tussen verschillende subpopulaties van 
CLL, M-CLL en U-CLL, zagen we dat M-CLL hogere basale intracellulaire Ca2+ niveaus had dan 
U-CLL. Wanneer we de BCR stimuleerden met een antilichaam zagen we dat CLL cellen een 
verminderde respons lieten zien ten opzichte van normale B cellen, en dat U-CLL iets meer 
respons vertoonde bij stimulatie van de IgM-BCR dan M-CLL. Hieruit concludeerden wij dat 
M-CLL minder gevoelig is voor BCR stimulatie dan U-CLL. 
In hoofdstuk 4 hebben we verder gekeken naar verschillen tussen CLL cellen van 52 
patiënten die wel of niet reageren op stimulatie van de BCR door de vrijgifte van Ca2+, en 
welke factoren in de cel een rol spelen bij deze verschillen. Wanneer we keken naar de 
fosforylering van verschillende signaleringsmoleculen zagen we dat CLL cellen die reageerden 
op IgM stimulatie (responsive CLL, n=24) meer fosforylering van PLCγ2 en AKT lieten zien dan 
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cellen die niet reageerden (unresponsive CLL, n=28). Deze responsive CLL bleken ook een 
hogere expressie van IgM, IgD, CD19, CD38 en CD43 te hebben dan unresponsive CLL. Onze 
RNA sequencing resultaten lieten zien dat verschillende NF-κB gerelateerde genen hoger tot 
expressie kwamen in unresponsive CLL. Dit waren voornamelijk genen die een rol spelen bij 
het remmen van NF-κB signalering, zo genoemde NF-κB inhibitors. Na stimulering van de 
IgM-BCR zagen we in responsive CLL een toename van de expressie van NF-κB inhibitors, 
maar ook van NF-κB subunit REL, terwijl in de unresponsive CLL er geen verschil was 
vergeleken met de basale (ongestimuleerde) niveaus. Hiermee toonden we aan dat NF-κB 
signalering heel belangrijk is voor CLL cellen en hun mogelijkheid om te reageren op BCR 
stimulatie. 
In hoofdstuk 5 hebben we binnen drie families met twee of meer CLL patiënten de 
karakteristieken van de BCR bestudeerd. Familie 1 bestond uit vier familieleden die allen een 
door SHM gemuteerde BCR vertoonden en dus M-CLL patiënt zijn, terwijl de twee broers 
van familie 2 beiden een ongemuteerde BCR hadden en dus tot de U-CLL groep behoren. 
Opmerkelijk was dat de vier patiënten van familie 3 allemaal een vrijwel identieke lichte 
keten hadden, waarvan bekend is dat deze behoort tot de stereotype CLL subset CLL#2. Een 
van deze vier patiënten had ook de kenmerkende CLL#2 zware keten, en is daarmee een 
prototype CLL#2, terwijl een ander familielid een BCR liet zien die sterk lijkt op een CLL#169. 
Daarnaast hebben we ook gekeken naar diverse genetische afwijkingen die bekend zijn voor 
CLL en prognostische waarde hebben. Hier zagen we ook overeenkomsten. Binnen familie 
1 en familie 3 hadden alle familieleden een chromosoom 13q14 deletie en binnen familie 2 
lieten beide familieleden een trisomie 12 zien. Van andere kleinere genetische veranderingen 
die eerder al geassocieerd zijn met CLL, vonden we enkele terugkerend binnen een familie. 
Of dit laatste komt door een genetische predispositie of een overeenkomstig patroon van 
klonale evolutie zal verder onderzocht moeten worden. 
In hoofdstuk 6 hebben we het effect van veroudering op B cel differentiatie en het BCR 
repertoire bestudeerd. Met behulp van flow cytometrie hebben we de B cel subsets in het 
bloed van 155 gezonde individuen, onderverdeeld in 4 leeftijdsgroepen, geanalyseerd. We 
vonden een afname van B cellen (totaal en relatief) bij veroudering, met een verlaging 
van transitionele B cellen, memory (geheugen) B cellen (met name non-switched en 
IgG+ memory cellen), en plasmablasten bij individuen boven 70 jaar. Verder hebben we 
het BCR repertoire van naïeve cellen en antigeen-gestimuleerde B cellen in verschillende 
leeftijdsgroepen bestudeerd en dit vergeleken met het klonale BCR repertoire van 920 CLL 
patiënten. We vonden weinig verschillen in BCR repertoire van naïeve mature B cellen en 
antigeen-gestimuleerde B cellen onder 70 jaar. Duidelijke verschillen in BCR repertoire, 
vooral voor IGHV-gengebruik vonden we in naïeve mature B cellen in de 70+ leeftijdsgroep. 
Het IGHV-gengebruik van CLL patiënten (zowel van de 50-70 en de boven 70 groep) leek 
het meest op dat van naïeve mature B cellen van de 50-70 leeftijdsgroep, maar niet van 
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de naïeve mature B cellen van de 70+ groep. Daarnaast vonden we dat CLL-geassocieerde 
stereotype BCR deel uitmaken van het normale BCR repertoire van gezonde individuen en 
dat hun aandeel toeneemt bij hogere leeftijd. 
Tenslotte bespreken we onze resultaten uit alle hoofdstukken in de General Discussion 
(hoofdstuk 7) en komen tot conclusies en verdere richtingen voor het onderzoek naar de 
BCR bij CLL. 
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